
















The Dissertation Committee for Bum Kyu Lee certifies that this is the 
approved version of the following dissertation: 
 
 
Genome-wide Target Identification of Sequence-specific Transcription 
























Genome-wide Target Identification of Sequence-specific Transcription 










Presented to the Faculty of the Graduate School of  
The University of Texas at Austin 
in Partial Fulfillment  
of the Requirements 
for the Degree of  
 
Doctor of Philosophy 
 
 










I would like to thank my advisor, Dr. Vishwanath Iyer for his patience, scientific 
guidance and support throughout graduate school. Without his constant encouragement, 
guidance and mentorship I would not have achieved my goals.  
I would also like to thank my committee members Dr. Arturo DeLozanne, Dr. 
Edward Marcotte, Dr Philip Tucker, and Dr. Scott Stevens for thoughtful advices and 
suggestions which guide me to perform my projects.  
I want to thank all Iyer lab members: Daechan Park, Yaelim Lee, Damon 
Polioudakis, Dia Bagchi, Yunyun Ni for discussion on my projects, especially Dr. 
Akshay Binge who helped me learn basic computational skills as well as gave me 
invaluable advices for data analysis and Anna Battenhouse who helped me not only 
analyze large scale data but also generate many figures for papers as well as editing my 
dissertation.   
I also want to thank all my friends, Hyung-Chul Kim, Dae-Suk Eeom, ji-Hoon 
Lee, Young-Sam Lee, Yong-Hwan Kim, and Hae-Ryung Chang who helped me get 
through core courses and gave invaluable advices to prepare my Part 1 exam.   
Finally, I would like to thank my parents who have been providing me ceaseless 




Genome-wide Target Identification of Sequence-specific Transcription 





Bum Kyu Lee, Ph.D. 
The University of Texas at Austin, 2011 
 
Supervisor:  Vishwanath R. Iyer 
 
The regulation of gene expression at the right time, place, and degree is crucial for 
many cellular processes such as proliferation and development. In addition, in order to 
maintain cellular life, cells must rapidly and appropriately respond to various 
environmental stimuli. Sequence-specific transcription factors (TFs) can recognize 
functional regulatory DNA elements in a sequence-specific manner so that they can 
regulate only a specific group of genes, a process which enables cells to cope with 
diverse internal and external stimuli. Human has approximately 1,400 sequence-specific 
TFs whose aberrant expression causes a wide range of detrimental consequences 
including developmental disorders, diseases, and cancers; therefore, it is pivotal to 
identify the binding sites of each sequence-specific TF in order to unravel its roles in and 
mechanisms of gene regulation.   
 vii 
Even though some TFs have been intensively studied, the majority of TFs still 
remain to be studied, particularly the tasks of identifying their genome-wide target genes 
and deciphering their biological roles in specific cellular contexts. Many questions 
remain unanswered: how many sites on the human genome a sequence-specific TF can 
bind; whether all TF-bound sites are functional; how a TF achieves binding specificity 
onto its targets; how and to what extent a TF is involved in gene regulation. 
Comprehensive identification of the binding sites of sequence-specific TFs and follow-up 
molecular studies including gene expression microarrays will provide close answers to 
these questions.  
Chromatin Immunoprecipitation coupled with recently developed high-throughput 
sequencing (ChIP-seq) allows us to perform genome-scale unbiased identification of the 
binding sites of sequence-specific TFs. Here, to gain insight into gene regulatory 
functions of TFs as well as their influences on gene expression, we conducted, in diverse 
cell lines, genome-wide identification of the binding sites of several sequence-specific 
TFs (CTCF, E2F4, MYC, Pol II) that are involved in a wide range of biological 
functions, including cell proliferation, development, apoptosis, genome stability, and 
DNA repair. Analysis of ChIP-seq data provided not only comprehensive binding profiles 
of those TF across the genome in diverse cell lines, but also revealed tissue-specific 
binding of CTCF, MYC, and Pol II as well as combinatorial usage among these three 
factors. Analyses also showed that some CTCF binding sites were inherited from parents 
to children and regulated in an individual-specific as well as allele-specific manner. 
 viii 
Finally, genome-wide target identification of several TFs will broaden our understanding 
of the gene regulatory roles of these sequence-specific TFs. 
 ix 
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Chapter 1: Introduction 
 
1.1 COMPLEXITY AND DYNAMICS OF THE GENOME IN EUKARYOTES  
Unlike prokaryotic genomes, eukaryotic genomes are packaged in vivo into 
compact DNA-protein complexes known as chromatin in the nucleus. Chromatin is 
composed of nucleosomes where 147 base pairs of DNA are wrapped 1.65 times around 
a core histone octamer (two copies of each H2A, H2B, H3, and H4) in a left-handed 
toroid (Luger et al, 1997). Nucleosomes can form a linear array along with DNA, and can 
further be compacted by H1 into higher-order 30nm fibers that are transcriptionally 
inactive (Campos & Reinberg, 2009). Thanks to this compact and highly-ordered 
chromatin structure, cells are able to carry an enormous amount of genetic information in 
the nucleus. For instance, the human genome has about 25,000 protein coding genes (J. 
Craig et al, 2001); the fruit fly Drosophila melanogaster ~13,000 (Adams et al, 2000); 
the rockcress plant Arabidopsis thaliana ~25,000 (The Arabidopsis Genome Initiative, 
2000); and the nematode worm Caenorhabditis elegans ~20,000 (C. elegans Sequencing 
Consortium, 1998 ). Chromatin structure is well conserved from yeast to humans, 
although mammalian chromatin has additional complexity required for cell 
differentiation (Rando & Chang, 2009).  
In addition to this complex chromatin structure, eukaryotic genomes are 




gene-rich regions in interphase chromosomes tend to localize in the nuclear interior 
whereas gene-depleted regions occupy more peripheral parts of the nucleus (Federico et 
al, 2006). This complex and dynamic organization of the genome emerges as a key 
regulatory determinant of gene expression by establishing and maintaining active, poised, 
or repressive chromatin states (Misteli, 2007; Schneider & Grosschedl, 2007).  
The interphase genomes in eukaryotes can be broadly classified into euchromatin 
and heterochromatin domains. Euchromatin replicates early and locates in the central 
position of the nucleus, whereas heterochromatin replicates late and occupies more 
peripherally in the nucleus (Wood et al, 2010) . In addition, euchromatin is not only less 
condensed but also actively transcribed while heterochromatin is tightly packed as well as 
transcriptionally inert (Manuelidis, 1991). Furthermore, recent study has revealed the link 
between chromatin structure and gene density, but not the status of gene activity, 
implying that more complex regulatory mechanisms are involved in gene expression such 
as DNA or posttranscriptional histone modification (Gilbert et al, 2004; Spector, 2004).   
Overall, eukaryotic genomes exist with the compact chromatin structure which 
provides poor DNA access to TFs and other DNA binding proteins. In order to maintain 
cellular homeostasis and properly respond to various internal and external stimuli as well 
as to accomplish cell proliferation, development, and DNA replication and repair, 
chromatin structures must be locally and dynamically adjusted into open structures either 




Two types of mechanisms exist to affect the temporal changes in chromatin 
structures needed to provide access to the DNA for transcriptional machineries. The first 
is multiple covalent posttranslational modification, which epigenetically modulates gene 
expression by changing histone tails in eight distinctive manners: acetylation, 
methylation, phosphorylation, ubiquitylation, sumoylation, ADP-ribosylation, 
deimination, and proline-isomerization (Kouzarides, 2007). These modifications are 
implicated in diverse biological processes including DNA condensation, transcription, 
and DNA replication as well as repair. A wide variety of combinatory histone 
modifications have been identified, and these modifications can either promote or impede 
the access of transcriptional machineries by altering intrinsic properties of chromatin, in 
particular neutralizing their positive charge (Hansen, 2002).  
Based on the presence of specific histone-modification marks, chromatin can be 
classified into active and inactive domains. Recent genome-wide mapping studies of 
histone modifications using ChIP-seq have revealed that transcriptionally active 
chromatin is generally enriched with H3K4me1 (in enhancer regions), H3K4me2, 
H3K4me3 (particularly at 5‟ ends of gene), H3K36me3 (in gene bodies and 3‟ end of 
genes), H3K9me1, H3K27me1, and H4K20me1; whereas repressive chromatin exhibits 
increased hypo-acetylation, H3K9 methylation, and H3K27me3 (Barski et al, 2007); 
(Wang et al, 2008). Interestingly, it has also been reported that repressive marks in active 
chromatin (and vice versa) as well as “bivalent chromatin domains” with both active 




development-related genes of ES cells (Bernstein et al, 2006). These complicated histone 
codes contribute to more sophisticated transcriptional gene regulation.  
The second mechanism of chromatin structure transformation is a chromatin 
modifying complex, or chromatin remodeler that utilizes ATP to remove, destabilize, or 
reorganize nucleosomes. Several chromatin-remodeling complexes including SWI/SNF, 
SWR, ISW, CHD, NuRD, and INO80 have been reported in eukaryotes (Kouzarides, 
2007). Additionally, advances have recently been made in understanding remodeling 
functions and mechanisms in different environmental conditions such as heat shock or 
DNA damage (Larsen et al, 2010; Shivaswamy & Iyer, 2008; Smeenk et al, 2010). 
However, the roles of many chromatin-remodeling complexes remain unclear, in 
particular the functions of each component in a complex and the functional interplay 
between a complex and histone modifications.  
In addition to the roles of post-translational histone modification and chromatin 
remodeling complexes, three-dimensional models of chromatin emerge as an additional 
sophisticated key regulatory mechanism of gene regulation. Most recently two 
independent studies have revealed inter-chromosomal as well as intra-chromosomal 
interactions of DNA in chromatin (Fullwood et al, 2009; Lieberman-Aiden et al, 2009).  
It has become clear that rather than simply being a passive DNA packing place, 
chromatin is a dynamic and active regulator for gene expression in eukaryotes (Lemon & 
Tjian, 2000). Nucleosome loss or relocation either by histone modifications or chromatin 




transcriptional activation in response to environmental stimuli. However, neither 
nucleosome removal nor relocation alone is sufficient to fully activate genes.  
Eukaryotes have several other regulatory machineries for gene expression, including 
transcription factors. Furthermore, these regulators must orchestrate their effects in order 
to achieve appropriate, context-specific gene expression (Lemon & Tjian, 2000). 
  
1.2 TRANSCRIPTIONAL REGULATION OF GENE EXPRESSION IN EUKARYOTE 
Transcription is a primary step in gene expression. Two main regulatory 
components for transcription in eukaryotes exit: cis-acting and trans-acting elements. The 
interaction between these two elements triggers transcription (Maston et al, 2006). 
Following signal transduction cascades which activate them, transcription factors bind 
the promoters (cis-acting elements) of genes and recruit co-activators, including histone 
modifying enzymes and chromatin remodelers. These sequential recruitments further 
facilitate open chromatin, which in turn facilitates assembly general transcription 
machinery near the transcription start sites (TSSs) of genes, forming a transcription-
initiation complex.  
Cis-acting regulators contain proximal regulatory elements, promoters as well as 
position-independent distal regulatory elements such as enhancers, repressors, silencers, 
and insulators that are located far away from TSSs (Maston et al, 2006). The general 




where basal transcriptional machinery assembles (Maston et al, 2006), and core 
promoters are highly conserved in orthologous genes (Smale & Kadonaga, 2003). A 
classical promoter consists of common elements including the TSS, TATA box, and 
initiator. The TATA box, an AT-rich site generally found 25 to 30bp upstream of the 
TSSs in metazoa, provides the binding sites for the TATA-binding protein (TBP) (Smale 
& Kadonaga, 2003). However, TBP can interact with a broad range of sequences instead 
of the defined canonical one, and several studies have revealed that many promoters are 
TATA-less and that approximately 50% of human genes have alternative promoters, 
spreading their regulatory elements over wider distances (Kimura et al, 2006). 
Furthermore, in metazoa, depending on the genes, promoters can have either only an 
initiator element or a TATA box, and in some case neither (Lee & Young, 2000; Maston 
et al, 2006). In addition to the TATA box, a subset of promoters have CpG islands, 
downstream promoter element (DPE), and TFIIB recognition element (BRD) (Sandelin et 
al, 2007), all of which can contribute to the recruitment and assembly of transcription 
machinery.  
Until now, tens of thousands promoters in human have been identified through 
both computational and experimental approaches, including high-throughput full length 
c-DNA sequencing as well as sequencing-based methods such as rapid amplification of 
5‟ complimentary DNA ends (5‟RACE) (CSH, 2005), cap analysis of gene expression 
(CAGE) (Shiraki et al, 2003), serial analysis of gene expression (5‟-SAGE) (Hashimoto 




 It is well established that many genes are under the control of distal cis-
regulatory elements. Numerous types of studies have attempted to identify cis-regulatory 
elements genome-wide and to elucidate their biological functions. For instance, serial 
deletion analysis identified several discrete enhancers that functions in a position- and 
orientation-independent manner and are normally located in far away from the TSSs of 
genes that they up-regulate; these enhancers assist in the recruitment of TFs onto 
promoters and can alter the activity of TFs (Valenzuela & Kamakaka, 2006). In 
vertebrates, enhancers are considered to be an aggregate location of TF binding sites 
(Panne, 2008) and many genes can be regulated by multiple arrays of enhancers (Visel et 
al, 2007). Several enhancers for developmental genes were also identified through 
transgenic mouse assays coupled with LacZ reporter gene assays using developing mouse 
embryos (Visel et al, 2009). Moreover, recent genome-wide discovery of enhancers, 
based on histone marks and p300 binding sites obtained from ChIP-seq, make it possible 
not only to predict many long-range cis-acting regulatory elements but also to reveal 
some of their tissue-specific functions (Heintzman et al, 2009; Heintzman et al, 2007). 
Many disease phenotypes are attributed to the genomic rearrangement of enhancers that 
disrupts the regulation of genes, even for enhancers located remote from the gene targets 
(Kleinjan et al, 2001). 
In contrast to gene activation by enhancers, other elements such as silencers and 
repressors can suppress gene expression regardless of their position and orientation. The 




such as histone deacetylases. Insulators are not only able to block the communication 
between promoters and enhancers of genes, but also inhibit the spread of repressive 
chromatin structures (Valenzuela & Kamakaka, 2006). Many insulators bind to the 
promoters of genes as well as to the binding sites of TFs, thus helping maintain the active 
and inactive regulation of gene expression by functionally insulating genes from 
neighboring positive or negative regulatory elements (Sproul et al, 2005; West et al, 
2002). Further studies have revealed the versatile roles of these non-coding cis-regulatory 
elements which are implicated in establishing various biological functions and lineage-
specific roles of diverse tissues (De Lucia & Dean, 2010; Huarte et al, 2010; Orom & 
Shiekhattar, 2011; Pauli et al, 2011).  
Trans-regulatory elements consist of a mediator complex as well as both general 
and sequence-specific TFs. The mediator complex, composed of multiple proteins, is a 
general regulator of transcription in eukaryotes and its function is evolutionally 
conserved from yeast to mammals (Myers & Kornberg, 2000). Recent research has 
revealed that the mediator complex can link distal cis-regulatory elements (in particular 
enhancers) to promoters by recruiting a cohesion-containing protein complex which 
forms a bridge between enhancers and promoters (Kagey et al, 2010). The interaction of 
mediator complex and distal cis-regulatory elements with promoters further stabilizes the 
assembly of the transcription pre-initiation complex (Taatjes, 2010). In addition to the 
mediator complex, general TFs including TATA binding protein (TBP) recognize core 




and form a transcriptional pre-initiation complex which facilitates recruitment of RNA 
polymerase II (Pol II).  
Among many transacting factors, sequence-specific TFs are key cellular 
components regulating the expression of only a subset of target genes, enabling cells to 
cope with diverse environmental stimuli (Farnham, 2009). Due to their specificity to 
target genes, TFs are involved in diverse biological processes including cell proliferation, 
development, and swift responses to intracellular as well as external stimuli. 
 
1.3 SEQUENCE-SPECIFIC TRANSCRIPTION FACTORS 
A sequence-specific TF can be defined as a protein containing both a DNA-
binding domain that recognizes DNA in a sequence-specific manner and a trans-acting 
domain that modulates its downstream target genes. Computational analysis of DNA 
sequences, based on distinctive properties of TFs, reveal that approximately 2,000 TFs 
exist in humans, of which about 1,400 have sequence-specific DNA-binding 
characteristics (Vaquerizas et al, 2009).  
Expression analysis of 873 sequence-specific TFs using Affymetrix GeneChips 
across 32 human samples has revealed that genes of sequence-specific TFs have lower 
expression than non-TF genes. The low expression level of a TF makes it easier to 
rapidly alter its concentration (hence its activity), and also promotes precise target 




2009). Finally, both target specificity and regulatory flexibility are enabled by 
combinatory functioning of TFs with other activators. Multiple TFs can bind onto an 
enhancer element, which is called the enhanceosome (Merika & Thanos, 2001). This 
combinatorial usage allows very low concentrations of TFs to influence transcription, 
while the cooperative assembly of enhanceosome variants can provide tissue-specific 
programming (Levine & Tjian, 2003; Panne et al, 2007).  
The most important role of sequence-specific TFs is that they are key players in 
transcriptional gene regulation, especially in dealing with internal or external demands to 
maintain cellular life. For example, a heat shock transcription factor (HSF) is activated in 
response to physiological stresses such temperature elevation or chemical exposure that 
disrupts metabolic processes (Mosser et al, 1990). Moreover, sequence-specific TFs are 
expressed either in one cell line or in almost all tissues, implying they can trigger 
transcriptional gene regulation either in a ubiquitous or a cell-type specific manner 
(Vaquerizas et al, 2009).  
Many tissue-specific TFs have been reported: three retina-specific TFs, cone-rod 
homeobox protein (CRX), neural retinal-specific leucine zipper (NRL), and nuclear 
receptor subfamily 2, group E, member 3 (NR2E3) (Qian et al, 2005); a muscle specific 
TF, MEF-2 (formyocyte-enhancer-binding-factor); a liver-specific TF, hepatocyte 
nuclear factor3 (HNF3 or FOXA) (Kaestner et al, 1998); and a brain-specific TF, Nuclear 




system (CNS) and is crucial for the development of dopamine neurons (Law et al, 1992; 
Perlmann & Wallen-Mackenzie, 2004). 
Numerous diseases including cancers as well as developmental disorders can be 
caused by the abnormal regulation of transcription. For instance, many TFs have 
oncogenic properties whose deregulation induces a wide range of tumors (Furney et al, 
2006; Jimenez-Sanchez et al, 2001); malfunction of TFs implicated in one-third of human 
developmental disorders (Boyadjiev & Jabs, 2000); and it has been reported that 164 TFs 
are directly responsible for 277 diseases (Vaquerizas et al, 2009). Moreover, much 
phenotypic diversity and evolutionary adaptation are attributed to the adjustment of the 
activity and regulatory specificity of TFs (Bustamante et al, 2005; Lopez-Bigas et al, 
2008).  
Until now, only a limited number of human sequence-specific TFs have been well 
characterized. To better understand the functions of sequence-specific TFs and in 
particular to increase insights into their physiological roles in different tissues it is pivotal 
to identify their binding sites across the genome in diverse cell lines under various 
environmental conditions. 
 
1.4 GENOME-SCALE IDENTIFICATION OF SEQUENCE-SPECIFIC TF BINDING SITES. 
Genome-wide mapping of TF binding sites is essential not only for understanding 




regulatory networks implicated in various biological processes. The ENCODE Project 
Consortium commenced in 2004 with the goal of advancing our understanding of human 
genome functions (Birney et al, 2004). One of the major tasks of the ENCODE project is 
to identify and catalogue all possible functional DNA elements in the human genomes 
using high-throughput experimental methods as well as computational approaches. By 
investigating 1% of the human genome (30Mb) covering 44 genomic regions including 
protein-coding and non-coding loci, many novel non-coding transcripts and regulatory 
sites have been identified (Birney et al, 2007). Furthermore, the ENCODE Consortium is 
now scaling up its project from 1% to whole genome in order to identify genome-wide 
functional cis-regulatory elements, including TF binding sites for several dozen TFs in 
diverse human tissues. 
Before ChIP coupled with next generation sequencing method (ChIP-seq) was 
developed, chromatin immunoprecipitation followed by microarrays (ChIP-chip) was one 
of the major tools for investigating genome-scale precise locations where protein 
interacts with DNA in vivo. The conventional ChIP-chip method made it possible not 
only to identify numerous novel TF binding sites but also to elucidate several unknown 
functions. For instance, E2F4 and SRF ChIP-chip experiments have revealed several 
hundred putative binding sites using core-promoter arrays covering -800 to +300 from 
TSSs in the human genome (Balciunaite et al., 2005, Cooper et al., 2007, Xu et al., 2007). 
However, the genome-wide identification of TFs binding sites using ChIP-chip focused 




TSSs; these region-limited studies prevented us from drawing conclusions regarding 
whether the discovered TFs binding sites were comprehensive across the genome. In 
addition, conventional ChIP-chip is limited in its ability to pinpoint precise binding sites 
of TFs due to its low resolution, generally 30-100 bp, even though whole-genome tilling 
arrays, which produce 5-20bp resolution, partially overcome these drawbacks (Liu, 
2007). 
More recently, ChIP-seq technology has enabled the genome-scale unbiased 
identification of TFs binding sites without the scale and resolution limitation of 
conventional ChIP-chip, and at a cost 3-5 times lower (Park, 2009). In ChIP-seq, the 
DNA fragments pulled down with a specific antibody are directly sequenced rather than 
being hybridized on an array. ChIP-seq has several advantages compared with the 
conventional ChIP-chip: higher resolution (single nucleotide), higher coverage in 
repetitive regions normally masked out of an array, fewer artifacts caused by cross 
hybridization, lower requirement for initial ChIP materials, a higher dynamic detection 
range without the limit of low as well as high signal, and cost effectiveness (Park, 2009). 
 Several next-generation sequencing methods have been developed in recent years 
including Solexa (Illumina), Solid (Life Technologies), and 454 (Roche) (Park, 2009). 
Among them, Solexa and Solid sequencing technology can generate several hundred 
millions of short (35-50bp) reads in one time sequencing (Metzker, 2010). Thanks to this 
advance in technology, tremendous progress has been made in identifying protein-DNA 




histone modification sites. For example, studies of histone modification sites have not 
only established histone marks for active as well as repressive genomic regions but have 
also defined precise locations of enhancers which in general had strong H3K4me1 
occupancy signal but weak H3K4me3 (Kim et al, 2010; Rada-Iglesias et al, 2010 
). The comprehensive analysis of TF binding sites using ChIP-seq provides new 
insights into TFs binding patterns that change depending on environmental conditions, 
and allows us to understand the consequences of TFs binding onto diverse cis-regulatory 
element of the genome. 
 
1.5 SUMMARY OF RESEARCH GOALS 
In order to broaden our knowledge of the transcriptional regulation of genes and 
compose a picture of the overall regulatory network of gene expression, genome-wide 
profiling of each sequence-specific TF‟s binding sites must be first be obtained. Among 
~1,400 sequence-specific TFs, genome-scale target identification has been performed in 
only a limited number. Here, we investigated the binding sites of several TFs including 
E2F4, MYC, CTCF and Pol II in diverse cell lines.   
 In Chapter 2, we investigated genome-wide E2F4 binding sites using ChIP-seq 
to identify and catalogue all putative binding sites of E2F4 (a member of the E2F family 
of TFs) across the human genome. In addition, we performed overexpression of E2F4 




relevance of E2F4 and its cofactors binding to their target gene expression. We also 
investigated putative E2F4-bound enhancer sites based on published enhancer histone 
marks, and further validated the enhancer function of some distal E2F4 sites using 
luciferase reporter gene assays. 
 In Chapter 3, we examined genome-wide binding sites of CTCF, MYC, and Pol 
II in diverse cell lines as part of the ENCODE project to characterize the binding 
preference of each TF for genomic loci having different properties, such as CpG islands 
and gene-dense regions, and to investigate the influence of each TF binding on its target 
gene expression. Furthermore, we examined the combinatory usage of these TFs and their 
influence on gene expression. Finally, we investigated tissue-specific TF binding and its 
consequences for gene expression. 
In Chapter 4, we scrutinized individual-specific and allelic-specific CTCF binding 
sites in six different individuals including two different parent-daughter trio sets (CEPH 
and Yoruba families) in order to investigate the influence of single nucleotide 
polymorphism (SNP) on CTCF recruitment on the genome and subsequent influences of 









Chapter 2: Versatile functions of E2F4 in transcriptional gene 
regulation revealed by genome-wide analysis  
 
2.1 INTRODUCTION 
The E2F transcription factor (TF) family consists of 8 different proteins including 
E2F1, E2F2, E2F3a, E2F3b (an isoform of E2F3) and E2F4 to E2F8. Those proteins play 
crucial roles in cell cycle regulation as well as development by activating or suppressing 
certain classes of E2F responsive genes (Attwooll et al, 2004; Rowland & Bernards, 
2006). E2Fs can functions as either activators (E2F1-E2F3) or repressors (E2F4-E2F8) 
(Crosby & Almasan, 2004). Interestingly, recent research revealed that E2F1-E2F3 can 
switch from being activators to repressors in differentiating cells (Chong et al, 2009). The 
expression of E2F1-E2F3 is tightly regulated during cell cycle progression while E2F4 
and E2F5 are constitutively expressed (Crosby & Almasan, 2004). 
Several mechanisms are involved in regulation of E2F4 activity: sub-cellular 
localization, interactions with retinoblastoma proteins (RB), post translational 
modification such as phosphorylation, and decreased translation mediated by antisense 
transcripts (Lindeman et al, 1997; Yochum et al, 2007). Unlike E2F1, E2F4 primarily 
exists in the cytoplasm during cell cycle progression due to lack of a nuclear localization 
signal (NLS). Upon cell cycle arrest, cells start to enter into G0, and cytoplasmic E2F4 




complexes into the nucleus in a CRM1 mediated manner (Gaubatz et al, 2001; Moberg et 
al, 1996). Nuclear localized E2F4 complexes bind to target promoters and regulate 
expression of diverse classes of genes involved in cell cycle, DNA repair and apoptosis 
(Balciunaite et al, 2005). Three pocket proteins including pRB, p107/RBL1, and 
p130/RBL2 are crucial cofactors for the regulation of E2Fs, and their expression level 
changes during cell cycle (Roman, 2006). Thus, it is believed that it has crucial roles in 
mediating cell cycle arrest along with RBL2 in G0 rather than promoting cell cycle 
progression. The binding of the E2F4-RBL2 complex to E2F4 responsive promoters 
triggers the recruitment of HDAC complexes or other co-repressors, resulting in the 
repression of target gene expression (Crosby & Almasan, 2004; Meloni et al, 1999). 
Other observations however are not consistent with the view that E2F4 is 
exclusively a repressor of cell proliferation. Aberrant expression or mutation of E2F4 
triggers the malfunction of cell cycle controls and results in malignant tumors. 
Transfection of E2F4 into non-transformed cells induces the oncogenic activity of E2F4 
(Souza et al, 1997). Moreover, overexpression of E2F4 in transgenic mice causes tumors, 
providing evidence for the oncogenic activity of E2F4 (Wang et al, 2000). Many cancers 
have mutated E2F4 such as colorectal carcinomas, endometrial cancers, gastric 
adenocarcinomas, prostatic carcinomas, and ulcerative colitis-associated neoplasms. 
These facts further emphasize the important role E2F4 plays in tumorigenesis 
(Schwemmle & Pfeifer, 2000; Souza et al, 1997). The newly discovered function of 




other members of this family of regulators may be also be more malleable than 
previously thought (Chong et al, 2009). In order to better understand the physiological 
roles of E2F4 and reconstruct its regulatory network, it is essential to identify genome-
wide E2F4 targets and establish how target promoters respond to it. 
Several chromatin immunoprecipitation (ChIP) coupled with chip (ChIP-chip) 
experiments have been conducted on core-promoter arrays with quiescent and 
continuously growing cells. These studies have revealed that several hundred E2F4 
targets that are involved in diverse functions such as cell cycle regulation, DNA damage 
repair, apoptosis, mRNA processing, ubiquitination, etc (Balciunaite et al, 2005; Cam et 
al, 2004). A recent ChIP-chip study of E2F4 using tiled ENCODE arrays identified 187 
E2F4 binding sites in 1% of the human genome in lymphoblastoid cells (Xu et al, 2007), 
suggesting the possibility that E2F4 may have more than 10,000 binding sites across the 
entire human genome. Moreover, although E2F4 showed a strong binding preference to 
promoters, some E2F4 binding sites were discovered in non-promoter regions. Without a 
comprehensive and unbiased genome-wide target analysis of E2F4, it is difficult to 
evaluate its promoter binding preferences or gain a complete understanding of its 
functions as a transcription factor. 
The recently developed chromatin immunoprecipitation (ChIP) followed by 
sequencing (ChIP-seq) technique allow us to investigate a genome-wide unbiased search 
for binding sites of TFs (Barski et al, 2007; Ji et al, 2008; Mikkelsen et al, 2007; Valouev 




human B-lymphoblastoid cell line, GM06990. We discovered 16,246 putative E2F4 
binding sites distributed across promoters to coding and non-coding regions, providing 
evidence to support diverse roles of E2F4, which were not reported in previous studies. 
Furthermore, gene expression profiling in response to overexpression of E2F4 in the 
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2.2 MATERIALS AND METHODS 
Cell culture 
The lymphoblastoid (GM06990) cell line was purchased from Coriell and 
cultivated in RPMI medium containing 15% fetal bovine serum (FBS) as well as 1% 
antibiotics (penicillin/streptomycin). To perform time course ChIP experiments, cells 
were harvested every 24 hr for 5 days. Serum starvation was achieved by washing cells 
cultured for 72 hr three times with RPMI medium without FBS, then adding low-serum 
RPMI medium containing 0.1% FBS and then cultivating them for 2 days. For serum 
activation, low serum medium was replaced with RPMI containing 15% FBS. Cells were 
then cultivated and harvested at 3, 9, and 18 hr.  
ChIP sequencing 
ChIP assays were performed as described previously (Kim et al, 2008). Briefly, 
GM06990 cells cultured for 72 hr were cross-linked with 1% formaldehyde and 
incubated for 7 min at room temperature. Formaldehyde was deactivated by the addition 
of glycine (125 mM final concentration). Sonicated cell lysate containing an average size 
of 500 bp DNA fragments was used for immunoprecipitation to enrich E2F4-DNA 
complexes using an anti-E2F4 antibody (SC-1082X, Santa Cruz Biotech). 
Immunoprecipitated DNA was sequenced using Illumina sequencing technology (single 
end sequencing). Data from this study is available at the Gene Expression Omnibus 





Primer pairs for 42 targets and a negative control region (Appendix A) for 
normalization were designed using Primer3 (http://frodo.wi.mit.edu/primer3/input.htm). 
Quantitative-PCR (qPCR) was performed using the SYBR green PCR kit from Applied 
Biosystems with 1 ng of ChIP and input DNA. Fold enrichment of targets in ChIP DNA 
relative to input was calculated from an average of three replicate qPCR reactions. 
E2F4 overexpression and expression microarrays 
Full length E2F4, DP-1, and RBL2 clones were purchased from Open Biosystems 
and subcloned into the pcDNA 3.1 vector (Invitrogen). Either full length expression 
constructs or empty vectors as a control were transfected into HeLa cells using 
Lipofectamine 2000 from Invitrogen. Total RNA was extracted from cells transfected 
with combinations of the three factors (E2F4, DP-1 and RBL2) or vector transfected cells 
using Trizol. Microarray experiments were performed using spotted HEEBO 
oligonucleotide human arrays (Kim & Pollack, 2009), which has 44,308 probes, using the 
protocol described previously (Gu & Iyer, 2006). Briefly, total RNA was converted into 
cDNA and labeled with Cy dyes (Cy3 for control and Cy5 for TF overexpression). Dye-
coupled cDNA was combined and hybridized onto the oligo arrays for 14 hr. Cy5/Cy3 
ratios were calculated from scanned intensity data from each channel. Data were 




TaqMan assay for miRNA expression 
Total RNA was extracted from relevant samples by Trizol. All primer sets for 
specific miRNAs and PCR reagents for TaqMan miRNA assay were purchased from 
Applied Biosystems and real time PCR was performed using a 7900HT real time PCR 
machine from Applied Biosystems. RNU66 was used as an internal control for 
normalization. miRNA gene expression levels relative to the control was calculated from 
an average of 4 replicate qPCR reactions. 
Luciferase reporter gene assay 
Around 700 bp of PCR-amplified insert from each of ten distal binding sites was 
cloned into the upstream position of a SV40 promoter in a pGL3 plasmid (Promega cat. # 
E1761) between the KpnI and XhoI restriction sites. All primers used for cloning are 
listed in Appendix A. For the luciferase reporter gene assay, approximately 3x10
5
 HEK 
293 cells were co-transfected with 200 ng of the pGL3 vector or reporter construct 
containing the Firefly reporter gene as well as 10 ng of pRL-PK vector (Promega cat. # 
E2241) containing a Renilla reporter gene, which served as an internal control reporter, 
using 1 µl of lipofectamine 2000 (Invitrogen) and Opti-MEM medium (Invitrogen). After 
transfection and incubation for 24 hr, cells were washed with PBS once, lysed, and 
assayed to measure luciferase activity using the Dual Luciferase assay Kit (Promega cat. 
# E1910) according to manufacturer‟s instructions. Firefly luciferase activity from the 




expression fold change, Firefly activity of the pGL3 vector containing a distal E2F4 
binding site was further normalized with that of an empty pGL3 vector. P-value was 
calculated from three independent transfections using a t-test. 
Identification of ChIP-seq binding peaks and sites 
Illumina sequencing generated 23-32 base pair short reads from the ends of ChIP-
enriched DNA fragments. These short reads were mapped back to the genome using the 
ELAND algorithm. We obtained 6,508,011 uniquely aligning reads from the E2F4 chip 
library and 8,474,489 uniquely aligning reads from the input library. To identify E2F4 
binding sites from high-throughput Illumina sequencing data, we used a Parzen window 
based algorithm as described previously with minor modifications (Shivaswamy et al, 
2008). Each read was assigned a score that was essentially the frequency of observing 
that read in the sequencing library. The plus strand reads and the minus strand reads were 
analyzed separately to find peaks on the plus and minus strands respectively. The 
algorithm begins by assigning the score of each read to its neighboring nucleotides as a 
function of the read‟s distance from that nucleotide. The function used to assign scores 
was a Gaussian kernel with a defined band-width. Local maxima on the plus and minus 
strands were defined as peaks. High scoring plus peaks that are upstream and within 500 
bp of minus strand peaks were considered to be paired and the distance between the 
paired plus and the minus peak was calculated as the fragment length. A second iteration 




direction by half of the previously estimated fragment length, to effectively represent the 
center of the ChIP fragment. The peak-finding algorithm described above was used again 
on these positions to find local maxima across the genome thereby defining binding sites. 
The score associated with the nucleotide corresponding to the maxima was assigned to 
the binding site. 
Input correction 
In order to correct high ChIP-seq scores arising from repetitive sequences or copy 
number repeats rather than true ChIP enrichment, we normalized the E2F4 scores by the 
parallel input sequencing scores. Scores for E2F4 peaks that were within 500 bp from any 
input peak were divided by the corresponding input peak score. If a given E2F4 peak 
overlapped with more than one input peak, the higher scoring input peak was used for the 
correction. E2F4 peaks mapping to within 10,000 bp from any TSS of a gene were not 
input corrected, since peaks near promoters in sonicated crosslinked chromatin can arise 
even in input DNA due to transcription factor binding (Auerbach et al, 2009). 
False discovery rate 
We ran the peak-finding algorithm on a set of randomly simulated read 
coordinates equal in number to the ChIP-seq data. These simulations were repeated 20 
times. At each of a series of different score thresholds, the number of E2F4 peaks found 
after input correction was compared to those found in the random simulations to give the 





We used a capture-recapture analysis to estimate saturation of binding sites in our 
E2F4 data. Capture-recapture analysis has been used to estimate population sizes of 
animals in a given area. The reads from the E2F4 chip library were obtained in two sets 
or “lanes”, the first set having 2,305,280 reads and the second set having 4,202,731 reads. 
Each set was treated as an independent capture. The entire genome was binned into 500 
bp bins and reads mapping to each bin were counted for the two sets separately. Each bin 
was now assigned a p-value value dependent on the number of reads observed within that 
bin according to a random Poisson model. At different p-value thresholds, we calculated 
the following: 
N1: Number of bins in set 1 
N2: Number of bins in set 2 
K: Number of bins common to set 1 and set 2 
E1: Expected number of bins in set 1 according to a random Poisson model 
E2: Expected number of bins in set 2 according to a random Poisson model 
FDR1: (E1/N1)*100 
FDR2: (E2/N2)*100 
E1 and E2 represent the expected number of false positives at each enrichment cut-off. 
The estimated number of E2F4 bins at each p-value cut-off was calculated as: 
P = (N1 – E1)(N2 – E2)/ min[ k(1 – E1/N1), k(1 – E2/N2) ] 




O = (N1 – E1) + (N2 – E2) – min[ k(1 – E1/N1), k(1 – E2/N2) ] 
The percentage saturation was calculated as: 
S = (O/P)*100 
For each p-value cut-off, we calculated the average false discovery rate as the geometric 
mean of FDR1 and FDR2. The percentage saturation (S) was now plotted as a function of 
the average FDR. 
Mapping binding sites to gene features 
To detect E2F4 target genes, E2F4 sites were mapped to within 2 kb from the TSS of all 
genes annotated in the RefSeq database. In order to estimate the number of sites mapping 
to different gene features, it was necessary to assign one site to one and only one gene 
feature. Since E2F4 has been known to preferentially bind near the TSSs of genes, we 
used the following hierarchy to assign sites to features: core > upstream > intron > exon > 
intergenic. Core was defined as 2,000 bp upstream and downstream from the TSS, 
upstream was defined as greater than 2,000 bp upstream to a maximum of 20,000 bp 
upstream from the TSS. Binding sites that could not be mapped to within 20,000 bp 
upstream of any TSS and were not assigned to any intron or exon were termed intergenic. 
Genes that had E2F4 binding sites within the core were defined as targets. 
Mapping binding sites to miRNAs 
In order to identify miRNA targets of E2F4, we excluded binding sites that 




annotated gene or the miRNA using binding data alone. We included miR-22 as a special 
case for further characterization because we have identified a role for miR-22 in the cell 
cycle (unpublished data). Sites mapping to intergenic regions, introns and exons were 
mapped to within 10,000 bp of the annotated starts of mature miRNAs. The data for 
mature miRNA start/stop coordinates was downloaded from miRBase 
(www.mirbase.org). 
Generating TSS/TTS profiles 
A region of 20 kb around the TSS (10 kb upstream and 10 kb downstream), was 
binned in 50 bp size bins and E2F4 sites were mapped to each bin. Each bin was assigned 
the score of the peak that mapped to it. Corresponding bin scores were averaged across 
all genes to generate an average peak score profile across the TSS. This average profile 
was smoothened by a moving window of 3 bins. The same procedure was used to 
generate TTS profiles. 
Motif analysis 
Since attempting to run motif discovery algorithms on all binding sites would 
have been computationally expensive, we divided the binding sites into strong (score ≥ 
24.93), moderate (scores 8.01 to 9.01) and weak (scores 5.6 to 5.75) categories and 
considered the top 500 sites from each category for motif discovery. A 200 bp region 
centered on each site was extracted from the human genome assembly hg18. Motif 




separately at a p-value threshold of 1 x 10
-5
. A random background was generated by 
sampling 200,000 sequences of 200 bp from the genome. 55.9% of E2F4 sites occurred 
within 2 kb upstream and downstream of TSSs of genes and this ratio was maintained in 
the random sample. In addition, we calculated the enrichment of each motif with respect 
to the random background as a function of the peak score. To analyze the relationship 
between each motif and different gene features like core, upstream, intron, exon and 
intergenic (as defined above), we divided sites into different features such that each site 
was assigned to one and only one feature (as described above) and then extracted 
sequences associated with these feature-specific sites (200 bp centered on the site). Then, 
for each feature, we counted the number of sites that had a given motif and divided this 
number by the total number of sites that had that specific motif. This was repeated for 
each of the 5 analyzed features for a given motif and the data was displayed as a heat-
map.  
Motif co-enrichment 
Conserved TF binding site data for the human genome assembly hg18 was 
obtained from http://genome.ucsc.edu. This data contains TF bind sites (TFBS) for 398 
TFs from the TRANSFAC database that are conserved between human, mouse and rat 
(http://genome.ucsc.edu/cgi/bin/hgTrackUi?hgsid=118849564&c=chr13&g=tfbsConsSite
s). A TFBS was considered associated with an E2F4 site if it was found within 250 bp of 




peaks as well as for the randomly generated peaks. The analysis was performed on the 
strong, moderate, and weak categories separately and p-values were calculated according 
to a binomial model. We excluded TFBS that were not enriched at a p-value of < 1 x 10
-6
 
and were associated with less than 4% of the E2F4 sites under consideration. 
Motif co-occurrence 
We counted the number of different motifs that were associated with each binding 
site peak (that is, within 100 bp on either side of the peak), and compared the distribution 





Optimal cell culture conditions for E2F4 ChIP in lymphoblastoid cells. 
Since E2F4 is reported to bind its target promoters in quiescent cells, we first 
investigated E2F4 ChIP efficiency in lymphoblastoid cells that were grown for 24, 48, 72 
and 96 hours after replating by hybridizing the ChIP-enriched DNA to a core-promoter 
array that covered -750 bp to +200 bp from the transcription start site (TSS) of ~9000 
genes. We also examined E2F4 occupancy onto its target promoters in serum-starved as 
well as serum-fed cells on core promoter arrays because it is known that upon serum 
starvation, E2F4 accumulates in the nucleus and is recruited to its target promoters, 
resulting in cell cycle arrest (Deschenes et al, 2004). Strong occupancy signals for E2F4 
were observed at 72 hr and were maintained at 96 hr. We found that the E2F4 binding 
profile was not significantly affected by serum-starvation or stimulation in 
lymphoblastoid cells (Fig. 2-1). Based on the above results, we generated ChIP-seq data 










Figure 2-1. Time-course ChIP-chip experiments for E2F4 on core promoter arrays.  
(1) 72 hr culture, (2) 96 hr culture, (3) serum starvation for 72 hr, (4) serum activation for 3 hr. The ratio of 
ChIP to input determined by microarray hybridization is plotted using the color scale shown. 
 
Identification and verification of E2F4 binding sites from ChIP-seq data 
ChIP-seq of E2F4 generated around 6.5 million uniquely mapped reads to the 
reference human genome. In order to identify E2F4 binding sites from this data, we 
developed a peak detection program using a Parzen windows density estimation 
algorithm we have previously used to map nucleosome positions (Shivaswamy et al, 




cells as a control to ensure that enriched sites were not an artifact of the processing and 
sequencing. Our algorithm identifies discrete regions of approximately 150 bp around 
each ChIP-seq peak which we refer to as sites. Known E2F4 targets were easily detected 
in our ChIP-seq data (Fig. 2-2A). We observed that some strong peak in the ChIP dataset 
corresponded to equally strong peak in the input sequencing data (Fig. 2-2B). Such peaks 
may arise due to the presence of repeat regions in the genome and are thus false positives.  
To minimize such false positive targets, we first normalized the ChIP peaks by 
dividing the ChIP peak scores with their corresponding input peak scores. Next, we 
calculated a false discovery rate (FDR) based on random simulations to decide an 
appropriate significance threshold (Fig. 2-2C). At 1% FDR, which corresponded to an 
input-corrected peak score of 4.4, we identified 16,246 putative E2F4 binding sites across 
the entire genome. To verify the quality of the putative E2F4 binding sites, we examined 
overlaps between ChIP-seq targets with those from our core promoter arrays. About 84% 
of core promoter targets were also overlapped with those of the ChIP-seq data. We 
further verified our ChIP-seq data by performing quantitative-PCR (qPCR) for 42 
randomly selected targets, including 30 targets with a score between 4.4 and 8, as well as 
12 targets with a score less than 4.4, which was below our 1% FDR threshold. Overall, 
binding sites with stronger ChIP-seq scores showed higher fold enrichment by qPCR. 
Specifically, more than 90% of the targets above the 1% FDR threshold showed an 
enrichment of at least 1.5 fold by qPCR. On the other hand, only 41% of sites below the 




We also estimated the extent to which we identified all E2F4 sites in the genome, 
using a tagging-recapture saturation analysis (see Methods). At the FDR threshold of 1% 
and our given sequencing depth, we estimated that we identified more than 80% of all 





































Figure 2-2. E2F4 ChIP-seq reveals genome-wide E2F4 binding sites.  
(A) An example of a known E2F4 binding site that was identified in our ChIP-seq data. Chromosome 
coordinates are indicated on top. The plot in the middle shows the density of ChIP-seq reads, with the peak 
score indicated on the Y axis. The bottom track shows the CDC25C gene with coding regions, exons and 
introns indicated by thick or thin boxes and line respectively. The direction of transcription is indicated by 
the arrows from right to left. (B) An example of strong peaks discovered in both input and ChIP likely due 
to copy number differences between the cell genome and the reference sequence. Such sites were removed 
by input correction (see Methods). (C) FDR calculation based on random simulations. The 1% FDR 
threshold was used for further analysis. (D) Quantitative PCR verification of 42 randomly selected targets 
identified by ChIP-seq. Blue diamonds represent targets which passed the 1% FDR ChIP-seq threshold, and 
red squares represent targets below this threshold. (E) Capture-recapture analysis to estimate saturation for 
E2F4 targets (see Methods). X-axis represents - log10 FDR and the Y axis shows the saturation as a 




Distribution of E2F4 binding sites in relation to gene annotations 
We first investigated the relationship between E2F4 binding sites with gene 
density. E2F4 binding sites are positively correlated with gene density across the genome 
(r
2
 = 0.75) (Fig. 2-3A). Next, we examined the distribution of E2F4 binding sites in 5 
different genomic regions including promoter, exon, intron, intergenic and upstream 
regions by mapping E2F4 sites relative to RefSeq annotated genes. Approximately 56% 
of the sites occurred within promoters (Fig. 2-3B). In addition, the binding profile of 
E2F4 around TSSs also provided evidence that E2F4 had a preference for binding 
promoters, especially near the TSS, whereas no significant binding preference was 
observed near the transcription termination sites (TTSs) (Fig. 2-3C). This result is 
consistent with previous studies using selective arrays, showing that the binding sites of 
several TFs, including E2F1, were mainly distributed near the TSSs (Ren et al, 2002; 
Tabach et al, 2007; Xu et al, 2007).  
Since E2F4 showed preferential binding at promoters, we examined whether the 
binding strength as measured by the peak score of E2F4 sites at promoters was stronger 
than sites at other genomic regions. E2F4 promoter sites showed significantly higher 
peak scores compared to those from other genomic regions (Fig. 2-3D). Taken together, 
these results show that not only does E2F4 bind preferentially to promoters, but it also 















Figure 2-3. The genome-wide distribution pattern of E2F4 binding sites.  
(A) The correlation between E2F4 binding sites and gene density. Each point on the plot represents a 20 
Mb bin. (B) A pie chart representation of the distribution of E2F4 binding sites in 5 different genomic 
regions. The definition of each genomic region is described below. Core promoters are within ± 2 kb from 
the TSS, upstream is from 2 kb to 20 kb upstream from the TSS, and intergenic is a region not included as a 
promoter, upstream region, intron or exon. (C) Distribution of E2F4 binding sites within ± 10kb. Inset 
shows a close up of a 1 kb region centered on the TSS. (D) A box-plot shows the ChIP-seq peak score 
distribution across 5 different genomic regions. Peak scores in core promoters were significantly higher 
compared to those from other genomic regions (P < 5.5 x 10
-15
, Wilcoxon test with Bonferroni correction). 
(E) Distribution of E2F4 binding sites depending on peak scores. Even though the number of intergenic 
sites decreased with increasing score, a substantial proportion of intergenic sites (10%) still remained at a 




E2F4 and bidirectional promoters 
It has been reported that approximately 11% of all genes have bidirectional 
promoters in mammalian genomes (Adachi & Lieber, 2002; Trinklein et al, 2004). 
Recent computation analysis has also reported that consensus E2F4 motifs are 
significantly overrepresented in bidirectional promoters (Lin et al, 2007). In order to 
examine whether E2F4 binding sites showed a bias toward binding to bidirectional 
promoters, we first defined bidirectional promoters as the region of DNA between the 
TSSs of two genes that were divergently transcribed from opposite strands and separated 
by less than 2 kb. Based on this criterion, we identified 918 bidirectional promoters 
corresponding to 1836 genes (9.8%) among the 18,693 genes annotated in RefSeq. We 
mapped E2F4 sites to these bidirectional promoters and found 572 (31%) genes to be 
bound by E2F4 (Appendix B), which was a significant enrichment over background 
(hypergeometric P < 1.1x10
-10
), indicating that many divergently transcribed genes in the 
genome might be co-regulated by E2F4. Divergently transcribed E2F4 target genes were 
highly overrepresented in the categories of RNA processing, DNA repair, protein folding, 
and cell cycle. 
Distal E2F4 sites could be enhancers or other regulatory elements 
In addition to strong promoter occupancy and bidirectional promoter enrichment 
of E2F4 binding sites, a proportion of E2F4 sites were also detected in introns (7.8%), 




approaches have not identified this latter class of E2F4 sites that are not at the core 
promoter. To exclude the possibility that the limited number of TSS annotated in Refseq 
(~18,000) was resulting in an overestimate of the number of intergenic binding sites, we 
mapped all E2F4 sites to an expanded data set of approximately 60,000 TSSs derived by 
combining RefFlat annotated genes with additional gene annotations obtained from the 
UCSC table browser (http://genome.ucsc.edu/cgi-bin/hgTables) and further filtered to 
remove redundant TSS coordinates. Even with the much larger number of TSSs used in 
this analysis, the number of intergenic E2F4 sites showed only a modest decrease from 
22.5% to 17.5%, indicating that a significant proportion of E2F4 sites are truly intergenic. 
We then analyzed the distribution of E2F4 sites at different peak score cut-offs to 
investigate whether the percentage of intergenic sites was dependent on the score. 
Although the proportion of intergenic sites decreased with an increase in the score 
threshold, it remained fairly constant above a score cut-off of 10, where approximately 
10% of E2F4 sites were deemed intergenic (Fig. 2-3E). Overall, these results indicate the 
existence of a significant number of strong E2F4 sites that were found greater than 20 kb 
away from any annotated TSS. 
It is well established that TFs are able to regulate the expression of target genes 
by binding to promoters or long-range regulatory elements such as enhancers and 
insulators. To investigate the possibility that some of the distal (9.6% of upstream and 
17.5 % of intergenic) E2F4 binding sites represent enhancers, we examined these distal 




published histone modification data (Barski et al, 2007; Heintzman et al, 2007; Wang et 
al, 2008). Genome-wide histone signature analyses have revealed that the three forms of 
H3K4 methylation (H3K4me1, H3K4me2, and H3K4me3), H3K9me1, H3K18ac, and the 
variant H2A.Z are highly enriched in enhancer sites. We found that 36% of the intergenic 
E2F4 binding sites and 68% of the upstream sites had at least one histone enhancer 
marker, with most of these E2F4 sites showing multiple enhancer makers (Fig. 2-4A). To 
verify the possibility that distal E2F4 binding sites could function as enhancers, we first 
tested whether they showed binding by p300, a known marker of enhancers in 
mammalian cells. We tested p300 binding at 10 randomly selected distal E2F4 enhancer 
candidate sites using ChIP followed by real-time PCR. We found that 9 out of 10 sites 
showed significant binding by p300 (Fig 2-4B), which supported the possibility that some 
of the distal E2F4 binding sites we identified by ChIP-seq could function as enhancers.  
To functionally test this possibility further, we cloned these 10 candidates into 
pGL3 promoter-containing enhancer reporter vectors and performed luciferase reporter 
gene assays. Five of the 10 sites showed significant increase in expression of their 
reporter genes (P < 0.005), which confirmed that a subset of distal E2F4 binding sites 
could as enhancers (Fig. 2-4C). Based on the reporter assays, we can roughly estimate 
approximately 1,048 out of 4147 distal E2F4 binding sites may function as enhancers. 
Distal E2F4 sites that did not show any enhancer marks may potentially regulate non-
coding genes such as miRNAs whose promoters are not well defined, or these distal sites 




















Figure 2-4. Some E2F4-bound distal sites function as enhancers.  
(A) Relationship of histone enhancer marks with the 2,857 intergenic E2F4 sites (a) or 1560 upstream E2F4 
sites (b). Data for histone modifications indicative of enhancers was obtained from Barski et al. 2007 and 
Wang et al. 2008, assigned to E2F4 binding sites identified here and hierarchically clustered for display. 
The relative strength of the histone modification signal is indicated in the heat-map according to the 
indicated color table. 68% of upstream and 36% of intergenic E2F4 sites contains at least one enhancer 
mark. (B) Fold enrichment of p300 binding for 10 randomly selected enhancer candidates from E2F4 ChIP-
seq data. (C) Luciferase reporter gene assays for randomly chosen 10 distal E2F4 binding sites. The Y-axis 
represents the expression fold change of a luciferase reporter gene normalized to an empty-vector control. 
P-values were calculated using t-test from three independent transfections. E1 through E10 represent 10 
enhancer candidates randomly selected from among distal E2F4 binding sites. P represents a positive 





Putative E2F4 target genes are involved in a broad range of biological processes. 
In order to investigate the functions of E2F4 suggested by its genome-wide 
binding profile, we first considered all E2F4 sites that occurred within ± 2 kb from the 
TSS of all genes annotated in the RefSeq database. We found 7,346 genes that had E2F4 
binding sites in their promoters, which cover almost 30% of all annotated human genes.  
Next, we analyzed functional categories among these putative E2F4 target genes 
using the Database for Annotation, Visualization and Integrated Discovery (DAVID) 
(Dennis et al, 2003). In agreement with previously reported results, E2F4 target genes 
were highly enriched for cell cycle, DNA repair, RNA processing, stress response, 
apoptosis, and ubiquitination (Table 2-1). We also found significant enrichment among 
E2F4 targets for additional functions that have not previously been associated with E2F4, 
such as protein transport and targeting, protein folding, and I-kappaB kinase/NF-kappaB 
cascade. KEGG pathway analysis also showed strong enrichment of E2F4 in the 
categories of cell cycle, ubiquitin-mediated proteolysis, p53 signaling pathway and 
chronic myeloid leukemia.  
We also found that E2F4 binds to the promoters of 780 TFs out of the ~2000 
known TFs in the human genome (Appendix C), which suggests that E2F4 regulates 
broad classes of genes indirectly. Taken together, these results suggest that E2F4 could 






Table 2-1. Functional categories of E2F4 target genes.  
Count represents the number of genes in the biological function category. Percent (%) shows the 








biopolymer metabolic process 2259 34.81% 1.36 6.32E-103 1.21E-99 
cell cycle 490 7.55% 1.77 8.05E-52 1.54E-48 
RNA processing 277 4.27% 1.96 1.55E-39 2.97E-36 
organelle organization and biogenesis 579 8.92% 1.57 3.36E-39 6.42E-36 
response to DNA damage stimulus 208 3.21% 2.07 7.92E-35 1.51E-31 
mRNA processing 172 2.65% 2.14 3.14E-31 6.01E-28 
RNA splicing 156 2.40% 2.22 3.23E-31 6.18E-28 
protein modification process 772 11.90% 1.38 1.98E-29 3.78E-26 
DNA repair 171 2.64% 2.07 1.48E-28 2.83E-25 
ubiquitin cycle 278 4.28% 1.74 7.46E-28 1.43E-24 
response to endogenous stimulus 230 3.54% 1.84 1.38E-27 2.64E-24 
macromolecule localization 401 6.18% 1.54 2.09E-25 4.00E-22 
protein transport 345 5.32% 1.6 2.64E-25 5.05E-22 
post-translational protein modification 653 10.06% 1.39 4.68E-25 8.96E-22 
transcription 1061 16.35% 1.27 1.67E-24 3.19E-21 
protein localization 373 5.75% 1.53 1.34E-22 2.56E-19 
DNA replication 145 2.23% 1.87 1.42E-18 2.73E-15 
apoptosis 356 5.49% 1.47 3.15E-18 6.02E-15 
chromatin modification 118 1.82% 1.9 1.11E-15 2.12E-12 
DNA packaging 166 2.56% 1.67 1.48E-14 2.85E-11 
chromosome segregation 50 0.77% 2.56 2.65E-14 5.05E-11 
ribonucleoprotein complex biogenesis and assembly 116 1.79% 1.85 2.84E-14 5.44E-11 
protein targeting 122 1.88% 1.8 7.12E-14 1.36E-10 
cell development 489 7.54% 1.27 1.16E-10 2.21E-07 
RNA localization 58 0.89% 2.1 1.36E-10 2.61E-07 
sister chromatid segregation 28 0.43% 2.82 6.29E-10 1.20E-06 
protein ubiquitination 51 0.79% 2.11 1.76E-09 3.37E-06 
ribosome biogenesis and assembly 55 0.85% 1.95 2.16E-08 4.14E-05 
protein kinase cascade 174 2.68% 1.43 2.96E-08 5.67E-05 
response to stress 416 6.41% 1.24 6.16E-08 1.18E-04 
spindle organization and biogenesis 19 0.29% 3.06 6.67E-08 1.28E-04 
phosphate metabolic process 399 6.15% 1.25 1.07E-07 2.04E-04 
phosphorus metabolic process 399 6.15% 1.25 1.07E-07 2.04E-04 
protein folding 127 1.96% 1.49 2.01E-07 3.85E-04 
DNA damage response, signal transduction 33 0.51% 2.22 3.98E-07 7.62E-04 
protein-RNA complex assembly 62 0.96% 1.73 1.07E-06 0.002 
regulation of gene expression, epigenetic 34 0.52% 2.11 1.43E-06 0.002 
chromatin assembly or disassembly 73 1.12% 1.63 2.06E-06 0.003 
lipid biosynthetic process 124 1.91% 1.44 2.09E-06 0.004 
microtubule organization and biogenesis 17 0.26% 2.89 2.53E-06 0.004 
centrosome organization and biogenesis 17 0.26% 2.89 2.53E-06 0.004 




E2F4 potentially regulates other E2F family members and its cofactors. 
Previous ChIP-chip studies have revealed that members of the E2F family 
transcriptionally regulate each other (Balciunaite et al, 2005; Ren et al, 2002). For 
instance, E2F4 occupies the promoters of activator E2Fs (E2F1, E2F2, and E2F3) and 
represses their expression to cause cell-cycle arrest. We found that E2F4 occupied the 
promoters of all E2F family genes including E2F7 and E2F8, which are RB independent 
repressors (Rowland & Bernards, 2006). The notable exceptions were E2F4 itself, and 
E2F6 (Table 2-2), which interestingly, functions redundantly with E2F4 as a repressor. 
E2F4 also occupied the promoters of the three RB family proteins (pRB, p107/RBL1, and 
p130/RBL2), and two binding partners (DP1 and DP2). In particular, E2F4 showed 
strong binding at the promoters of E2F1-E2F3, which are genes involved in cell cycle 
progression. To identify targets that were common to E2F1 and E2F4, we compared our 
E2F4 targets with previously published E2F1 targets obtained from ChIP-chip data in the 
same cell line (Xu et al, 2007). Among the top 2,000 known E2F1 targets, 1,416 targets 
(~70%) overlapped with our E2F4 targets identified by ChIP-seq. Functional analysis 
revealed that cell cycle and DNA repair functions were highly enriched among these 
genes that were occupied by both E2F1 and E2F4. 
The retinoblastoma (RB) protein family has important roles in the regulation of 
E2F activity. Several studies have showed that E2F4 can form a complex with one of 
three RB proteins, and that the abundance of the E2F4-RB complex varies depending on 




our E2F4 targets with previously known RBL1 and RBL2 targets identified by ChIP-chip 
using a core-promoter array of 14,000 genes (Balciunaite et al, 2005). We found that 
approximately 87% of previously identified RBL1 and RBL2 targets were also bound by 
E2F4 in our ChIP-seq data. Additionally, we found that 75% of genes previously reported 
as being bound RBL1 alone were in fact occupied by E2F4 in our dataset, and the 
majority of the remaining 25% of "RBL1-alone" targets contained E2F4 sites in their 
promoters that were just below our 1% FDR threshold. This suggests that almost all 
RBL1/p107 and RBL2/p130 targets are in fact also occupied by E2F4 (Table 2-3). 
Table 2-2. E2F4 targets in E2Fs family and their cofactors. 
E2Fs and their cofactors # of reads score alias 
RB1 19 8.95 pRB 
RBL1 74 41.86 p107 
RBL2 20 11.57 p130 
DP-1 41 17.55   
DP-2 23 7.58   
E2F1 52 23.47   
E2F2 52 33.85   
E2F3 71 36.8   
E2F4 0 0   
E2F5 8 4.99   
E2F6 5 3.71   
E2F7 80 35.06   
E2F8 53 26.58   
 Table 2-3. Overlap of E2F4 targets with its cofactors.   
Gene 
# of E2F4 target from 
Balciunaite et al. 2005.  
# of E2F4 target from 
Chip-seq 
% overlap 
E2F4(G1) 299 267 89.30 
p130(G1) 227 202 88.99 
p107(G1) 244 216 88.52 
E2F4(G0) 266 238 89.47 
p130(G0) 364 318 87.36 
E2F4_all 357 314 87.96 
p130_all 383 333 86.91 




Motif analysis of E2F4 binding sites 
E2F family proteins bind to DNA as a heterodimeric E2F-DP complex to the 
motif TTTc/gGCGCc/g (Zheng et al, 1999). We examined the presence of the consensus 
E2F motif (TTTSSCGC) over all E2F4 binding sites identified by ChIP-seq. 
Interestingly, we found that only 5% of E2F4 sites contained the consensus motif, 
suggesting that E2F4 might be recruited to its sites either through a novel motif or via 
interaction with other proteins. In order to discover alternative E2F4 motifs, we 
performed a de novo motif search using the DRIM algorithm (Discovering Rank 
Imbalanced Motifs) (Eden et al, 2007). We first classified E2F4 sites into three different 
groups, namely strong, moderate, and weak, based on binding strength. Next, we 
extracted the top 500 sites from each group and then executed DRIM on each set 
separately. We found a total of 5 different motifs that were significantly enriched over 
background (P < 1x10
-5
) (Fig. 2-5). Of these, Motif 2 and Motif 3 were similar to motifs 
recently identified using microarray based in vitro binding experiments for mouse E2F2 
and E2F3 (Badis et al, 2009).  
To investigate motif occurrence and enrichment, and their dependence on binding 
strength, we mapped all 6 motifs (1 canonical and 5 newly discovered) back to all E2F4 
sites. Fig. 2-5 represents the enrichment of each motif over background as a function of 
ChIP-seq peak score. The canonical motif (Motif 1) and motif 2 showed the strongest 
enrichment over background indicating that these two motifs correspond to high 




and 6 showed weak enrichment over background. All motifs except motif 4 showed a 
gradual increase in the enrichment as well as in the percentage prevalence amongst 
binding sites as a function of peak score. Motif 4 hit the highest enrichment around score 
10 and showed an apparent decrease of enrichment over background at higher ChIP-seq 
peak scores. This was mainly because only a small number of high scoring E2F4 sites 
had this motif. Additionally, we found that for most binding sites, at least one of the 6 
different E2F4 motifs was found less than 20 bp from our estimated peak position (Fig. 2-
6A). 
To investigate whether different motifs are used to recruit E2F4 to different 
genomic regions, we examined the percentage occurrence of all 6 motifs at five different 
genomic regions (promoters, upstream, intergenic, introns, and exons) to investigate any 
regional binding bias of each motif. Most motifs, with the exception of motif 6, were 
highly overrepresented in promoters, consistent with the occurrence and scores of peaks 
in these 5 genomic regions (see Fig. 2-3B and Fig. 2-3D). Motif 6 was distinct in that it 
showed comparable enrichment in promoters and intergenic regions as well as in introns, 
but not in upstream and exons (Fig. 2-6B), suggesting that motif 6 may have distinct 
regulatory roles in intergenic and intronic regions. We also examined the number of 
motifs within each binding site. On average, each E2F4 site contained 2 motifs, while 
sites with higher scores contained more than 2 motifs (Fig 2-6C), suggesting the 
possibility of either multiple E2F4 DNA interactions per regulatory region, or usage of 





















Figure 2-5.  Enrichment of indicated motifs over background is plotted on the Y axis, as a 




























Figure 2-6. E2F4 motif analysis.  
(A) Distribution of motifs around E2F4 binding sites identified by ChIP-seq. E2F4 motifs were mapped to 
E2F4 binding sites and the distance of the identified motif from the maxima of the binding site was plotted 
as a histogram. The Y-axis shows the percentage of peaks that had an E2F4 motif within the specified 
distance shown on the X-axis. The figure indicates that the majority of E2F4 peaks had an E2F4 motif 
within 20 bp of the indicated nucleotide that was designated as the binding site. (B) Frequency of motif 
occurrence in 5 different genomic regions. The heat-map shows the percentage distribution of E2F4 
binding sites found in each genomic region for each of the 6 different E2F4 motifs used in this study. E2F4 
motifs 1-5 were found predominantly in sites that mapped to the core promoter except motif 6. Motif 6 was 
found at almost equal frequency in sites that mapped to the core and intergenic regions. Color bar indicates 
% of a motif in a given genomic region. For a given motif, the sum of the percentages across all 5 different 
genomic regions is 100%. (C) Number of motifs discovered within E2F4 sites segregated by their ChIP-seq 
score. The density plot shows the relative frequency of sites on the Y axis containing each indicated 
number of motifs on the X axis. Sites with stronger ChIP-seq scores had more motifs and overall, E2F4 





In order to investigate whether specific binding motifs were associated with 
specific functions, we grouped genes based on the presence of specific motifs in their 
promoters and performed KEGG pathway analysis for each group (Table 2-4). All E2F4 
motifs were used to regulate the cell cycle pathway and most motifs were used in several 
different pathways. However, we found that some pathways were significantly enriched 
with only one motif. For instance, motif 2 was overrepresented in the biosynthesis of 
steroids pathway while motif 3 was enriched in the N-glycan biosynthesis pathway, and 
motif 4 in the chronic myeloid leukemia pathway. Additionally, we found that motif 6 
was associated exclusively with cell cycle genes. These results suggest that E2F4 may 
use distinct motifs to perform specific physiological functions.  
Table 2-4. Motif usage of E2F4 within different biological pathways.  
Each number indicates one of six E2F4 motifs, assigned to a KEGG pathway category. 
KEGG pathway terms Motifs 
   Cell cycle 1, 2, 3, 4, 5, 6 
   Ubiquitin mediated proteolysis 3, 4, 5 
   Pyrimidine metabolism 1, 3, 5 
   DNA polymerase 1, 3, 5 
   p53 signaling pathway 3, 5 
   Chronic myeloid leukemia 4 
   N-Glycan biosynthesis 3 
   Biosynthesis of steroids 2 





We found several other TF motifs to be significantly co-enriched within 500 bp of 
E2F4 binding sites (Table 2-5). Among them, 10 TFs (EGR1-3, ELK1, PAX5, RFX1, 
SP1, STAT1, RFX1, and YY1) were also targets of E2F4 in our ChIP-seq data. Many 
cell cycle progression-related TFs such as AP1, MAZ, ELK1 were also highly enriched 
in the neighborhood of E2F4 binding sites and such TFs may regulate genes along with 
E2F4 in a combinatorial or competitive manner. 





Overexpression of E2F4 and its cofactors reveal that E2F4 functions as an activator 
and a repressor. 
It has been reported that siRNA-mediated E2F4 knock-down leads to drug- or 
irradiation-induced apoptosis (Crosby & Almasan, 2004) while E2F4 knock-down in 
T98G cells does not affect gene expression due to its functional redundancy with E2F5 
and E2F6 (Balciunaite et al, 2005). In order to identify genes whose expression levels are 




perturbed E2F4 expression levels by transient overexpression and analyzed gene 
expression using microarrays. We initially tried overexpressing E2F4 in lymphoblastoid 
cells; however, the transfection efficiency was too low to discriminate overexpression 
effects given the background of untransfected cells. We therefore used HeLa cells for 
gene expression profiling. Before performing overexpression experiments, we compared 
our E2F4 binding targets from lymphoblastoid cells with targets from HeLa cells 
obtained from previously published data (Xu et al, 2007) to confirm that E2F4 binding 
profiles were comparable between the two cell lines. About 81% of the E2F4 targets from 
HeLa cells were also found in lymphoblastoid cells (Figure 2-7), justifying the use of 

















Figure 2-7. E2F4 target comparison between lymphoblastoid and HeLa cells.  
Black, blue and red indicate numbers of targets from ChIP-seq with lymphoblastoid cells, 
numbers of targets from core promoter array with lymphoblastoid cells, and numbers of targets 
from core promoter array with HeLa cells, respectively. Targets from core promoter arrays were 
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Transient overexpression of E2F4 alone did not trigger dramatic expression 
changes, even though some E2F4 responsive genes were up- or down- regulated. This 
result is likely due to low levels of its cofactors, which are required for E2F4 localization 
and binding. We therefore performed expression profiling after co-transfecting E2F4 with 
its cofactors (DP-1 and RBL2). Co-transfection resulted in increased levels of mRNA and 



































Figure 2-8. Overexpression of E2F4 and its cofactors (DP-1 and RBL2). 
(A) Quantitative PCR verification of increase in mRNA of E2F4 and its cofactors. GAPDH was used as an 
internal control and the log-scaled Y-axis shows the fold increase of the indicated mRNA relative to the 
empty vector control. (B) Western blotting confirming overexpression of E2F4 and its cofactors at the 
protein level. Empty vector was used as a control. (C) K-means clustering of E2F4 targets identified by 
ChIP-seq along with gene expression data obtained in 4 different overexpression conditions. The 
expression data plotted is the expression value relative to that of a vehicle transfection control. The 
significance value (X) obtained from error model analysis was used for the clustering. A significance value 




We performed at least 2 biological replicates of the expression arrays and used an 
error-model to identify statistically significant genes whose expression was altered in 
response to overexpression of the regulators (Hu et al, 2007). Compared to 
overexpression of E2F4 alone, co-transfection of E2F4 and its cofactors increased the 
number of targets that showed significant expression changes (Table 2-6). Overall, 
combinatorial overexpression of E2F4 and RBL2 or E2F4 and DP-1 caused the 
downregulation of more E2F4 target genes than overexpression of E2F4 alone. However, 
co-expression of E2F4 and DP-1 also activated several genes.  
 
Table 2-6. Number of up- or down- regulated genes after overexpression of E2F4 and its 
cofactors. 
 (p<0.001) Number of expression-changed genes 
Overexpression Up-regulated Down-regulated 
E2F4 167 128 
E2F4+DP-1 314 341 
E2F4+RBL 105 171 
E2F4+DP-1+RBL2 228 281 









K-means clustering revealed four distinct clusters of genes whose expression was 
significantly altered: genes activated by overexpression of E2F4+DP-1 (cluster I), genes 
repressed by overexpression of E2F4+DP-1 (cluster II), genes activated by E2F4 alone 
(cluster III), and genes repressed by E2F4+RBL2 (cluster IV) (Fig. 2-8C). Cell cycle 
genes were highly enriched in both cluster I and cluster IV. Cluster I contained DNA 
replication and repair genes, while response to endogenous stimulus and programmed cell 
death were categories enriched in cluster III. These results indicate that E2F4 can 
function as either an activator or a repressor of transcription, and is involved in diverse 
physiological processes.  
More importantly, several genes whose expression is positively associated with 
cell cycle progression were activated by E2F4 and its cofactors overexpression (CDC6, 
CDCA5, CEP55, MYBL2, RPA1, SGOL2, and SMC3). Only a subset of E2F4 binding 
targets showed significant expression changes, which suggests that the regulation of 
E2F4 target genes may be more complex than currently perceived. Interestingly, even the 
low scoring ChIP-seq binding targets were just as likely to be differentially expressed as 
the high-scoring ChIP-seq targets, and are therefore likely to be just as biologically 



























Figure 2-9. Box plot shows no expression difference between high ChIP-score E2F4 targets and 
low ChIP-score E2F4 targets.  
Y-axis represents log2 expression fold change after E2F4 overexpression. High scores are from top 25% of 
E2F4 targets and low scores are from bottom 25% of E2F4 targets. Non-E2F4 targets represent genes that 
were not bound by E2F4 in our ChIP-seq. P-values were calculated by t-test. 
 
E2F4 can regulate miRNAs 
miRNAs have been implicated in fine tuning gene expression by cleaving target 
mRNAs or inhibiting their translation, and some of them cooperate to regulate specific 
cellular events (Croce, 2009; Stark et al, 2005; Sun et al, 2005). The expression of 
miRNAs is modulated by TFs and reciprocally, TFs are also regulated by miRNAs (Lal 
et al, 2009; O'Donnell et al, 2005; Sampson et al, 2007). To address whether E2F4 
potentially regulates miRNAs, we first compared E2F4 binding sites with predicted 
human miRNA promoters that were identified based on histone modification signatures 




Since miRNA promoters are not well-defined, we also examined E2F4 binding 
sites located within 10 kb upstream of mature miRNA coding sequences. For this latter 
analysis, we excluded miRNAs present within exonic or intronic regions as it was not 
possible to assign E2F4 binding sites unambiguously to the miRNA or its parent gene. 
We thus identified an additional 161 miRNAs that showed E2F4 binding within 10 kb 
upstream of their coding regions (Appendix E). E2F4 showed strong binding to the 
putative promoters of the mir-17-92 cluster and let-7a, which are highly conserved 
miRNAs, as well as miR-22, an exonic miRNA (Fig. 2-10A).  
Quantitative ChIP-PCR confirmed that E2F4 was indeed recruited to these three 
miRNA promoters in lymphoblastoid cells (Fig. 2-10B). To investigate whether E2F4, 
either by itself or in combination with its cofactors, could regulate these miRNAs, we 
first established that E2F4 did bind to the promoters of these miRNAs in HeLa cells also 
(Fig. 2-9B). We then used a quantitative TaqMan qPCR assay to measure expression 
changes of those three miRNAs in response to overexpression of E2F4 and its cofactors. 
All three miRNAs showed modest down-regulation upon overexpression of E2F4 alone 

















Figure 2-10. E2F4 can regulate miRNAs. 
(A) ChIP-seq data showing E2F4 binding within 10 kb upstream of the mir-17-92 cluster. The positions of 
the miRNAs are shown in red. The bottom track shows phylogenetic conservation across vertebrates 
species (Vertebrate Multiz Alignment & PhastCons Conservation: http://genome.ucsc.edu) with darker 
vertical bars indicating greater conservation. (B) Quantitative PCR verification of E2F4 binding sites 
upstream of indicated miRNAs in lymphoblastoid and HeLa cells. (C) TaqMan qPCR data for miRNA 
expression upon overexpression of E2F4 and its cofactors. Different combinations of E2F4 overexpression 
with its cofactors caused a modest decrease in the expression of all three miRNAs. The data plotted is the 





The 16,246 E2F4 binding sites in the human genome that we identified by ChIP-
seq are consistent with the number estimated by extrapolation from the sites previously 
identified using tiling microarrays covering 1% of the human genome (187 sites) (Xu et 
al, 2007). About 56% of E2F4 sites were found at promoters, and the average binding 
profile of E2F4 relative to a gene showed a preference of E2F4 to bind near the TSS. This 
finding also agrees with previously published E2F4 ChIP-chip data (Xu et al, 2007). 
Overall, our E2F4 binding site analysis suggests that E2F4 mainly regulates the 
expression of target genes by being recruited to their core promoters. However, our 
unbiased ChIP-seq approach revealed a significant proportion of distal E2F4 sites that 
have not been noted before. This implies that in addition to regulating target genes by 
binding to the core promoter, E2F4 may be involved in additional modes of gene 
regulation.  
Many TF binding sites in eukaryotes occur far away from TSSs and these distal 
regulatory regions are believed to have important physiological roles (Kim et al, 2007; 
Kimura-Yoshida et al, 2004). For instance, a TF can play diverse roles by interacting 
with different cis-regulatory elements such as enhancers, insulators, or silencers. It is 
reasonable to speculate that some distal E2F4 binding sites function as enhancers or 
silencers to modulate target gene expression. Half of the distal E2F4 sites showed histone 
modification signatures characteristic of enhancers, suggesting that E2F4 may act like an 




some of our distal E2F4 sites can function as enhancers. However, 5 out of 10 distal 
E2F4 binding sites did not show enhancer activity in the luciferase reporter assays even 
though those sites were highly enriched with enhancer marks of histone and p300 
binding. This discrepancy may be in part because enhancers are cell-type specific, and 
the histone modification data were generated in a different cell type from the ChIP-seq 
data, and in part because histone modifications are not sufficient to fully specify 
enhancers. Nonetheless, our study suggests that in addition to a role at core promoters, 
E2F4 may act as a long-range regulator. 
We found that E2F4 binding sites were highly enriched in bidirectional 
promoters, which is consistent with previously published data (Lin et al, 2007). 
Bidirectional promoters may be an efficient way to modulate gene expression where the 
same DNA element regulates two different downstream genes at the same time. Genome-
wide studies of bidirectional promoters in several mammalian genomes have suggested 
that they are evolutionarily conserved and functionally related in certain categories like 
DNA repair (Adachi & Lieber, 2002; Trinklein et al, 2004). We also found that E2F4 can 
modulate most E2F family members, as well as its own cofactors. Comparing our E2F4 
target genes with all known RBL1 and RBL2 targets revealed that almost all cofactor 
targets overlapped with E2F4 targets. A number of studies have shown that E2F promoter 
specificity is determined by its cofactors. For instance, E2F4-p130/RBL2 is a major 
complex in quiescent cells, whereas an E2F4-pRB or –p170/RBL1 complex is important 




cell cycle stages (Ikeda et al, 1996; van der Sman et al, 1999). The facts that E2F4 binds 
and may directly regulate its cofactors and family members suggest the possibility of 
feedback loops where the activity of E2F4 can be potentiated.  
Motif analysis revealed that the canonical E2F4 motif was present in only 5% of 
the 16,246 E2F4 binding sites. This result implies the possibility that E2F4 uses other 
unknown motifs or is recruited to target promoters by the aid of other cofactors. De novo 
motif analysis using DRIM discovered 5 putative novel motifs. All motifs were found to 
be positioned near the peak of the ChIP-seq signal. As a corollary, this suggests that the 
peak position identified by our algorithm from ChIP-seq read data denotes the actual 
binding site of the protein. This level of resolution has not been achieved before in 
previous studies of E2F4 binding since they all used lower resolution tiling array 
approaches to identify binding sites. 
Pathway analysis suggested that all E2F4 motifs were likely used to regulate the 
cell cycle pathway. Specifically, motif 1 (RTTYGAA) which was similar to a cell cycle 
repressor element, CHR (cell-cycle homology region; TTGAA) where E2F4/RB 
complexes were recruited (Yang et al, 2008; Zwicker et al, 1995), was highly enriched 
only among cell cycle pathway genes. Co-enrichment analysis identified several TFs that 
may co-regulate genes with E2F4. For example, many E2F4 targets such as E2F1, b-
MYB, and HSORC1 contain SP1 motifs near E2F binding sites (Li et al, 1997); MYB 
and YY1 are known to be transcriptional partners of several E2F proteins (Giangrande et 




binds to several cell cycle related E2F target promoters, and helps other regulatory 
proteins (PCAF and p300) gain access to target promoters to activate downstream genes 
(Caretti et al, 2003). 
E2F4 was classified as a repressor of cell proliferation because it binds to its 
target promoters involved in cell cycle progression in G0/G1 and represses them. Even 
though E2F4 was previously known as a repressor, some studies introduced the 
possibility that E2F4 may function as an activator by showing that it was able to trigger 
cell proliferation. In addition, overexpression of E2F4 in transgenic mice induced cell 
propagation in the basal layer of the epidermis (Lukas et al, 1996; Pierce et al, 1998). Our 
genome-wide identification of E2F4 binding targets and transient perturbation of E2F4 
followed by gene expression profiling indicate that E2F4 can indeed function as either an 
activator or a repressor of transcription. In particular, cluster I, consisting of genes 
activated by E2F4 and DP-1, contains genes implicated in positive regulation of the cell 
cycle, suggesting that E2F4 may function as a cell cycle activator.  
Our data further revealed that E2F4 is capable of repressing the expression of 
several miRNAs such as the mir-17-92 cluster, mir-22, and let-7a, albeit by modest 
amounts. The mir-17-92 cluster, encoding 6 miRNAs, is known to be regulated by MYC, 
E2F1, and E2F3, and this regulation promotes cell proliferation (O'Donnell et al, 2005; 
Pickering et al, 2009; Woods et al, 2007). E2F4 may mediate its anti-proliferative role 
partly by repressing the mir-17-92 cluster. E2F4 is not only capable of repressing the 




binds to the mir-17-92 cluster promoter and directly regulates it, suggesting that it 
mediates a feedback loop for the regulation of the miR-17-92 cluster. Another miRNA 
target of E2F4, let-7a, is able to downregulate the expression of MYC as well as trigger 
cell cycle arrest (Sampson et al, 2007). Thus, E2F4 can not only regulate the expression 
of MYC directly (Chen et al, 2002), but also indirectly via let-7a, suggestive of another 
regulatory feedback loop. In summary, our genome-wide E2F4 target analysis reveals 
diverse functions of E2F4 and provides support for E2F4 functioning both as a long-
range transcriptional regulators of mRNAs as well as a miRNA regulator, which allowed 


























  Chapter 3: Lineage-specific and combinatorial usage revealed by 





In order to maintain cellular life, cells must rapidly and appropriately respond to 
various environmental stimuli by regulating the expression of a specific group of genes. 
Sequence-specific transcription factors (TFs) can recognize functional DNA elements in 
a sequence-specific manner, enabling cells to cope with diverse internal and external 
stimuli by regulating only a subset of their target genes (Vaquerizas et al, 2009). In 
addition, cellular diversity in a multicellular organism like the human is achieved in part 
by distinct programs of gene expression at the level of transcription, which in turn are 
mediated by sequence-transcription factors (TFs). Human has approximately 1,400 
sequence-specific TFs (Vaquerizas et al, 2009). Identifying the genomic binding 
locations of TFs offers a means of understanding how their activities shape gene 
expression. Recent genome-wide studies have revealed more precise locations of 
functional elements including promoters, enhancers, insulators, and silencers with which 
several sequence-specific TFs interact (Cuddapah et al, 2009; Kim et al, 2007; Kim et al, 




location information is available for only a limited number of TFs in a few cell lines so 
that the majority of TFs still remain to be studied.  
The Encyclopedia of DNA Elements (ENCODE) pilot project investigated 1 % of 
the human genome (30Mb) covering 44 genomic regions including protein-coding and 
non-coding loci (Birney et al, 2007). In its current second phase, the ENCODE 
Consortium is scaling up to whole genome studies in order to identify genome-scale cis-
regulatory elements in a wide variety of cell lines. As a part of this ENCODE2 project we 
investigated the genome-wide binding sites of c-Myc (MYC), CTCF, and RNA 
polymerase II (Pol II) on the human genome. 
In multiple signaling cascades, MYC plays an important role as a central hub 
integrating diverse internal and external stimuli (Wierstra & Alves, 2008). MYC, as a 
global regulator of transcription, can regulate approximately 15 % of human genes (Dang 
et al, 2006; Meyer & Penn, 2008) that are implicated in a wide range of biological 
functions including cell cycle progression, differentiation, apoptosis, DNA repair, 
angiogenesis, chromosomal instability, and ribosome biogenesis (Adhikary & Eilers, 
2005; Dai & Lu, 2008; Dang, 1999; Knoepfler et al, 2006). In addition, MYC is a crucial 
factor for lineage-specific cell growth and metabolism so that it decides cell fate 
(Grandori et al, 2000). However, it is not clear how many lineage-specific genes are 




The CCCTC binding factor (CTCF) is evolutionally highly conserved and 
ubiquitously expressed. CTCF contains 11 zinc-fingers DNA binding domains through a 
combinatorial use of which CTCF can be recruited onto diverse cis-regulatory sequences 
(Bell et al, 1999; Burcin et al, 1997; Filippova et al, 1996; Vostrov & Quitschke, 1997). 
This versatile binding capacity of CTCF allows multiple regulatory functions including 
gene activation as well as repression, hormone-responsive gene silencing, imprinting of 
genetic information, enhancer blocking, and chromatin insulation (Burcin et al, 1997; 
Filippova et al, 1996; Hark et al, 2000; Vostrov & Quitschke, 1997; Vostrov et al, 2002). 
Aberrant expression of either CTCF or MYC can cause detrimental consequences such as 
developmental disorders, disease, and a wide range of cancers (Ladomery & Dellaire, 
2002; Ohlsson et al, 2001; van Riggelen et al, 2010). 
Pol II is responsible for synthesizing precursors of mRNA, miRNA, and most 
snoRNA from DNA as a template (Sims et al, 2004). Following signal transduction 
cascades, activated sequence-specific TFs bind onto cis-regulatory elements of genes and 
recruit co-activators including histone modifying enzymes as well as chromatin 
remodelers. These sequential recruitments further facilitate open chromatin, enabling 
general transcription machineries including Pol II and several auxiliary factors to 
assemble near the transcription start sites (TSS) of genes. Most recent genome-wide 
mapping of Pol II in diverse tissues in mice identified many novel promoters and 




Recent studies have also reported the interaction of Pol II with CTCF as well as 
MYC (Chernukhin et al, 2007; Rahl et al, 2010). CTCF has been shown to interact with 
Pol II both in vitro and in vivo, with significant co-localization of Pol II and CTCF 
observed in the nucleus (Barski et al, 2007; Chernukhin et al, 2007). In addition, CTCF-
Pol II protein complexes are found in distal genomic regions, 1.5-15kb away from the 
nearest (TSS), and remain intact until Pol II release (Chernukhin et al, 2007). Genome-
scale location analysis of CTCF has also revealed that approximately one-third of about 
20,000 CTCF binding sites are located in protein-coding regions of the human genome 
(Barski et al, 2007). However, it is unclear how many Pol II binding sites are co-localized 
with CTCF genome-wide, whether there is lineage-specific co-localization in various 
tissue types, and how the interaction between Pol II and CTCF affects expression of their 
target genes. MYC can promote phosphorylation of the C-terminal domain of Pol II as 
well as mRNA cap methylation (Chernukhin et al, 2007). Most recently, c-MYC has been 
reported as a major regulator of the release of paused Pol II more so than recruiting Pol II 
at its promoters (Rahl et al, 2010) . 
In order to identify the genome-wide binding sites of CTCF, MYC, and Pol II in 
diverse cell lines and elucidate possible combinatorial TF binding effects, we performed 
chromatin immunoprecipitation (ChIP) followed by high-throughput sequencing (ChIP-
seq) experiments. Across eleven cell lines we found an average number of binding sites 
on the order of 45,000 for CTCF, 30,000 for Pol II and 8,000 for MYC. Among those we 




properties. Interestingly, we also found that binding of either CTCF or MYC upstream of 
a gene, or even in the gene body, increases the expression of their targets genes, and that 
combinatory binding of MYC and Pol II notably enhanced expression of their target 
genes compared to binding of MYC or Pol II alone. Thus, our genome-scale investigation 
of sequence-specific TF binding sites advances the genome-wide understanding of the 
categories of genes governed by MYC, CTCF, and Pol II in diverse cell types, how the 
combinatory binding of Pol II with MYC or CTCF affects the expression of their target 















3.2 MATERIALS AND METHODS 
Cell culture 
The ENCODE Consortium has designated GM12878, K562, HeLaS3, HepG2, HUVEC, 
NHEK and H1ESC cells as Tier 1 and Tier 2 cell lines. The source and cell growth 
conditions for these cells are described at the ENCODE web site 
(http://genome.ucsc.edu/ENCODE/cellTypes.html). Additional cell types analyzed in this 
study listed in Table 3-1 were cultured under standard culture conditions. Cells were 
grown to appropriate numbers and processed for chromatin immunoprecipitation. 
ChIP sequencing 
ChIP assays were performed as described previously (Lee et al, 2011). Briefly, 
cells were cross-linked with 1% formaldehyde for 10 min at room temperature. The 
cross-linked cells were sheared by sonication until average fragmented DNA size reached 
500 bp, then TF-DNA complexes pulled down with specific antibody for CTCF (07-729, 
Millipore), MYC (SC-764X, Santa Cruz Biotech), and Pol II (MMS-126R, Covance 
Inc.). ChIP for Pol II was performed by Ryan, a graduate student in Iyer lab and ChIPed 
DNA was sequenced primarily using single-end Illumina Solexa sequencing technology, 




Peak calling and statistical correction 
Sequencing generated 32-36 bp of short reads from the ends of ChIP-enriched 
DNA fragments and from corresponding non-enriched control DNA fragments (Input). 
These short reads were mapped back to the human genome (hg18) using the Maq aligner  
(Li et al, 2008). Total number of mapped reads from ChIP and Input sequencing are listed 
in table S1. In order to identify precise binding sites of a TF from high-throughput 
sequencing data, we used a Parzen window based algorithm as described previously with 
minor modifications (Lee et al, 2011; Shivaswamy et al, 2008). Each aligned read was 
assigned a value representing the frequency of observing that read in the sequencing 
library. After extending reads in the 3' direction by half (67 bp) the sequencing library 
fragment length, a Gaussian kernel with a defined bandwidth was applied to weight the 
occupancy scores based on the proximity of neighboring nucleotides. Local maxima of 
these Parzen scores were used to define binding sites along with IQR-based calculations 
to determine the adjacent region of highest read density. The total number of reads was 
recorded for each binding site, along with chromosomal locus information and the 
position of maximum weighted read density. The resulting set of candidate binding sites 
was then subjected to input correction, filtering, and statistical significance determination 
steps. 
First, to normalize for non-specific binding represented by the Input control for 




Input site (within 200bp) with the highest read count. A binomial P-value was computed 
for each binding site under the null hypothesis that ChIP and Input reads are equally 
likely. A simple ratio of total ChIP to Input reads was used to normalize for differences in 
read depth before applying the binomial cdf; however, to avoid inflating read numbers, 
the library with higher sequencing depth was always scaled downward. Next, the 
binomial P-value was used to adjust the binding site‟s read count by calculating the 
number of ChIP reads there would be if no input were present, solving pbinom(input, 
chip+input, .5) = pbinom(0, corChip, .5) for corChip. This binomial P-value corrected 
number of reads (binCorRd) score was recorded for each binding site and was used in all 
further occupancy score-based analyses. 
Initial filters were then applied. Input-dominated binding sites were discarded and 
only sites where the sequencing-depth-scaled ChIP read count exceeded Input were 
retained. Binding sites in the standard Duke-defined ENCODE2 filtering regions were 
also discarded. Finally, sets of high-confidence sites were identified based on the ECDF 
of the filtered binding sites. Strictly quantitative determination of target cutoff levels is an 
elusive goal given the large number of data sets under analysis, their temporal separation 
as underlying sequencing technology advanced, differences in both library preparation 
and sequencing-run quality, and notable differences in binding characteristics among the 
factors. Qualitatively, CTCF binding sites tend to be narrow and sharp while the dynamic 
Pol II transcription machinery produces broad, dense binding signals, and MYC sites 




percentage level of highest-scoring binding sites was chosen for each TF: 4% for CTCF, 
2% for Pol II and 0.5% for MYC, and a corresponding threshold binCorRd score cutoff 
was identified for each data set. Since this binCorRd score has both read density and 
significance probability components, minimum and maximum score considerations were 
applied across all datasets to account for experiment-specific quality differences. Data 
sets with target percentile cutoff scores below that roughly corresponding to a binomial 
P-value of .0005 had their thresholds adjusted upwards (removing the lowest scoring 
sites) and data sets with scores corresponding to a binomial P-value of 1E-10 had 
thresholds adjusted downward (capturing additional high-scoring sites). The final count 
of significant binding sites identified for each data set, along with the corresponding 
cutoff scores and percentage of top-scoring sites represented, is shown in Table 3-2. 
Mapping binding sites to gene features 
CTCF, MYC, Pol II binding sites were mapped to within ± 2 kb from the TSSs of 
all annotated genes generated by combining gene lists from RefSeq, UCSC, Ensemble, 
Vega, and SIB downloaded from UCSC genome browser (http://genome.ucsc.edu/cgi-
bin/hgTables?command=start), resulting in a total of 348,592 TSSs. We defined a distinct 
gene as a combination of chromosome number, start, and number of exons unique across 
annotation files. To assess the number of sites mapped to different genomic features, we 
assigned one site to only one feature using following hierarchy: promoter > upstream > 




TSSs of genes. A promoter was defined as 2 kb up- and downstream from the TSS, 
upstream as between 2 kb and 20 kb upstream from the TSS. Binding sites that could not 
be mapped to within 20 kb upstream of any TSS, nor to any exon or intron, were termed 
intergenic. Genes that had TF binding sites within the promoter were defined as TF target 
genes. 
Mapping binding sites to CpG island 
CTCF, MYC and Pol II binding sites in CpG islands were investigated by 
mapping their binding sites in CpG islands downloaded from UCSC genome brower. 
Binding sites of a TF were assigned into CpG binding peaks as long as the sites were 
located within CpG islands. 
Mapping binding sites of bidirectional promoters 
We defined a bidirectional promoter as a genomic region that is not only 
exclusively upstream from the gene but also between the TSSs of two genes which were 
separated by maximum of 2kb in length and divergently transcribed from opposite 
strands. Based on this criterion, we identified 1233 bidirectional promoters corresponding 
to 2466 genes (11.06 %) among the 22,279 genes annotated in RefSeq. In order to 
investigate enrichment of CTCF, MYC and Pol II binding in bidirectional promoters, we, 
first, searched target genes of CTCF, MYC and Pol II by mapping their binding sites 
within 2Kb upstream from all TSSs annotated in RefSeq. Among those target genes, we 




hypergeometric distribution, we finally calculated significance of CTCF, MYC and Pol II 
enrichment in bidirectional promoters. 
Profiling TSS/TTS binding 
A 10 kb region around the TSS including both 10 kb upstream and 10 kb 
downstream was binned with a 50 bp bin, and then CTCF, MYC, and Pol II binding sites 
were mapped to each bin. The score of a peak that was mapped to each bin was assigned 
into the bin. A profile of average peak score across TSSs was generated by averaging 
corresponding bin scores across all genes. The same procedure was applied to generate 
TTS profiles. 
Overlap analysis 
Overlapping binding sites among different ChIP-seq datasets were evaluated by 
scanning overlapping sites across the genome whose centers resided within a 300bp 
window of each other. In this evaluation, we compared the binding sites of one ChIP-seq 
dataset at a threshold cut-off with the binding sites of another ChIP-seq dataset at a looser 
threshold obtained by multiplying the original threshold by 0.5 to avoid false positive 
cell-type specific binding sites arising to overlapping binding sites in another cell type 




Pol II analysis 
Relationship between a Pol II binding pattern and its consequent gene expression was 
investigated in 4 Pol II binding groups (HH: high occupancy in both the promoter and the 
body of a gene; HL: high occupancy only in the promoter; LH: high occupancy only in 
the gene body; LL: low occupancy signal in both promoter and gene body) that were 
divided based on the occupancy signal intensity from proximal promoters (ranging from 
2 kb upstream to 300bp downstream from a TSS) to gene bodies. First, we assigned 
occupancy score into promoters and gene bodies by mapping Pol II binding in them. 
Next, using empirical cumulative distribution function (ECDF), we rank both promoter 
and gene body scores from highest to lowest occupancy signal. To classify 4 Pol II 
binding patterns we used high occupancy threshold as 0.7 and low as 0.3 in ECDF. We 
considered HL group as genes having paused Pol II. We also determined the significance 
of enrichment of CTCF and MYC around Pol II sites in promoters as well as gene bodies 
using the hypergeometric distribution function. 
Expression profiling 
RNA expression profiling was carried out independently as part of the cell line 
phenotyping component of the ENCODE project. For GM12878, K562, HeLaS3, HepG2 
and H1ES, RNA was generated from the same culture of cells used for ChIP; for 
HUVEC, NHEK, MCF7, FB8470, FB0167P and H54 cells, different cultures were used 




these data were deposited to the Gene Expression Omnibus (GSE15805) (Boyle et al, 
2011). 
Motif analysis 
Motifs of sequence-specific TF (CTCF and MYC) binding sites were investigated 
using discriminating matrix enumerator (DME) (Smith et al, 2005). First, we divided the 
binding sites of a TF into three group: strong (top 25%), moderate (middle 50%), and 
weak (bottom 25%) binding sites based on ChIP score, and considered the top 500 sites 
from each group for motif search. A 200 bp region obtained from 100 bp up-and down-
stream sequences from the center of a peak was extracted from the human genome 
assembly hg18, and then applied for motif discovery. A random background was 
generated by sampling 200 bp of 100,000 sequences from the genome. Since 
approximately 15% of CTCF sites and 50% of MYC sites across the cell lines analyzed 
occurred in promoters ranging from 2 kb upstream to 2 kb downstream of TSSs of genes, 
this promoter binding portion of each factor was maintained in the random sample 










ChIP-seq identifies genome-wide high confidence binding sites for CTCF, MYC, 
and Pol II  
We performed ChIP-seq for CTCF, MYC, and Pol II in 11 different human cell 
types including primary, disease, and cancer cells to identify their the genome-wide 
binding locations. In parallel with sequencing chromatin immunoprecipitated DNA we 
also sequenced a non-enriched input DNA control for each cell type. We generated at 
least two biological replicates of ChIP-seq data for each factor in all cell types except H1 
ES and NHEK cells (Table 3-1).  












To identify binding sites of CTCF, MYC and Pol II, we first aligned the raw 
sequence reads onto the human reference genome, and then used a Parzen window kernel 
density estimation algorithm to detect binding sites from each replicate dataset 
(Methods). Next, we investigated the reproducibility of our ChIP-seq data by analyzing 
the overlap between two biological replicates for each factor in a given cell line. In most 
cell lines, CTCF and Pol II showed high consistency between replicates (80% overlap), 
and MYC exhibited moderate reproducibility ranging from 50-80% (Fig 3-1A). 
Therefore, we combined reads from all replicates from each factor-cell line combination, 
and then performed peak detection again to generate an initial set of candidate binding 
sites for CTCF, MYC, and Pol II (Fig.3-1B). In order to minimize false positives, we 
normalized TF binding scores with corresponding input scores after correcting for 
sequencing depth. We calculated P-values, normalized scores and determined appropriate 
thresholds for targets (Methods; Table 3-2). Most subsequent analysis was performed 
using putative binding sites at this target cutoff level, except where indicated.  
Although there is some variation in the number of binding sites of each factors in 
11 cell types, CTCF, MYC, and Pol II had approximately 45,000, 8000, and 30,000 sites 
on average, respectively. Particularly for Pol II, these numbers include partially 
overlapping sites in each cell and thus don't directly reflect the number of genes that are 
potentially targeted. For each factor, additional cell line continued to show additional 
binding sites rather than reaching saturation (Fig. 3-1C), implying many cell-type specific 




















Figure 3-1. ChIP-seq produces genome-wide high confidence binding sites of CTCF, MYC, and 
Pol II in diverse cell lines. 
(A) Overlap analysis between two biological replicates of ChIP-seq data for each factor in each cell line. 
The top 50,000 CTCF, 15,000 MYC, and 30,000 Pol2 binding sites from one replicate were compared with 
the top 65,000, 30,000, and 50,000 binding sites from the other replicate, respectively. The Y-axis shows 
percent overlap between replicates for the cell types indicated on the X-axis. Overlap values for Pol II are 
not shown for Keratinocytes and FB8470 because only one replicate was used for Keratinocytes, and no 
data was generated for Pol II in FB8470. (B) Occupancy signal in ChIP-seq tracks shows distinct TF 
binding sites relative to background. Blue, red, and green colors indicate CTCF, MYC, and Pol II 
occupancy signals respectively. Chromosome coordinate are shown on top. Each lane shows a TF ChIP-seq 
track from one cell line. Gene name and location were shown in bottom track, with direction of 
transcription with arrows. (C) Additional cell reveal increasing numbers of CTCF, MYC, and Pol II 




Table 3-2. The Number of CTCF, MYC, and Pol II binding sites at a cutoff threshold in 















CTCF prefers to bind onto intergenic regions while MYC and Pol II mainly 
associate with promoters 
Since it is widely accepted that sequence-specific TFs have a strong binding 
preference for the TSSs of genes (Ren et al, 2002; Tabach et al, 2007), we examined the 
average binding profile of CTCF, MYC, and Pol II around the TSS in 11 cell types.  
Consistent with previous studies, strong occupancy signal of binding sites was enriched 
around the TSS (Fig. 3-2A). Importantly, our ChIP-seq score normalization (Methods) 




factors and cell types. As Pol II binding sites are expected to show higher enrichment in 
the promoters or genic regions of transcribed genes rather than the intergenic regions, we 
found that Pol II, regardless of cell line, showed the strongest propensity to bind at TSSs. 
The two sequence-specific TFs (CTCF and MYC) also showed a strong preference for 
binding near TSSs (Fig. 3-2A). These three factors often occupied at TSS in a 
combinatorial manner, as illustrated in the example track image in Fig 3-1B. In contrast 
to the TSS profiles, all three factors showed depleted binding near the transcription 
termination sites (TTSs) of genes where Pol II disassembles its transcriptional 
machineries (Fig. 3-2B).  
 In addition to averaging TSS profiling, we also examined gene-wise occupancy 
signals of these three factors within ± 10 kb from TSSs. Strikingly, the patterns of 
occupancy signals were maintained across the cell types we analyzed for all three factors 
(Fig. 3-2C). Furthermore, subset of genes has its own unique occupancy pattern, in 
particular distinctive CTCF binding signal in distal as well as gene bodies of many genes 


























Figure 3-2. The genome-wide distribution patterns of CTCF, MYC, and Pol II binding sites in 
diverse cell types. 
(A) Average binding profiles of CTCF, MYC, and Pol II sites within ± 1.5 kb from all annotated TSSs and 
(B) TTSs in 10-11 different cell types. Zero in X-axis indicates transcription start sites of all annotated 
genes. (C) Patterns of CTCF, MYC and Pol II occupancy around genes. The heat map shows normalized 
occupancy scores for each gene with available data (rows) within ±10 kb from TSS (columns are 100 bp 
bins). Arrow indicates TSS and direction of transcription. For each factor, data in the first listed cell line 
was clustered using K-means clustering and data for the other cell lines are displayed in the same order. 
The ordering of genes is not the same for the 3 factors. The number of genes listed in the Y-axis is 13,610 




Next, we investigated the distribution of CTCF, MYC, and Pol II binding sites 
across the genome by mapping their binding sites relative to RefSeq annotated genes or a 
combined gene set including RefSeq, UCSC, Ensembl and Vega annotated genes from 
the UCSC genome browser (http://genome.ucsc.edu/). We defined a region within ± 2 kb 
from a TSS as a promoter, between 2 kb and 20 kb from a TSS as an upstream region, 
and more than 20 kb away from a TSS (not including exons or introns) as an intergenic 
region. We found that each factor had a distinctive pattern in the distribution of its 
binding sites across the genome. For instance, MYC varied substantially, depending on 
the cell line, in the proportion of its binding sites at promoters from ranging from 45 % to 
75 % (Fig. 3-3A). The ES cells however were an outlier in this regard, with only 6% of 
its binding sites at promoters. Unlike MYC, Pol II and CTCF showed a relatively 
constant proportion of their sites (~70 % and 15% respectively) at promoters across all 
the cell types we analyzed (Fig. 3-3A). More than 60% of CTCF binding sites, across all 
cell types, were in distal upstream and intergenic regions. This distinct distribution of 
CTCF binding sites from other factors is consistent with previous genome-wide binding 
studies of CTCF in individual cell types, which showed that CTCF binding sites were 
widely dispersed across the genome (Barski et al, 2007; Schmidt et al, 2010). Since TF 
binding to a proximal promoter is most likely to regulate the expression of its immediate 
downstream gene, comparing the proportion of TF binding sites in TSS to the proportion 
of all TSS bound by the TF provides an indication of promoter selectivity of a TF. This 




of all genes and ~15 % of CTCF sites may regulate as much as a quarter of all genes in 
the genome (Fig. 3-3B). Both CTCF and Pol II showed small variations in the number of 
putative target genes across the different cell types, while MYC generally exhibited 
substantial variation, from 10% to 35% of genes, CTCF regulates functionally conserved 
genes across different cell lines, whereas MYC may modulate various functional classes 
of genes in different cell lines.  
In addition to the promoter binding preference of MYC and Pol II, they showed 
significantly higher occupancy scores at promoters than in other genomic regions (Fig. 3-
2F). In contrast to MYC and Pol II, CTCF showed significantly higher occupancy signals 
in upstream regions rather than promoters (Fig. 3-3C), consistent with a prominent role 
for CTCF as an insulator binding protein, functioning between a promoter and an 
enhancer. Consistent with these findings, about half of all MYC and Pol II sites were 
located in CpG-islands, which are known to be associated with promoters, whereas the 
majority of CTCF binding sites were located in CpG-depleted regions (Fig 3-4A). 
Conversely, the binding sites of these three factors in CpG islands were enriched for 
promoters (Fig 3-4B). Moreover, the binding sites of CTCF, MYC and Pol II in CpG 
islands had significantly higher occupancy scores than their sites in non-CpG-containing 
sites across all cell types (Fig. 3-4C). Taken together, these results indicate that MYC and 
Pol II regulate genes primarily by binding to proximal promoters, with MYC exhibiting 




expression of a more conserved set of targets by associating with distal cis-regulatory 












Figure 3-3. The genome-wide distribution patterns of CTCF, MYC, and Pol II binding sites in 5 
different genomic regions in diverse cell types.  
 (A) Pie charts show the distribution of CTCF, MYC, or Pol II binding sites in 5 different genomic regions. 
A promoter is defined as a region within ± 2 kb from the TSS of a gene, upstream is between 2 kb and 20 
kb upstream from the TSS, and intergenic is a region excluding a promoter, upstream, intron and exon. 
Each locus was coded with a different color. (B) Percent binding sites of each TF within ± 2 kb from TSSs 
and percent TSSs within ± 2 kb from binding sites of TFs. Circle size correlated with number of binding 
sites. Each color represents a specific factor. An arrow points a specific cell line. (C) Box plots showing 
ChIP-seq score distribution of CTCF, MYC, and Pol II binding sites in 5 different genomic regions across 
the cell lines we analyzed. MYC and Pol II binding sites in promoters had significantly higher ChIP scores 
than other genomic regions, whereas CTCF had higher ChIP score in upstream. P-value was calculated by 


























Figure 3-4. The genome-wide distribution patterns of CTCF, MYC, and Pol II binding sites in 
CpG and non-CpG sites.  
(A) CTCF prefers to bind in non-CpG islands. X-axis shows a factor and Y-axis represents % binding sites 
in CpG and non-CpG loci. CpG and non-CpG sites are labeled with red and blue. (B) The distribution of 
CpG and non-CpG binding sites of CTCF, MYC, and Pol II in 5 different genomic regions. (C) Boxplots 
show a significantly higher occupancy signal of MYC and Pol II binding sites in CpG island than in non-







CTCF, MYC and Pol II sites are positively correlated with gene density across the 
genome  
The human genome has different gene density from one locus to another, with 
gene-rich or gene-poor regions are disseminated across the genome. (Lander et al, 2001). 
Since all three TFs occupied distal binding sites in addition to promoters, we investigated 
the relationship between TF binding sites and gene density. The correlation coefficient of 
CTCF, MYC, and Pol II binding sites with gene density in 2 Mb bins in K562 was 0.81, 
0.79 and 0.82, respectively (Fig. 3-5A) and similar correlation was observed across all 
analyzed cell types (Fig3-5B), indicating a positive correlation between TF binding sites 
and gene-density. Interestingly, although our genome-wide binding analysis of CTCF 
showed a clear preference of CTCF for intergenic regions (Fig 3-3A), its binding was 
nonetheless positively correlated with gene density. Excluding CTCF binding sites within 
genes as well as up to 20 kb upstream of TSS did not completely abrogate the correlation 
between binding sites and gene-density (Fig 3-5B), suggesting that CTCF regulates gene 




















Figure 3-5. TFs‟ binding sites are positively correlated with gene density. 
(A) Pearson correlation coefficient (r) was calculated using the number of a TF binding sites and the 
number of genes in 2Mb bin across the genome. Red, blue, and green represent CTCF, MYC, and Pol II 
respectively. A linear line was drawn by fitting data into linear regression. (B) Pearson correlation 
coefficients between the number of CTCF, MYC, and Pol II binding sites and gene density. Removing all 
binding sites of CTCF, MYC, and Pol II still shows a positive correlation. Shuffling of data exhibited no 




MYC is enriched in divergent promoters 
It has been reported that the motifs of some sequence-specific TFs including 
GABPA, MYC, E2F1, E2F4, and YY1 are overrepresented in bidirectional promoters 
(Lin et al, 2007), and we have previously reported that E2F4 binding sites are 
overrepresented in bidirectional promoters (Lee et al, 2011). We therefore examined 
whether any of the transcription factors showed a bias in binding to bidirectional 
promoters. Based on annotations for 22,279 genes in RefSeq, there are 1233 promoters 
corresponding to 2466 bidirectionally transcribed genes in the human genome. In the 
majority of cell types, bidirectionally transcribed genes were significantly 
overrepresented among the targets genes of Myc where it bound within 2 kb of the TSS 
(Fig. 3-6A). This overrepresentation of bidirectional promoters was specific to Myc 
binding sites as it was not observed for CTCF and Pol II binding sites. We also found that 
in most cases, the binding of CTCF, MYC, or Pol II at bidirectional promoters activated 




















Figure 3-6. MYC is enriched in bidirectional promoters.  
(A) Bar graphs show MYC enrichment in bidirectional promoters. X-axis shows different cell types. Y-axis 
shows 1-log (P-value) calculated using hypergeometric distribution. (B) TFs binding in bidirectional 
promoters activates both genes equally, regardless of its binding distance from transcription start site of 





CTCF and Pol II sites are ubiquitous, whereas MYC sites are cell-type specific 
Different tissues require distinct expression patterns of certain groups of genes to 
fulfill cell-type specific demands or to determine cell fate during differentiation. Visual 
inspection of CTCF, MYC and Pol II sites in the genome browser showed that all three 
factors had cell-type specificity to some extent (Fig. 3-7A). To examine the cell-type 
specific binding sites of CTCF, MYC, and Pol II, we first analyzed overlap of TF binding 
sites in 11 different cell lines including primary as well as cancer cells. When the centers 
of binding sites overlapped within 300 bp distance in all cell lines analyzed we defined 
them as ubiquitous; otherwise the sites were considered as cell-type specific (Methods). 
Among cell-type specific sites, we further classified the binding sites found in only one 
cell line as unique binding sites, recognizing that analysis of additional cell types might 
reveal these to be not truly unique. We found that overall, the MYC binding sites were 
highly divergent from one cell line to another, and less than 10% of MYC sites were 
ubiquitous, suggesting that a large portion of MYC sites in a given cell line is cell-type 
specific (Fig. 3-7B). Interestingly, the majority of cell-type specific binding sites of MYC 
were detected in ES cells. In contrast to MYC, more than half of CTCF binding sites 
were ubiquitous across the 11 cell lines. More than three quarters of CTCF binding sites 
were identified in at least 7 cell types, with less than 3 % of CTCF sites unique in any of 
the cell types we analyzed, except ES (6.4%) and MCF7 (3.4%) (Fig 3-7B). Similarly, 
Pol II also exhibited a strong binding preference for ubiquitous sites; however, unlike 




type (an average of 7.7 % across cell types). Taken together, these results suggest that 
MYC binding predominantly regulates unique cell type functions whereas CTCF‟s 
regulatory role is largely consistent across diverse cell types. Moreover, the unique 
binding sites of CTCF, MYC and Pol II had lower occupancy scores across all cell types, 
compared with their ubiquitous binding sites (Fig. 3-8A), suggesting that cell-type 
specific functions might be regulated by several TFs in a combinatory manner in which 
TFs cooperate to bind DNA sites particularly favorable for the lower occupancy TFs.  
In order to assess the number of target genes of the unique or ubiquitous sites of 
CTCF, MYC, and Pol II, we assigned the downstream gene of a TF-bound promoter as 
its target gene. Across the 10-11 analyzed cell types, we found an average number of 91, 
155, and 233 unique targets and 3,321, 185, and 8,167 ubiquitous target genes, 
respectively, for CTCF, MYC, and Pol II (Fig 3-8B). We also found most of the 
ubiquitous sites of MYC and Pol II occurred in promoters, while their unique sites were 
found in distal as well as intronic regions (Fig 3-8C), suggesting that the unique sites of 
MYC and Pol II may play roles as distal regulatory elements like enhancers. In addition, 
we found that the cell-type specific sites of CTCF, MYC, and Pol II lacked CpG islands 


















Figure 3-7. CTCF, MYC, and Pol II have many cell-type specific regulatory elements.  
(A) Many cell-type specific sites were visualized in track images of genome browser. 
Chromosome coordinate are shown on top. Each lane shows a TF ChIP-seq track from one cell line. Gene 
name and location were shown in bottom track, with direction of transcription with arrows. Cell-type 
specific sites of CTCF, MYC, and Pol II were highlighted with color bar of sky blue, orange, and pink 
respectively. (B) Heat maps show the distribution of cell-type specific and ubiquitous binding sites of each 
factor in 10-11 different cell types. X-axis represents the number of cell types sharing a binding site across 
the cell types. „1‟ represents „unique sites‟ that were found in only one cell line, „All‟ indicates „ubiquitous 
sites‟ that were found in all the cell types we examined. Cell-type specific sites are all sites except for 
ubiquitous sites. Y-axis represents cell types. Color bar indicates percent binding sites. The sum across X-



















Figure 3-8. Cell type specific binding properties of CTCF, MYC, and Pol II.  
(A) Boxplots exhibit the ChIP-seq score distribution of unique and ubiquitous sites across the cell types 
analyzed. Unique sites have significantly lower ChIP-seq score than the other sites. One, some, and all 
indicate unique sites, cell-type specific sites except unique ones, and ubiquitous sites, respectively. P-
values were calculated by Wilcoxon rank sum test. Three stars (***) indicate P-value of zero. (B) The 
number of unique and ubiquitous target genes of CTCF, MYC, and Pol II in diverse cells. The downstream 
genes of TF-bound promoters (within ± 2 kb from TSSs) are considered as target genes. (C) The 
distribution patterns of unique and ubiquitous binding sites of CTCF, MYC, and Pol II across the cell types 
analyzed in 5 different genomic regions. X-axis represents each factor in either unique or ubiquitous sites. 
Y-axis shows % binding sites in the genomic regions. (D) Percent CpG and non-CpG sites in unique and 
ubiquitous binding sites of three factors across the cell types analyzed. X-axis represents each factor in 







In order to examine biological functions targeted by the unique and ubiquitous 
binding sites of the three TFs we used the Genomic Regions Enrichment of Annotations 
Tool (GREAT) (McLean et al, 2010). In particular, unique sites frequently targeted genes 
in functional categories that were relevant to the biological characteristics or tissue of 
origin of a cell type (Table 3-3). Interestingly, even though the unique sites of Myc 
tended to have the lowest ChIP-seq scores in our overall analysis, this class of site 
targeted genes in meaningful functional categories more frequently than CTCF unique 
sites, which had higher scores. Moreover, the unique sites of Pol II and MYC frequently 
targeted overlapping functional categories in several cell types including GM12878, 
HepG2, HUVEC, and NHEK, suggestive of combinatorial usage of these two factors in 
specifying cell function (Table 3-3). Ubiquitous binding sites might be expected to target 
housekeeping functions; for example ubiquitous MYC binding site target genes showed 
moderate enrichment in translational elongation (Table 3-4), consistent with previously 
reported functions for Myc in regulating translation and cell growth (Boon et al, 2001; 









Table 3-3. Functional categories enriched among target genes occupied by unique sites 























Table 3-4. Functional categories enriched in ubiquitous binding sites of CTCF, MYC, 





















In order to identify cancer-specific binding sites, we also looked into cancer-
specific binding sites that were present only in the cancer cell lines we investigated. We 
grouped the cell types into two categories: normal (GM12878, FB8470, HUVEC, NHEK 
and H1ESC) and cancer (HelaS3, K562, HepG2, MCF7 and H54). By comparing binding 
sites between these two groups, we found several cancer-specific binding sites of CTCF, 
MYC, and Pol II where binding was observed in all the cancer cell types but not in the 
normal cells. For example, Pol II occupied the promoters only in cancer cells, of 6 
cancer-related genes including an isoform of PDE11A (Faucz et al, 2011; Libe et al, 
2008), SATB2 (Patani et al, 2009), ALDH3B1 (Marchitti et al, 2010), SIX1 (Micalizzi et 
al, 2009), RAGE (Logsdon et al, 2007), and AK022914 (Zhao et al, 2007) as well as 2 
more genes (PASK and MNX1) whose deregulation has not been reported in cancer (Fig. 
3-9A). Interestingly, most cancer-specific binding sites were also observed in fibroblasts 
derived from a patient affected with Progeria, a disease characterized by rapid aging. This 
could reflect an underlying biological relationship between cancer and Progeria. Some of 
the cancer-specific binding targets showed higher expression in cancer cells compared to 
normal cells in accord with binding (Fig 3-9B). This raised the question of whether 
binding provides independent information in separating normal vs cancer, or is simply 
















Figure 3-9. ChIP-seq revealed several cancer-specific binding sites. 
(A) 8 cancer-specific sites were shown in track images of genome browser. Cancer, normal, disease 
(Progeria) cells were distinguished by color-coded Y-axis, pink for normal, orange for cancer, and blue for 
Progeria. Chromosome and coordinates are displayed on top. Cancer-specific binding sites are highlighted 
with sky-blue box. Gene information is shown in bottom. (B) Expression level of cancer-specific target 
genes in 11 different cell lines. X-axis represents cell lines and Y-axis indicates absolute expression level. 




MYC and Pol II co-localized in many promoters 
To examine relationships between genes potentially targeted by TF binding, we 
performed clustering analysis of their target gene sets. There was generally higher 
correlation between the target genes of one factor across all cell types, consistent with our 
earlier analysis of cell-type specific and ubiquitous sites. Thus, CTCF targets generally 
correlated well with each other across all cell types, with Pol II targets showing lower 
correlations, followed by Myc (Fig. 3-10A). Between factors, there was weak, but 
positive correlation between CTCF and either MYC or Pol II targets (Pearson correlation 
coefficient r=~0.2), but moderate correlation between MYC and Pol II (r=~0.4), 
consistent with a functional relationship among the three factors (Fig. 3-10A).  
We further investigated single or combinatorial occupancy of these factors at their 
target sites. We first classified binding sites into 7 groups: three single (CTCF-alone, 
MYC-alone, Pol II-alone) and four combinatorial (CTCF-MYC, CTCF-Pol II, MYC-Pol 
II, CTCF-MYC-Pol II), then examined single and combinatorial sites across cell types. 
Even though the largest portion (~ 86 %) of CTCF, MYC, and Pol II binding sites was 
bound by only one of factor, a considerable proportion of binding sites (~ 14 %) were co-
localized with at least two factors in K562 (Fig. 3-10B). Similar single and combinatorial 
binding patterns were observed overall across other cell types. Among the combinatorial 
binding sites in K562, 21 % were occupied by all three factors, 10 % by CTCF-MYC, 12 




the co-occupied sites in this cell line were shared by MYC and Pol II reinforces the idea 
of a strong functional relationship between them. Associations between these factors 
were further supported by the fact that both CTCF and MYC were co-enriched at Pol II 
sites (Fig 3-10C). Although there were variations between cell types, we observed similar 
relationships between target genes occupied singly or in combination by these three 
factors (Fig. 3-11A). Taken together, these results suggest that a substantial set of genes 
may be regulated by combinatorial binding of these three factors, in particular Myc and 
Pol II.  
We also examined the distribution of single or multiple-factor binding sites in the 
five different genomic regions relative to genes. In general, co-occupied sites were over-
represented in promoters as compared to sites occupied by single factors, particularly 
when a combination included Pol II. 70% of the MYC-Pol II and CTCF-MYC-Pol II 
combinatorial sites were in promoters, which was an enrichment over the Pol2-only sites 
seen in promoters (Fig. 3-11B). 
To globally visualize combinatorial occupancy patterns of the three factors over 
genes and possible functional outcomes, we first clustered Pol II occupancy signals 
within a 10 kb window around the TSS then visualized the corresponding signals for Myc 
and CTCF binding. Although dominated by the strong binding signal at the TSS, Pol II 
showed a few distinct clusters of binding patterns, with MYC (Fig 3-11C). These clusters 




of combinatorial binding, we analyzed the enrichment of functional categories among 
genes targeted by each of the 4 combinatorial binding groups. Target genes bound by the 
combination of MYC-Pol II or CTCF-MYC-Pol II showed an enrichment for genes in the 
functional categories of translation, RNA processing, RNA splicing, and ribosome 
biogenesis across all cell types, which suggests combinatorial factor usage in the 
regulation of genes implicated in general biological processes (Table 3-5). However, 
target genes occupied by CTCF-MYC or CTCF-Pol II did not show strong functional 
enrichment even though they exhibited moderate enrichment of some functional 































Figure 3-10. CTCF, MYC, and Pol II can regulate their target genes in a combinatorial manner. 
(A) A heatmap of correlations between the target genes of each factor in given cell types. The Pearson 
correlation coefficient was calculated between the set of target genes of each factor and those of other 
factors in a binary mode (target or non-target). (B) Proportion of single and combinatorial binding sites of 



































Figure 3-11. Combinatorial binding of MYC and Pol II are involved in various biological 
functions. 
(A) Proportion of single and combinatorial target genes of the three factors in diverse cell types. The 
percentage of target genes in each category is shown on the vertical axis, for each of the cell types shown 
below. (B) The distribution of single or combinatorial binding sites of the three factors in 5 different 
genomic regions. The percentage of binding sites in each region is shown on the vertical axis, for each of 
the combinations shown below. (C) K-mean clusters show co-enrichment of CTCF and MYC with Pol II at 
TSS. Arrows indicate TSS as well as direction of transcription. Factors are shown in bottom. The number 
inside bracket indicates minus log transformed P-value (Bonferroni) from DAVID functional analysis. 





Table 3-5. Functional categories enriched among target genes occupied by combinations 
















CTCF, MYC, or Pol II binding positively correlates with target gene expression 
We investigated the influence of CTCF, MYC, and Pol II binding on the 
expression of target genes by comparing transcript levels of genes bound by any one of 
the factors with genes not bound by any of them. Genes whose promoters were occupied 
by any one of the three TFs showed significantly higher expression than genes whose 
promoters were not occupied by that TF, across all cell types (Fig. 3-12A). Both MYC 
and Pol II, compared with CTCF, showed more dramatic effects on the expression of 
their target genes. We could visualize the positive relationship between ChIP-seq scores 
and gene expression levels by plotting average binding profiles around the TSS 
separately for the high, medium and low expression level groups (Fig 3-12B). 
In addition to the influence of TF occupancy in target gene promoters, we also 
investigated the effects of binding upstream (between 2 kb and 20 kb) of a TSS or within 
the gene-body (within exons and introns of the gene). We first assigned an upstream or 
gene-body binding site to the nearest gene as its target, then evaluated the expression 
levels of genes in each of the eight groups formed by the combination of upstream, 
promoter and gene-body binding by the TF (Fig 3-12C). Unlike gene body binding, 
upstream CTCF binding did not significantly affect target gene expression when CTCF 
occupied in promoter (Fig. 3-12C). Intriguingly, both upstream and gene-body binding of 
MYC exhibited remarkably positive effects on target gene expression only when MYC 
did not bind onto the promoters. Pol II upstream and gene-body binding in general were 




further looked into the influence of upstream binding distance on expression by dividing 
binding sites into four groups, based on distance from TSS. Interestingly, while there was 
a modest association of upstream binding with increased expression levels compared to 
no binding, there was no significant drop-off with increasing distance of binding ranging 
from 5 kb to 20 kb (Fig 3-12D). 
Previously we showed that many promoters had a combinatorial recruitment 
among CTCF, MYC, and Pol II (Fig 3-12A B and D). A gene can often be 
transcriptionally regulated by a combinatorial binding of different transcription factors. 
To investigate the influence of combinatorial TF binding on target gene expression, we 
examined the expression level of genes whose promoters were bound by different 
combinations of the three factors. Genes whose promoters were bound by a single TF 
exhibited the highest expression levels for Pol II binding and lowest expression levels for 
CTCF, with MYC being intermediate (Fig. 3-12E). Genes occupied by both MYC and 
Pol II showed higher expression levels than the genes bound by either MYC or Pol II 
alone. In contrast, combinatorial binding MYC or Pol II with CTCF decreased expression 
level of their target genes, indicating CTCF functions as a negative regaulator of 
expression. These results suggest that depending on the combination of TFs, the 
combinatorial TF binding can either enhance or reduce the effect on expression compared 































Figure 3-12. CTCF, MYC, or Pol II binding activates expression of its target genes.  
(A) Boxplots show that the downstream genes of promoters (within ± 2 kb from TSSs) bound by either one 
of these three factors have significantly higher expression than genes not occupied by them across the cell 
types analyzed. P-values were calculated by Wilcoxon rank sum test. Three asterisks (***) indicates P-
value of zero. (B) TSS profiles of CTCF, MYC, and Pol II among 3 different expression groups including 
top 33 %, middle 33 %, bottom 33 % in K562. (C) The upstream or the gene-body of a gene bound by 
either one of these three factors promotes its expression. Boxplots show distribution of genes expression 
bound by CTCF (upper panel), MYC (middle panel), and Pol II (bottom panel) in three different genomic 
regions including promoters, upstream, and gene bodies. P-values were calculated by Wilcoxon rank sum 
test. Three asterisks (***) indicates P-value of zero. (D) Location effect of CTCF, MYC, and Pol II sites on 
expression of target genes. P-values were calculated by Wilcoxon rank sum test. (E) Boxplots show 
expression of single and combinatorial binding of these three factors across the cell types analyzed. 




Pol II regulates gene expression in four distinctive binding patterns across the 
promoter and body of a gene 
RNA polymerase II (Pol II) is an enzyme that synthesizes premature forms of 
mRNAs, snoRNAs, and microRNAs using DNA as a template. RNA Pol II associates not 
only with promoters in a simple relationship to transcription, but also shows evidence of 
pausing (Krumm et al, 1995). In the previous section, we showed that Pol II binding 
increased the expression of its target genes. Here, we investigated in further detail how 
location and occupancy strength of Pol II binding affect gene expression. We first 
classified genes into four groups based on how Pol II was bound to different gene 
regions: HH – showing high occupancy in both the promoter and the gene body; HL – 
high occupancy in the promoter and low occupancy in gene body; LH – low occupancy 
in promoter and high occupancy in the gene body; LL – low occupancy in both promoter 
and gene body (Fig. 3-13A; Methods), and then examined the expression level of each 
group of genes. Genes showing the HH pattern of Pol II binding had the highest level of 
expression whereas genes in the LL group showed the lowest level of gene expression 
(Fig. 3-9B). Compared to the HH group, the HL group containing paused Pol II at 
proximal promoters but little signal in the gene body showed significantly lower gene 
expression (Fig. 3-13B), which is consistent with results from Pol II profiling in D. 
melanogaster (Zeitlinger et al, 2007). To further investigate how these different modes of 
Pol II occupancy affected gene expression, we ranked genes by their expression values 




function of expression. The proportion of genes in the HH group decreased with 
decreasing expression levels while those in the LL group gradually increased (Fig. 3-
13C). While genes in the HL group were distributed from highest to lowest expression, 
they were more biased towards highly expressed genes than genes in the LH category 
(Fig. 3-13C, 13D). 
We next clustered genes in each of the four Pol II binding groups in order to 
analyze whether these distinct occupancy patterns could potentially align with functional 
outcomes. While there were ubiquitous as well as cell-type specific clusters in all 4 Pol II 
binding groups, only genes in the HH group showed strong functional enrichment across 
all cell types, with housekeeping functions enriched in the ubiquitous clusters where 
genes showed Pol II occupancy constitutively in all cell types (Fig. 3-13D). Genes in the 
HH group where Pol II occupancy was observed in a cell-type specific manner showed 
functional enrichment for cell-type specific functions, such as angiogenesis for HUVECs 
and lymphocyte activation in lymphoblastoid cells (Fig. 3-13D). None of the other three 
Pol II occupancy groups including HL, LH, and LL showed functional enrichment across 
all cell types, with the exception of a ubiquitous cluster in the HL group that was 
moderately enriched in chromatin organization/modification, DNA repair, and stress 















Figure 3-13. Pol II binding regulates gene expression in 4 distinct binding modes.  
(A) Wiggle track images show 4 distinct Pol II binding groups classified based on its occupancy signal in 
the promoter and the body of a gene. HH: high occupancy in both the promoter and the body of a gene; HL: 
high occupancy only in the promoter of a gene; LH: high occupancy only in the body of a gene; LL: low 
occupancy signal in the promoter as well as the body of a gene. Chromosome and coordinates information 
are shown on top. Maximum occupancy signal are shown in left side of a track with a green color. (B) 
Boxplots shows distribution of expression level among 4 classes of Pol II binding sites. X-axis represents 4 
different Pol II binding groups. Y-axis indicates log-transformed expression level of genes. P-values were 
calculated by Wilcoxon rank sum test. Three stars (***) indicates P-value of zero. (C) Distribution of genes 
of 4 Pol II groups in the expression rank map. X-axis indicates expression ranking from highest (left) to 
lowest (right). Y-axis represents number of genes in 4 groups, mapped into the expression map. (D) K-
mean clusters shows significantly enriched functions in cell-type specific as well as ubiquitous Pol II sites 
in the HH group. Cell types are shown in top. Presence and absence of Pol II binding are displayed with 
blue and white color, respectively. Web-based functional annotation program, DAVID (Dennis et al, 2003), 
was used to search functional enrichment. Annotated functional groups of each cluster are shown with 





We examined in further detail the co-enrichment of Pol II with CTCF and MYC 
in promoters as well as gene bodies in the above 4 Pol II binding groups. CTCF showed 
significant enrichment only in the promoters of genes in the HH group and the gene 
bodies of the LH as well as LL groups while MYC exhibited highly significant 
enrichment in all promoters except the LL group and in the gene bodies of the HH and 
LH groups (Fig. 3-14), indicating that MYC occupancy at Pol II occupied genes tends to 

















Figure 3-14. CTCF and MYC enrichment with Pol II in promoters (P) as well as gene bodies 
(GB) in the 4 Pol II groups.  
P-values were calculated by hypergeometric distribution. X-axis represents location plus group. Y-axis 




Novel promoters and alterative promoter usage of Pol II 
From mapping of our Pol II sites into 5 different genomic regions using combined 
gene annotations from RefSeq, UCSC, Ensembl, Vega, and SIB genes from UCSC 
genome browser, we found a considerable proportion of Pol II binding sites (7~20%) in 
distal (upstream and intergenic) regions across the 10 cell types, suggesting the possible 
presence of novel promoters. In order to discriminate novel promoters from ChIP-seq 
false positives, we first scanned the 100 bp region around the distal Pol II binding sites 
for known core promoter element motifs such as initiator (INR), TATA box, TFIIB 
recognition element (BRE), downstream core promoter element (DPE), and motif 10 
element (MTE) (Jin et al, 2006). 93 % of our distal Pol II sites contain at least 2 core 
promoter elements including INR, the most abundant promoter element, as well as DPE, 
generally found in TATA-less promoters in Drosophila (Fig. 3-15A). We further 
compared these distal Pol II binding sites with expressed sequence tag (EST) data to see 
whether the distal Pol II binding sites were associated with transcription. We considered a 
Pol II site to be associated with a transcript and thus potentially a novel promoter if it lay 
from 2 kb upstream to 300 bp downstream of the 5' end of the EST. On average, 74 % of 
the distal Pol II sites across all cell types corresponded in this manner to EST tag mRNA 
(Fig. 3-15B). Taken together, these results indicate that most distal Pol II sites could be 




Many genes in the human genome have multiple promoters for a gene 
corresponding to distinct transcript isoforms. These alternative promoters are 
differentially utilized under different cellular contexts. In order to evaluate to what extent 
alternative promoters are used in diverse cell types, we first identified alternative 
promoters for RefSeq annotated genes by flagging genes that had the same gene symbol 
but contained different TSS annotations in the RefFlat file. We then mapped Pol II 
binding sites to these alternative promoters. Fig. 3-15C shows one example of cell-type 
specific alternative promoter usage. Across the genome, we found that a considerable 
number of genes (~4.3 %) were transcribed utilizing at least two alternative promoters 

























Figure 3-15. ChIP-seq of diverse cell types revealed many novel promoters as well as cell-type 
specific alterative promoter usage. 
(A) A pie chart shows number of Pol II distal sites containing different number of core promoter elements 
in K562. N indicates total number of distal sites in K562, which has at least one core element. (B) Percent 
overlap of Pol II distal sites with expressed sequence tag (EST). (C) An example of cell type-specific 
alternative promoter usage is shown in genome browser tracks. Blue, red, and green indicate cell types 
using promoter 1, promoter 2 or both promoters respectively. Chromosome and coordinates are shown on 
top. Arrow indicates Two TSS locations as well as direction of transcription. Numbers in Y-axis represent a 
maximum peak score. (D) A pie chart represents number of genes utilizing different number of alternative 




Pol II shows higher occupancy at initial and terminal exons than adjacent introns 
Recent studies have noted that chromatin structure differs at exons and introns, 
likely reflecting an effect of co-transcriptional splicing (Schwartz & Ast, 2010). To 
examine whether co-transcriptional splicing might be more directly reflected in Pol II 
occupancy over transcripts, we examined ChIP-seq signal for Pol II at exons and introns. 
We first examined the Pol II enrichment around the initial and terminal exon/intron 
junctions. Strong Pol II occupancy around the TSS, combined with the highly variable 
lengths of the first exon and intron make it difficult to reliably quantify specific 
differences in occupancy between the first exon and intron. We visualized Pol II 
occupancy over the first exon/intron junction by generating gene-wise heat maps where 
we aligned all genes by their TSS and sorted genes by the length of their first exons. This 
analysis showed that in addition to the high occupancy at the TSS, Pol II also binds 
preferentially to the first exon compared with the intronic region downstream of it. This 
enrichment was seen in all 10 cell types when either input-corrected Pol II ChIP peaks 
(Fig. 3-16A). Similarly, to evaluate bias in Pol II occupancy at the last intron/exon 
junction, we aligned genes by the 5' end of their last exon and sorted them by the length 
of their last intron. Pol II occupancy signal was lower within the last introns while both 
upstream and downstream exons exhibited stronger signals (Fig. 3-16B). 
To evaluate the occupancy of Pol II at internal exons, we generated heat maps of 




the exon length. The small exon sizes and relatively sparse Pol II peaks over this region 
made it difficult to visualize a significant difference in occupancy between exons and 
intron when we considered peaks. Heat maps of raw Pol2 ChIP-seq reads revealed higher 
signal within the internal exons compared with adjacent regions, but a similar enrichment 
over the internal exons was also seen for reads from input samples (Fig. 3-16C). This 
enrichment is partly, but not entirely due to the greater uniqueness of sequence content 
within exons which results in higher alignability. To overcome the problem of sparse 
peaks, we combined the data for Pol2 ChIP peaks, which was corrected for input signal, 
to generate a combined heat map across all 10 cell types which confirmed that Pol II 
showed higher occupancy within internal exons (Fig. 3-16C). Thus RNA Pol II 














Figure 3-16. Pol II is enriched in exons. 
(A) Pol II ChIP-seq peaks (top row, red) and reads (bottom row, blue) are plotted with respect to TSS. Each 
row indicates a gene which is aligned by its TSS and sorted by the length of its first exon. Pol2 signals in 
the form of input corrected peak scores (red) or read counts (blue) were assigned to 10 bp bins across the 4 
kb region shown in the plots (1 kb upstream and 3 kb downstream of TSS). Only genes with at least one 
peak or read occurrences within 4 kb of their TSS are plotted. (B) Pol II has higher occupancy in the last 
exon compared with last intron. Genes are aligned with the start of their last exons and sorted by the length 
of their last introns. Pol2 signal across the 9kb region (7kb upstream and 2kb downstream of the start of the 
last exon) is represented similarly as in panel A. Most of the long genes at the bottom of the read plots 
(blue) do not have significant Pol2 binding peaks and therefore are not part of the peak plots (red), 
contributing to the pattern difference between read plots and peak plots. (C) Middle exons have higher Pol2 
occupancy signal than introns. Pol2 signal across the10kb region (5kb upstream and 5kb downstream of the 
start of each middle exon) is represented similarly as in panel A. All these analyses were performed by 





In order to identify sequence motifs present within the binding sites of the sequence 
specific transcription factors CTCF and MYC, we used the Discriminating Matrix 
Enumerator (DME) algorithm (Smith et al, 2005). We divided binding sites into strong, 
moderate, and weak groups based on their ChIP-seq scores, and searched for motifs de 
novo in these three groups. The algorithm identified only the previously known canonical 
motif for both CTCF and MYC in their respective binding sites in all cell types except in 
the case of MYC in ES cells (Fig. 3-17A). Next, we examined the enrichment of the 
motif in binding sites relative to background as a function of the binding site score for all 
significant binding sites of CTCF and MYC. Motif enrichment relative to background 
gradually increased along with ChIP-seq score for both CTCF and MYC in all 11 cell 
















Figure 3-17. Motif analysis.  
(A) Motif logo showing position weight matrix (PWM) of CTCF and MYC motifs discovered from 11 












We generated genome-wide high confidence binding sites of sequence-specific 
transcription factors including CTCF and MYC as well as Pol II in 10-11 different cell 
types using high-throughput ChIP-seq. The functions of TFs are governed by the location 
of their binding sites in genome, and the most basic regulatory mechanism is to bind onto 
the promoter of their target genes. In accordance with this fundamental mechanism, our 
genome-wide binding analysis of CTCF, MYC and Pol II showed that all three factors 
were overrepresented in TSS regardless of cell types. However, unlike other two factors, 
CTCF exhibited a distinct binding distribution across the genome where it had the largest 
portion of binding sites in distal sites including upstream and intergenic. These 
preferential CTCF binding in distal sites is consistent with its function as either an 
enhancer blocker which in general, locates between an enhancer and a promoter and 
prevents communication between them or an insulator which positions at chromatin 
boundaries and prevent the spreading of repressive chromatin modification signals 
(Cuddapah et al, 2009) . Other than the binding properties of CTCF, MYC, and Pol II we 
also showed that the number of binding sites of each factor positively correlated with 
gene density, indicates TF play functions near genes rather than gene desert. Bidirectional 
promoters are able to regulate expression of two downstream genes and are responsible 
for expression of ~11 % genes in human (Trinklein et al, 2004). It has been reported that 




overrepresented in bidirectional promoters (Lin et al, 2007). Our genome-wide in vivo 
binding data also revealed that MYC is highly enriched in bidirectional promoters. 
Through overlap analysis of binding sites of CTCF, MYC, and Pol II among 10-
11 different cell types we revealed that binding sites of CTCF were highly conserved 
across the investigated cell types whereas those of MYC were more distinctive in each 
cell type, suggests global roles of CTCF and cell-type specific roles of MYC. Unlike 
dominant CTCF binding in ubiquitous sites, the binding sites of Pol II had not only high 
portion of ubiquitous sites but also considerable amount of unique sites, which implies 
Pol II is involved in both general and cell-type specific roles. Of cell-type specific sites 
and ubiquitous sites we found that ChIP-seq scores of ubiquitous sites were significantly 
higher than those of cell-type specific sites, in particular unique ones, implying cell type 
specific sites might be regulated by combination of several TFs, which cooperate with to 
bind onto DNA. Functional category analysis for targets of these three factors further 
unveiled that unique sites of MYC and Pol II had strong enrichment in representative 
functions of a specific cell type even though they had lower occupancy scores, but those 
of CTCF did not. In addition to cell-type-wise overlap analysis, we also examined factor-
wise overlap, through which we revealed moderate target correlation between MYC and 
Pol II as well as weak but constant correlation between CTCF and MYC across cell lines 




By comparing the binding sites of CTCF, MYC and Pol II with Affy exon 
expression array data we showed that TF binding, in general, activated expression of its 
target genes for all three factors and in particular, combinatorial binding between MYC 
and Pol II enhanced their target gene expression. These results suggest that single TF 
binding promotes activation of target genes and combinatory TFs binding can enhance 
the effect on expression. Thus, it is reasonable to speculate that the effect of TF 
combinations is greater than the effect of stronger binding of a single TF. Recent research 
revealed that MYC had a crucial role in releasing paused Pol II, (Rahl et al, 2010), which 
could explain why sites co-occupied with MYC and Pol II had higher expression. 
Moreover, we showed positive influence of CTCF, MYC, and Pol II binding in the 
upstream on their target genes, suggesting their binding on enhancers. 
By regulating the occupancy of Pol II in different genomic regions, cells can 
regulate transcriptional gene expression. Our genome-wide systematic analysis of Pol II 
binding sites in a gene elucidated distinctive Pol II binding patterns, showing the 
influence of Pol II binding location on its target gene expression. In particular, although 
the HL group having promoter-paused Pol II showed significantly lower expression of its 
target genes compared to those of the HH group, genes in the HL group were still highly 
expressed. This result suggests that many actively transcribed genes also possess paused 
Pol II at their proximal promoters, but majority of Pol II pausing is transient rather than 
long-lasting, which keep genes from being expressed. Our observation is also in 




which revealed that Pol II proximal pausing is prevalent even in actively transcribed 
genes across the fly genome, in particular genes occupied by NELF as well as DSIF, 
negative effectors of transcriptional elongation (Gilchrist et al, 2010). We also found 
many novel promoters as well as cell-type specific alterative promoter usage, which 
allow cells to regulate gene expression in more diverse ways. 
It has been well established that splicing takes place while pre-mRNA is still 
being actively transcribed (Schwartz & Ast, 2010). Without intact Pol II, splicing of pre-
mRNA occurs less efficiently, implying Pol II has a role in splicing. Pol II elongation rate 
can be slowed down due to nucleosomes, which can function as a speed bumps (Hodges 
et al, 2009). Since exons have ~1.5 fold more nucleosome than introns it is reasonable to 
speculate that Pol II elongation rate could decrease in exons. Decreased elongation rate 
could increase recognition of exons and facilitates splicing (de la Mata et al, 2003; Ip et 
al, 2011; Schwartz et al, 2009). Previous Pol2 ChIP-ChIP studies in plants have shown 
that Pol2 binds to exons stronger than introns (Chodavarapu et al, 2010). However, it is 
not clear whether Pol2 is more enriched in exons than introns in human genome. We have 
shown that Pol2 enrichment is higher within exons in vivo through ChIP-sequencing in 
10 different human cell lines. We compared the level of Pol2 binding difference between 
exons and their adjacent introns across 5 cell lines and found that the extent of exon-bias 
is consistent for most exon/intron pairs across different cell types. It will be interesting to 



































Chapter 4: Allele-specific and individual-specific CTCF recruitment in 
the human genome  
 
4.1 INTRODUCTION 
Human has two alleles for every gene, and the regulation of a gene expression can 
differ between the two. Moreover, variations in genomic DNA, including single 
nucleotide polymorphisms (SNPs), insertion, deletion, and copy number variation 
(CNV), can alter gene expression in individuals (Fanciulli et al, 2007; Zeggini et al, 
2007). This allele-specific gene expression can be observed in development and in many 
diseases (Feagins et al, 2006; Walsh & Bestor, 1999). Recent analyses have revealed that 
allele specificity in individuals is responsible for the expression of 10%-22% of genes in 
human (Zhang et al, 2009), and upwards of 30% of genes have variations in gene 
expression at least in part due to genetic effects (Stranger et al, 2007).  
Gene expression is regulated transcriptionally by the interaction of TFs with cis-
regulatory elements in the genome; however, it is not well understood how and to what 
extent individual differences and genetic variations affect TF binding in cis-regulatory 
elements and subsequent effects on gene expression. Elucidating these allele-specific and 
individual-specific variances in gene expression is pivotal not only to understanding the 




unveiling the causative mechanisms of many diseases that are associated with common 
genetic variants occurring in non-coding cis-regulatory elements. 
Genome-wide identification of TF binding sites through chromatin immuno-
precipitation followed by (ChIP-seq) makes it possible to investigate the extent of 
variation in TF binding between either alleles or individuals. Here, we provide an 
inclusive list of individual-specific and allele-specific variation in CCCTC binding factor 
(CTCF) in different human individuals. CTCF has multiple regulatory functions 
including activating as well as repressing genes, blocking enhancers and insulating 
chromatin (Zlatanova & Caiafa, 2009).  
 We found the presence of both allele-specific and individual-specific CTCF 
binding in parent-child trios from European and African populations. We also found that 
these allele-specific and individual-specific CTCF binding sites were inheritable from 











4.2 MATERIALS AND METHODS 
Cell Line and Growth 
Lymphoblastoid cell lines from the CEU (CEPH - Utah residents with ancestry 
from northern and western Europe) and YRI (Yoruba in Ibadan, Nigeria) sample 
populations were purchased from Coriell and were cultivated according to standard 
growth procedures (http://ccr.coriell.org). Genotype information about those individual 
cell lines was obtained from the HapMap and 1000 Genomes Project (20981092). Cells 
were grown in the RPMI 1640 (2 mM L-glutamine) medium supplemented with 15% 
fetal bovine serum plus 1% pen/strep. Cells were split every 3 day into fresh media. Two 
biological replicates were grown on separate days for each cell line.  
ChIP sequencing  
ChIP for CTCF was conducted using a previously described method (Kim et al, 
2008). Fixed cells with formaldehyde (final concentration of 1%) were sheared with a 
Bioruptor into an average DNA size of 500 bp fragments. Sheared chromatin was used to 
pull down CTCF-DNA complex using an anti-CTCF antibody (07-729) from Millipore. 
After reverse crosslinking through overnight incubation in a 65 
o
C water bath followed 
by proteinase K treatment, purified ChIP DNA was used to generate ChIP-seq libraries 
according to Illumina's recommended protocols. Purified ChIP-seq libraries were 





Mapping and identifying peaks 
Reads were mapped to the reference human genome using Maq aligner (Li et al, 
2008). The reference genome excluded chromosome Y for female individuals and 
pseudo-autosomal regions of chromosome Y for male individuals. F-seq (Boyle et al, 
2008) was used at a low threshold (4 standard deviations above the mean) to generate 
putative CTCF binding sites across the genome. 
Gene expression analysis 
RNA was extracted from lymphoblastoid cell lines at the same time they were 
harvested for CTCF ChIP experiments. RNA was extracted using Trizol (Invitrogen), 
labelled, and hybridized onto Affymetrix 1.0 exon arrays.  Array CEL files were 
normalized with RMA. Gene level analysis was conducted using Expression Console 
from Affymetrix. Expression values from replicates were then averaged. To assess the 
binding site relevance to expression, each CTCF binding site was assigned to its nearest 
gene. Correlation analysis was performed with R.  
 
Allele-specific site discovery 
Alignment of reads to a single reference genome caused an artificial bias towards 
the reference genome in measuring allele specific binding bias in CTCF sites. To remove 
this bias we first reconstructed the single reference genome into two different hg18 




from the April 2009 1000 Genomes data release. The two bases in each heterozygous 
SNP were randomly assigned to either genome1 or genome2 at the respective position in 
hg18. All reads from CTCF ChIP-seq were aligned to both genome1 and genome2 
references for each individual using Maq. Approximately 5% of reads changed position 
in comparison to the other genomic alignment. The new mapping approach combining 
genome1 and genome2 improves reference genome mapping bias (Fig 4.1). The allele-
specific bias for 9,192 heterozygous CTCF binding sites was assessed across all 
individuals. P-values were calculated based on the binomial distribution coupled with a 
false discovery rate (FDR) multiple testing corrections at a threshold of 0.01. 11% of 
CTCF sites showed significant allelic bias. All analyses to identify allele-specific and 









Figure 4-1. New mapping strategy removed bias toward reference allele.  
X-axis represents % alignment. Y-axis represents a mapping bias. 0.5 indicates no bias. 




3.3 RESULTS AND DISCUSSION 
Genome-wide identification of CTCF binding sites 
We generated CTCF ChIP-seq data from two independent growths for each of the 
6 lymphoblastoid cells from CEU (CEPH Utah reference family) and YRI (Yoruba from 
Ibadan, Nigeria) family cell lines. All the samples were sequenced using Illumina Solexa 
sequencer through which we altogether generated over 200 million sequences for this 
analysis (Table 4-1). We first aligned raw sequences to the human reference genome 
using Maq (Li et al, 2008) followed by determination of CTCF binding sites using the F-
seq package. Correlation studies using Pearson correlation showed strong agreement 
between each replicate of CTCF, showing that the predominant genome-wide signal was 
consistent with a specific biological state associated with lymphoblastoid cell lines (data 
not shown).  
Table 4-1. Sequencing statistics of CTCF ChIP-seq 
  CTCF ChIP-seq 
Family 
Structure Cell line 
# of total 
sequences # of useable sequences 
% of 
total 
CEU Father GM12891 30,244,488 21,733,635 71.8% 
CEU Mother GM12892 44,885,150 34,494,412 77.0% 
CEU Daughter GM12878 32,547,270 25,846,561 79.4% 
YRI Father GM19239 26,628,402 20,232,825 76.1% 
YRI Mother GM19238 32,377,472 25,547,799 78.9% 
YRI Daughter GM19240 33,399,839 26,250,278 78.4% 




Individual-specific CTCF sites are correlated between parent and child 
We investigated overlap of CTCF binding sites in only the four parents that were 
unrelated to each other to identify individual-specific CTCF sites. We first integrated 
CTCF binding sites in individuals, and classified them as either “constant”, meaning that 
they were observed in all four parent lines, or “individual-specific”, meaning they were 
present in at least two individuals and absent in at least one individual. We found 58,192 
constant CTCF binding sites and 823 CEU-specific as well as 809 YRI-specific CTCF 
sites (Table 4-2). We also found concordance between parent CTCF sites and child CTCF 
sites in each population since strong occupancy signals in the parents also tended to be 
strong in their child.   
 
Table 4-2. Number of constant as well as individual-specific CTCF binding sites.  
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Influence of individual-specific CTCF binding on gene expression 
We examined the functional relevance of the individual-specific sites we 
identified by comparing individual variations in CTCF binding sites with variations in 
gene expression as measured by Affymetrix exon arrays. In general, CTCF sites near the 
transcription start site (TSS) showed strong positive correlation with expression levels, 
even though there were numerous examples of sites where there was an anti-correlation 
(Fig. 4-2A). To explore these relationships globally, we assigned CTCF site to its nearest 
TSS, and then calculated the correlation between CTCF signal and the corresponding 
gene expression level. Many CTCF sites have both positive and negative correlated 
values with gene expression for sites ranging 2.5 Kb to 10 Kb of the TSS (Fig 4-2B). In 
addition, constant as well as individual-specific CTCF sites also showed both positive 
and negative correlation between CTCF binding and expression, although individual-
specific site showed more positive correlation (Fig 4-2C, and D), suggesting that CTCF 
regulates gene expression in a more complex manner, instead of functioning just a 



































Figure 4-2. CTCF binding sites correlate with gene expression. 
X-axis represents Pearson correlation coefficient and Y-axis shows percent of total. Distribution of 
correlation values between CTCF and gene expression across individuals. CTCF binding sites were 
classified into those within 2.5 Kb of the nearest TSS (A), between 2.5 Kb and 10kb from the nearest TSS 










De novo identification of allelic bias on CTCF binding sites 
In order to identify allele-specific CTCF binding sites where the signals from the 
two alleles differed significantly without reference SNP bias due to mapping toward 
single reference genome, we aligned sequences from our CTCF ChIP-seq to each of two 
reference genomes, each containing one of the possible heterozygous SNP alleles based 
on genotype calls for these individuals obtained from the 1000 Genomes Project (Durbin 
et al, 2010). This new mapping strategy eliminated the background bias from alignment 
to a single reference genome. We then investigated the allele-specific bias for each 
heterozygous SNP of CTCF binding sites where at least 15 reads resided across all 
individuals. Among 9,192 heterozygous CTCF sites, we found 1034 (11%) CTCF sites 
showed significant allele bias with a P-value threshold of 0.01 calculated from a binomial 
P-value followed by a false discovery rate (FDR) multiple testing corrections (Table 4-3). 
Interestingly, we found significantly more allele-specific bias of CTCF binding on the X 
chromosome in females, compared with all other chromosomes. This result may be 
explained by X inactivation by which CTCF binding was biased towards one allele (Fig 
4-4).  
Table 4-3. Number of allele-specific CTCF binding sites.  
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Figure 4.3. Stronger allele-specific bias on chromosome X than autosomes. 
This analysis was done by Ewan Birney (McDaniell et al, 2010). 
 
  
Positive correlation of allele-specificity between individuals   
 
To test that individual-specific CTCF binding is direct consequence of genetic 
basis rather than random or environmental effects, including diet, infectious status at the 
time of isolation, and epigenetic (Hatchwell & Greally, 2007; Montgomery & 
Dermitzakis, 2009), we investigated the correlation of allele-specificity between 
individuals. We found strong correlated biases of CTCF binding to toward one of the two 
alleles in a heterozygous individual for the same allele between parent and child, and 
between individuals within and between the two populations. 98 % of inter-individual 
bias showed the same direction, whereas approximately less than 2% of inter-individual 




Chapter 5: Summary and Future Directions 
In order to identify and categorize genome-scale binding sites of sequence-
specific transcription factors (TF) we performed Chromatin Immunoprecipitation (ChIP) 
coupled with high throughput sequencing (ChIP-seq) for E2F4, c-Myc, CTCF, and Pol II 
in diverse cell lines. We found tens of thousands of high confident binding sites for each 
factors across the human genome.  
Through computational analysis using our genome-wide ChIP-seq data, we 
showed that all TFs analyzed had a propensity for binding near TSSs, in accordance with 
the fact that three TFs including E2F4, MYC and Pol II exhibited the largest portion of 
binding sites in promoters (among five different genomic regions: promoters, upstreams, 
introns, exons, and intergenics). Interestingly, unlike other TFs, CTCF showed 
preferential binding in distal sites including upstream and intergenic rather than 
promoters, which suggests a different mechanism of gene regulation (such as the well-
known function of CTCF as an insulator located between promoters and enhancers, 
which prevents genes from activation). We also showed that the number of these TFs‟ 
binding sites positively correlated with gene density, which indicates that these factors 
have functions near genes rather than in gene desert.  
In addition to TF binding properties, overlap analysis among 10-11 different cell 
lines for CTCF, MYC, and Pol II revealed many cell-type specific TFs‟ binding sites, 




as lower binding scores. We also investigated the relationship between a TF binding and 
its target gene expression. In general, TF-bound genes not only had higher ChIP-seq 
scores but also showed higher expression than genes not bound by TFs. However, there is 
no clear linear correlation between ChIP-seq score and expression levels, even for Pol II 
binding sites. 
In addition to regulating expression of target genes by associating with promoters, 
these TFs are able to manipulate gene expression in various other ways. For instance, our 
analysis of E2F4 showed that it could not only regulate microRNAs that were able to 
fine-tune gene expression by destabilizing translation or degrading mRNA, but also could 
bind distal enhancers that further activated target gene expression. We also showed in Pol 
II analyses that Pol II could transcribe genes using alternative promoters which could 
produce diverse isoforms of a given gene. Moreover, CTCF binding analysis among 
Europian and Yoruban family revealed allele-specific as well as individual-specific 
CTCF binding sites, which were inheritable from parents to their children.  
To date we have generated important information about four TF binding sites 
across the human genome in diverse cell lines using ChIP-seq. Follow-up computational 
as well as experimental studies including expression arrays and luciferase assays further 
revealed influences of TF binding either near the promoters of genes or in distal sites. 
However, in many cases we found that TF binding alone was not enough to interpret 
changes of gene expression. In order to comprehensively understand mechanisms of gene 




transcriptional cofactors; DNA hypersensitive site assays that search open chromatin; 
chromatin status investigations into histone modification as well as nucleosome position; 
and research into higher order chromatin structure. For instance, it is widely accepted that 
chromatin modification status is linked to gene expression. Genome-wide studies of 
histone modification have revealed many active and repressive histone marks including 
acetylation and methylation of a specific lysine residue of a histone, which determine 
open chromatin structure. One histone mark is recognized by other histone modification 
enzymes or histone remodelers. These sequential recruitment events result in 
consequential gene expression. Moreover, histone modification status can discriminate 
promoters enriched with H3K4me3 from enhancers with H3K4me1. Furthermore, recent 
genome-wide histone modification analysis has elucidated two classes of enhancers: one 
is an active enhancer overrepresented with H3K4me1 and H3K27Ac, and the other is a 
poised enhancer with H3K4me1 and H3K27me3. These poised enhancers are quiescent 
in ES cell, but are activated later during development by changing their histone 
modification status (decrease in H3K4me3 and increase in H3K4Ac). ENCODE projects 
have generated numerous histone modification datasets. It will be interesting to analyze 
ChIP seq data in conjunction with histone modification data. These combined analyses 
can answer many interesting questions: how many enhancer sites are regulated by a 
specific TF; are enhancer sites regulated by single TFs or in a combinatorial manner; and 




Higher-order chromatin structure is another key regulatory factor in gene 
expression. For example, a chromatin region can communicate with another far away 
region by structural looping mediated by transcription factors. Chromatin conformation 
capture (3C) technique makes it possible to investigate such small-scale long-range 
integration between different genomic regions. Finally, High-C and ChIA-PET, two 
recently developed techniques based on high-throughput sequencing technology, provide 
a way to investigate genome-scale higher-order chromatin structures. It waits the next 
generation of methods and analyses to reveal how higher-order chromatin structure 
affects TFs binding of DNA, how TFs contribute to form higher-order chromatin, and to 














Appendix A. Primer sequences for qPCR as well as cloning for 
luciferase assay  
Genes Left Right 
EBP ATCCCTAGTTCGGGCTCATC CCTTCTTCGCTTCACCATTG 
WDR19 CCGCGATGACTAAGATGTCA TGCGTCTTCTTTCCTTCAGC 
EID2B GTGCCGTTATTCCAGTCTCC GACATCTCCAACAGCCCAGT 
VPS37B GACGTCATTAATGCGCTCAC GGGACAGTCGGGACTTCTAA 
DCUN1D4 CTGGCTGGCTCTCTGCTACT AGCTGCCTGAAAATGCACTC 
CCDC41 CGCATCACTCAGACTCCAAG GACTCAGAGATCCCCAGAGC 
ZER1 ACCCGATCGCTGTTGCTAAG CCTCCGCTGTCAACAAACC 
RAD50 CAAAGCCGTAGCCACAATG GCCTAGAGGCCCACGTGAT 
WDFY2 TGGCCTAGCGGTCTTAACAA TGCATGTTGGGAGCAGTAAG 
PAPD1 ATCTTCTTTCCGGCCTCAAT GAGGGTCAAACTAGGCGAAA 
FAHD2A TGGCAGAGAATGATTTGTGG AGTCATCCCTCCCCTCCTC 
EIF2B2 GACGGTGAACGGAAGTAACC AGACTTGCTGCTCCCATAGC 
TMEM161B CAACTCCAGGGTGTCTGGTC ACTCCTGCCCTCACAGAAGA 
AP1B1 CCTCGCCCCACTTCTTCT CGGGAGCTATTGGGACCT 
PWP2 ACCCGGTAAGCGAACTTCAT CCCGGGAAGTGTCTCTGTG 
PHLDA3 CGTCCTAGCTTCCCAGAGC GAACCGATCCGGAAGTGAC 
TBCEL TCACCTAGTCCCCCACTCTG GGGTCACGTGTTGTTGTTGG 
FAM55C GCGACGTCTCCTCACCTC GTGCTGCTGTCAGTCAACG 
MTX3 GTGCCGGAAATTAGGAGGA CCCAGCAACTGAGTTCCAA 
COQ10B GAGTCCCTCAGATGCCAAAC GGTGCATTTCCGTGTCTTTAG 
CXorf39 GACCGGAGGAGGAACTGAA ATCCCTGATTCGATGCGTAG 
CLK3 GGCCTGAGGTCTGTGTGC AATGTGTCGTTCGCTCGTTT 
ARHGAP17 TAGTAGCTGCCAGGCTGTCC GCGGTTGAACTGCTTCTTCA 
IARS GGGATCCAGTGAAGGAGACA GCTTGTTGGCAGGTGTCAG 
AGXT2L2 GGATTTGGGGCTCAGGTTC AAGAAATGAACCACCGCAAC 
PROL1 CCAGTTTGGCAGCTTCATCT CTTGAGCATTCTGTGTGCTG 
CMTM6 GGATTCGGATGCTAAGATGC GGGTTGACCTCAGCAGTCTC 
SORT1 GGGTTGACCTCAGCAGTCTC GGATTCGGATGCTAAGATGC 
IAH1 CCACGCAGTCACTTTGGTG GAGCTTCTTGCAAACGGACT 
KLHL25 CTCTGATTGGCTGCTGCTC ACTAGTTTCTCCGGCCTTCC 
MAP2K3 GATTGGTCCTTTCGTTTCCA TTGACAGGCAGGGACAGG 
OAZ1 CCTGATTGGTGAAAGGGAAA AGGCTCACCAACCAATCTCC 
ZNF34 CTGTACACCGCTCCGTTCTC TCTGGAGTCCGAGAAGTCAAC 




HSD17B12 AGAAGCCGCTAGTGAATGGA TCCCAAAGTGCTGGGATTAC 
SMAP2 CTTCCTCCCCACCTCCAC CTGAAGGAAGAGCCCAGTGC 
TAF1C CTTGAGATTTCCCTCGTGGT GTCGTGGTCGTCTGGAAAAT 
ATF2 CCTTAAGCCTGACGGAATCA CCTTCTTGCCTTCCTTCTGA 
UBE2H GTAAGCAGCCCCCTCTCAGT GGGGGCTCAGTCACTCAC 
EYA2 ATGACCCCTGTGAAAGGAAC GGGTGGTTGAGTGAACGAAT 
TUBB3 AAGAGGGGCCATTGTCCT GAAAGGAGGGGCTGTCTCC 
ETV7 GAGCGCTCAAGACAGAAAGC GCCAGGCTCTTACCTGCAT 
mir-17 GTGGGGCTTGTCCGTATTTA AAGGACCATGTGGGTGAATG 
mir-22 AGTCCTTAAAGGGCGACAGC CGAGTCAGTTTGGGGAATGT 
let-7a AGTGAGGGGACGGACGAG AAGCCGTCTGATTGAAGTGC 
Negative control CCGGAAGCACTTCTCCTAGA AAGAGAGAGCGGAAGTGACG 
RBL2 TTGACTCCCAGAAGGGTGAC ATGCCTCCTTCCAAGTCCTC 
TFDP-1 CGGAGAACTCAAGGTCTTCAT GACGGTGGAGGGGTGAAC 
E2F4 TGCAGAAGTCCAGGGAATG TGAGCTCACCACTGTCCTTG 
GAPDH CTGGGCTACACTGAGCACCAG CCAGCGTCAAAGGTGGAC 
 
Primers for cloning distal sites  to perform luciferase assay 
  Left Right 
E1 GAGGTGCCCTTTGACTAGA TACAGACAGACCCTGCCACA 
E2 GGGAAGCTACCAAGGTCCAG TAGCAAAGGGCAGAGAGAGG 
E3 GGGCTCCTCTCCTAAAATGG GGGCTCACCAGAATGGTAAA 
E4 AGGAACTGGTGATGGAGGTG GTTCAGGTGTCCGCAACTTT 
E5 CCACACACACGCTCTCTGTT AGCAGCTCAGCTCTCCTACG 
E6 GCCATGGAGGTTTCTGACAT ACCAGCTCCTGGATTCATTG 
E7 AGGGGAAAACACAGCAAGTG GAACAAAAGGACCAGGAAACC 
E8 AGGGAGGGGGAAAAGAAAGT TACGCAAACGATTCTCATGG 
E9 TCGCATAATTGGGTCTTCAA CCCCAGGTCTCTGTTGAAAT 
E10 GAAAAAGTCCGGGTGACGTA TTTGCTACCATTTGCCCAAG 
Positive 








Appendix B. Bidirectional E2F4 binding sites  
  Chr Gene Strand  Start  Symbol Strand Sstart 
Peak 
position 
chr1 B3GALT6 + 1157491 SDF4 - 1157310 1157382 
chr1 RER1 + 2313073 MORN1 - 2312853 2312980 
chr1 TAS1R1 + 6538020 NOL9 - 6537168 6537244 
chr1 C1orf213 + 23568050 ZNF436 - 23567466 23568016 
chr1 ZCCHC17 + 31542428 WDR57 - 31542231 31542398 
chr1 RBBP4 + 32889410 ZBTB8OS - 32888772 32889291 
chr1 CDCA8 + 37930745 C1orf109 - 37928779 37928935 
chr1 C1orf50 + 43005502 LEPRE1 - 43005342 43005353 
chr1 PRPF38A + 52642806 ORC1L - 52642719 52642735 
chr1 LRRC42 + 54184624 HSPB11 - 54183876 54183900 
chr1 C1orf83 + 54291861 TMEM59 - 54291699 54291718 
chr1 EFCAB7 + 63761855 ITGB3BP - 63761423 63761516 
chr1 SFRS11 + 70443952 LRRC40 - 70443863 70443902 
chr1 DCLRE1B + 114249560 AP4B1 - 114249264 114249461 
chr1 PRUNE + 149247596 FAM63A - 149245957 149246677 
chr1 CKS1B + 153213837 SHC1 - 153213583 153213781 
chr1 TMEM79 + 154519362 SMG5 - 154519244 154519288 
chr1 C1orf66 + 154964901 ISG20L2 - 154964329 154964885 
chr1 IQWD1 + 166172531 BRP44 - 166171857 166172051 
chr1 C1orf112 + 168031173 C1orf156 - 168030655 168030803 
chr1 RGL1 + 181871830 ARPC5 - 181871608 181871616 
chr1 KIAA0133 + 227828603 TAF5L - 227828417 227828518 
chr10 FBXO18 + 5972219 ANKRD16 - 5971352 5971923 
chr10 CISD1 + 59698900 IPMK - 59697700 59697920 
chr10 UBTD1 + 99248757 MMS19 - 99248356 99248578 
chr10 FBXL15 + 104169560 PSD - 104168891 104169460 
chr10 SFXN2 + 104464287 ARL3 - 104464180 104464260 
chr11 RIC8A + 198529 BET1L - 197422 197692 
chr11 LRRC56 + 527526 HRAS - 525550 525826 
chr11 RASSF7 + 551449 C11orf35 - 550779 550997 
chr11 ILK + 6581539 KIAA0409 - 6581387 6581434 
chr11 C11orf17 + 8889276 ST5 - 8889074 8889264 




chr11 DNAJC24 + 31347952 DCDC1 - 31347897 31347901 
chr11 C11orf79 + 60954172 FLJ12529 - 60953849 60953875 
chr11 TTC9C + 62252527 HNRNPUL2 - 62251397 62251565 
chr11 NUDT22 + 63750313 TRPT1 - 63750257 63750295 
chr11 GPR137 + 63809906 BAD - 63808740 63809397 
chr11 CCS + 66117265 CCDC87 - 66117130 66117240 
chr11 C11orf82 + 82290384 PRCP - 82289205 82289242 
chr11 JMJD2D + 94346492 CWC15 - 94346424 94346467 
chr11 CEP57 + 95163289 FAM76B - 95162602 95162748 
chr11 JRKL + 95763461 CCDC82 - 95762731 95762942 
chr11 ATM + 107598768 NPAT - 107598575 107598626 
chr11 RBM7 + 113776593 C11orf71 - 113776349 113776466 
chr11 RNF214 + 116608613 PCSK7 - 116608021 116608063 
chr11 FOXRED1 + 125644264 SRPR - 125643960 125644197 
chr11 ACAD8 + 133628643 THYN1 - 133628470 133628632 
chr12 C12orf32 + 2856649 FOXM1 - 2856564 2856628 
chr12 RAD51AP1 + 4518316 C12orf4 - 4517898 4518262 
chr12 NCAPD2 + 6473558 MRPL51 - 6472732 6473366 
chr12 USP5 + 6831545 CDCA3 - 6830717 6830746 
chr12 C12orf60 + 14847772 WBP11 - 14847668 14847715 
chr12 GOLT1B + 21546066 RECQL - 21545796 21545880 
chr12 IRAK4 + 42439019 PUS7L - 42438863 42438974 
chr12 TARBP2 + 52180971 MAP3K12 - 52179538 52179883 
chr12 HNRNPA1 + 52960754 CBX5 - 52960182 52960185 
chr12 C12orf26 + 81276454 CCDC59 - 81276330 81276388 
chr12 VEZT + 94135652 FGD6 - 94135371 94135405 
chr12 APAF1 + 97563208 IKIP - 97562720 97562934 
chr12 SCYL2 + 99185679 DEPDC4 - 99184988 99185506 
chr12 C12orf48 + 101038085 NUP37 - 101036491 101038054 
chr12 ISCU + 107480423 SART3 - 107479295 107480334 
chr12 MVK + 108495882 MMAB - 108495741 108495759 
chr12 ERP29 + 110935534 TMEM116 - 110935318 110935390 
chr12 C12orf52 + 112107937 DDX54 - 112107667 112107675 
chr12 RNFT2 + 115660478 C12orf49 - 115660226 115660451 
chr12 DYNLL1 + 119392042 SFRS9 - 119391941 119391987 
chr12 KNTC1 + 121577761 RSRC2 - 121577500 121577721 




chr12 NOC4L + 131194945 DDX51 - 131194833 131194944 
chr12 PXMP2 + 131774264 POLE - 131774018 131774047 
chr13 EXOSC8 + 36472916 ALG5 - 36471477 36471502 
chr13 SETDB2 + 48916510 CAB39L - 48916222 48916297 
chr13 ALG11 + 51484550 ATP7B - 51483631 51484111 
chr13 TMCO3 + 113193308 DCUN1D2 - 113193024 113193042 
chr14 RNF31 + 23686498 PSME2 - 23685695 23686365 
chr14 C14orf21 + 23838937 DHRS1 - 23838506 23838833 
chr14 LTB4R + 23852356 CIDEB - 23850416 23850490 
chr14 FANCM + 44674885 FKBP3 - 44674272 44674854 
chr14 ATP5S + 49848796 L2HGDH - 49848697 49848724 
chr14 GPR137C + 52089615 TXNDC16 - 52088963 52089282 
chr14 SOCS4 + 54563593 WDHD1 - 54563557 54563564 
chr14 SLC38A6 + 60517632 TRMT5 - 60517535 60517622 
chr14 TTLL5 + 75197373 C14orf1 - 75196912 75197320 
chr14 C14orf174 + 76913514 TMED8 - 76913149 76913277 
chr14 KIAA1409 + 92869317 BTBD7 - 92869138 92869255 
chr14 FAM14B + 93617391 DDX24 - 93617311 93617376 
chr14 CCNK + 99017491 SETD3 - 99016979 99017106 
chr14 BTBD6 + 104786052 BRF1 - 104785267 104785886 
chr15 CHP + 39310728 EXDL1 - 39310187 39310704 
chr15 DTWD1 + 47700587 C15orf33 - 47700410 47700437 
chr15 IQCH + 65334241 FLJ11506 - 65334128 65334133 
chr15 LRRC49 + 68972040 THAP10 - 68971807 68971932 
chr16 C16orf33 + 43828 POLR3K - 43625 43717 
chr16 NUBP2 + 1772933 SPSB3 - 1772582 1772582 
chr16 UBN1 + 4837912 N-PAC - 4837304 4837414 
chr16 ASPHD1 + 29819647 SEZ6L2 - 29818081 29818945 
chr16 CCDC95 + 29915031 HIRIP3 - 29914888 29914929 
chr16 RNF40 + 30681130 LOC90835 - 30681043 30681096 
chr16 ORC6L + 45281058 VPS35 - 45280645 45281046 
chr16 PHKB + 46052710 ITFG1 - 46052516 46052524 
chr16 FBXL8 + 65751391 TRADD - 65751313 65751313 
chr16 SLC9A5 + 65840355 FHOD1 - 65838926 65839074 
chr16 SF3B3 + 69115201 COG4 - 69114958 69115198 
chr16 ZC3H18 + 87164344 C16orf85 - 87164049 87164212 
chr16 C16orf55 + 88251710 CHMP1A - 88251630 88251667 




chr17 TMEM93 + 3518838 TAX1BP3 - 3518722 3518820 
chr17 RNF167 + 4784374 SLC25A11 - 4784063 4784100 
chr17 MIS12 + 5330970 DERL2 - 5330218 5330631 
chr17 POLR2A + 7328573 ZBTB4 - 7328292 7328343 
chr17 WDR79 + 7532519 TP53 - 7531588 7532423 
chr17 CNTROB + 7776197 TRAPPC1 - 7775983 7776122 
chr17 PFAS + 8093361 C17orf68 - 8092138 8093295 
chr17 C17orf39 + 17883335 ATPAF2 - 17883205 17883295 
chr17 SMCR8 + 18159318 TOP3A - 18159046 18159049 
chr17 PIGW + 31965515 MYO19 - 31964838 31964895 
chr17 TUBG1 + 38015219 FAM134C - 38014928 38015192 
chr17 CNTD1 + 38204379 CCDC56 - 38204230 38204274 
chr17 TMUB2 + 39619879 C17orf65 - 39619608 39619674 
chr17 CCDC103 + 40332679 EFTUD2 - 40332289 40332390 
chr17 UTP18 + 46692895 MBTD1 - 46692426 46692878 
chr17 PRR11 + 54587874 FAM33A - 54587582 54587826 
chr17 CCDC45 + 59933619 DDX5 - 59932869 59933529 
chr17 TMEM104 + 70284216 NAT9 - 70284065 70284117 
chr17 TSEN54 + 71024203 CASKIN2 - 71023222 71023687 
chr17 SAP30BP + 71174993 RECQL5 - 71174864 71174990 
chr17 MFSD11 + 72245377 SFRS2 - 72245007 72245158 
chr17 TMC8 + 73638453 TMC6 - 73636456 73637397 
chr17 CCDC137 + 77244165 C17orf90 - 77244023 77244106 
chr17 ANAPC11 + 77442894 THOC4 - 77442758 77442879 
chr17 LRRC45 + 77574568 STRA13 - 77574062 77574353 
chr18 NDC80 + 2561604 METTL4 - 2561489 2561538 
chr18 PSMG2 + 12693063 CEP76 - 12692703 12692724 
chr18 RNMT + 13716703 C18orf19 - 13716591 13716653 
chr18 KIAA1468 + 58005503 PIGN - 58005269 58005361 
chr18 C18orf55 + 69966725 FBXO15 - 69965929 69965979 
chr18 TSHZ1 + 71051718 ZADH2 - 71050105 71050536 
chr19 REEP6 + 1442164 PCSK4 - 1441407 1441427 
chr19 SF3A2 + 2187815 PLEKHJ1 - 2187328 2187773 
chr19 SAFB + 5574163 SAFB2 - 5573938 5574083 
chr19 TMEM146 + 5671687 LONP1 - 5671176 5671224 
chr19 BTBD14B + 13090108 TRMT1 - 13088332 13089996 
chr19 CC2D1A + 13878051 C19orf57 - 13877909 13877932 




chr19 MYO9B + 17047590 NY-SAR-48 - 17047343 17047565 
chr19 RFXANK + 19164007 MEF2B - 19163933 19163977 
chr19 C19orf40 + 38154987 CCDC123 - 38154709 38154909 
chr19 PSENEN + 40928333 U2AF1L4 - 40928176 40928259 
chr19 C19orf55 + 40940883 HSPB6 - 40939770 40940825 
chr19 WDR62 + 41237622 THAP8 - 41237504 41237609 
chr19 EIF3K + 43801561 MAP4K1 - 43800483 43801518 
chr19 SNRPA + 45948618 C19orf54 - 45947668 45948533 
chr19 BCKDHA + 46595543 EXOSC5 - 46595096 46595103 
chr19 ZNF576 + 48792383 IRGQ - 48791516 48792283 
chr19 BLOC1S3 + 50373842 TRAPPC6A - 50373325 50373398 
chr19 QPCTL + 50887771 SNRPD2 - 50887282 50887344 
chr19 SYNGR4 + 53559468 TMEM143 - 53558998 53559396 
chr19 RUVBL2 + 54188967 GYS1 - 54188361 54188432 
chr19 ZNF524 + 60803541 FIZ1 - 60802705 60803352 
chr2 TTC15 + 3362452 TSSC1 - 3360605 3360691 
chr2 CENPO + 24869836 C2orf79 - 24869755 24869818 
chr2 C2orf13 + 68548245 FBXO48 - 68547894 68548005 
chr2 CCT7 + 73314912 C2orf7 - 73313864 73313893 
chr2 DOK1 + 74635367 LOXL3 - 74634570 74634829 
chr2 RBED1 + 85435446 RETSAT - 85435166 85435414 
chr2 CIAO1 + 96295610 TMEM127 - 96295459 96295528 
chr2 EIF5B + 99320265 TXNDC9 - 99319292 99320181 
chr2 DBI + 119840973 C2orf76 - 119840728 119840861 
chr2 ARL6IP6 + 153283375 PRPF40A - 153282221 153282290 
chr2 PKP4 + 159021721 CCDC148 - 159021460 159021643 
chr2 NIF3L1 + 201462390 PPIL3 - 201462244 201462362 
chr2 EEF1B2 + 206732562 NDUFS1 - 206732432 206732542 
chr2 RQCD1 + 219141921 USP37 - 219141328 219141594 
chr2 FAM134A + 219751182 C2orf24 - 219749946 219749993 
chr2 EIF4E2 + 233123600 TIGD1 - 233123470 233123502 
chr2 PPP1R7 + 241738574 PASK - 241737551 241737621 
chr20 CDS2 + 5055481 PCNA - 5055268 5055269 
chr20 MCM8 + 5879297 TRMT6 - 5879173 5879288 
chr20 C20orf72 + 17897761 SNX5 - 17897490 17897647 
chr20 POFUT1 + 30259356 PLAGL2 - 30259207 30259345 
chr20 RPRD1B + 36095361 KIAA0406 - 36095247 36095318 




chr20 C20orf177 + 57948950 PPP1R3D - 57948747 57948894 
chr20 C20orf11 + 61039885 DIDO1 - 61039719 61039752 
chr21 SON + 33837219 GART - 33836286 33836318 
chr21 SH3BGR + 39739666 LCA5L - 39737998 39739625 
chr21 RRP1B + 43903859 HSF2BP - 43903802 43903852 
chr21 C21orf57 + 46530694 MCM3AP - 46529664 46530554 
chr22 MRPL40 + 17800035 HIRA - 17799219 17799346 
chr22 CDC45L + 17847415 UFD1L - 17846726 17846755 
chr22 RANBP1 + 18485023 HTF9C - 18484768 18484900 
chr22 SNAP29 + 19543291 PI4KA - 19543070 19543268 
chr22 HSCB + 27468042 CHEK2 - 27467822 27467837 
chr22 MPST + 35745647 TST - 35745437 35745640 
chr22 XPNPEP3 + 39583039 ST13 - 39582633 39582990 
chr22 CRELD2 + 48698347 ALG12 - 48698110 48698220 
chr3 PARP3 + 51951400 RRP9 - 51950962 51951248 
chr3 IL17RB + 53855616 CHDH - 53855216 53855460 
chr3 ATXN7 + 63825272 THOC7 - 63824637 63825187 
chr3 SLC35A5 + 113763584 ATG3 - 113763175 113763289 
chr3 FAM162A + 123585712 CCDC58 - 123584764 123585686 
chr3 DIRC2 + 123996590 HSPBAP1 - 123995340 123995362 
chr3 IFT122 + 130641657 MBD4 - 130641542 130641609 
chr3 SMC4 + 161600123 IFT80 - 161600014 161600034 
chr3 POLR2H + 185563887 CLCN2 - 185562085 185562300 
chr3 FBXO45 + 197780121 WDR53 - 197779810 197779936 
chr3 PIGX + 197923642 C3orf34 - 197923520 197923580 
chr3 LMLN + 199171467 IQCG - 199171271 199171313 
chr4 TMEM175 + 916261 GAK - 916174 916195 
chr4 C4orf42 + 1234176 CTBP1 - 1232908 1233136 
chr4 TACC3 + 1693063 TMEM129 - 1692882 1693025 
chr4 GRK4 + 2935140 NOL14 - 2934916 2935093 
chr4 MGC21874 + 7096056 CCDC96 - 7095629 7095660 
chr4 NCAPG + 17421622 C4orf30 - 17421479 17421591 
chr4 ENOPH1 + 83570749 HNRPDL - 83570402 83570588 
chr4 CISD2 + 104009575 UBE2D3 - 104009473 104009502 
chr4 LARP7 + 113777568 C4orf21 - 113777505 113777541 
chr4 SPATA5 + 124063674 NUDT6 - 124063573 124063662 
chr4 ARFIP1 + 153920561 TIGD4 - 153920327 153920359 




chr5 EXOC3 + 496333 LOC116349 - 496210 496252 
chr5 TRIP13 + 946003 BRD9 - 945915 945987 
chr5 NDUFS6 + 1854508 MRPL36 - 1852956 1853047 
chr5 SRD5A1 + 6686499 NSUN2 - 6686157 6686341 
chr5 C5orf22 + 31568129 RNASEN - 31568039 31568075 
chr5 SKIV2L2 + 54639332 DHX29 - 54639278 54639323 
chr5 PPWD1 + 64894886 CENPK - 64894751 64894777 
chr5 PTCD2 + 71651955 MRPS27 - 71651840 71651860 
chr5 XRCC4 + 82409072 TMEM167A - 82408935 82409070 
chr5 ANKRD32 + 93980146 C5orf36 - 93980040 93980095 
chr5 RELL2 + 140996700 HDAC3 - 140996607 140996678 
chr5 HMMR + 162820240 NUDCD2 - 162819721 162820233 
chr6 THEM2 + 24775253 TTRAP - 24775094 24775110 
chr6 HIST1H2BH + 26359857 HIST1H3F - 26358814 26359156 
chr6 HIST1H2AG + 27208799 HIST1H2BJ - 27208554 27208779 
chr6 HIST1H2AI + 27883955 HIST1H2BL - 27883688 27883860 
chr6 HIST1H2BM + 27890800 HIST1H2AJ - 27890497 27890609 
chr6 TCF19 + 31234281 CCHCR1 - 31233994 31234279 
chr6 PSMB9 + 32929915 TAP1 - 32929726 32929898 
chr6 SYNGAP1 + 33495824 CUTA - 33494043 33494141 
chr6 NFYA + 41148687 C6orf130 - 41148166 41148306 
chr6 KLHDC3 + 43089954 MEA1 - 43089596 43089645 
chr6 POLH + 43651855 XPO5 - 43651642 43651840 
chr6 MAD2L1BP + 43705256 GTPBP2 - 43704914 43705126 
chr6 CENPQ + 49539054 MUT - 49538990 49538992 
chr6 DOPEY1 + 83834103 UBE2CBP - 83832264 83832342 
chr6 ORC3L + 88356561 RARS2 - 88356440 88356524 
chr6 C6orf182 + 109523048 SESN1 - 109521970 109522817 
chr6 PEX3 + 143813809 ADAT2 - 143813534 143813658 
chr6 MRPL18 + 160131481 TCP1 - 160130725 160130754 
chr7 CBX3 + 26207623 HNRNPA2B1 - 26206938 26206966 
chr7 CPSF4 + 98874498 PTCD1 - 98874355 98874436 
chr7 AP4M1 + 99537065 MCM7 - 99536316 99536438 
chr7 CNPY4 + 99555200 TAF6 - 99554915 99555149 
chr7 MEPCE + 99865464 ZCWPW1 - 99864238 99864345 
chr7 LRWD1 + 101892394 ALKBH4 - 101892293 101892338 
chr7 DNAJB9 + 107997591 THAP5 - 107997403 107997538 




chr8 ESCO2 + 27687976 CCDC25 - 27686089 27686099 
chr8 ADAM9 + 38973661 TM2D2 - 38973198 38973236 
chr8 MCM4 + 49036046 PRKDC - 49035296 49035995 
chr8 CHCHD7 + 57286868 PLAG1 - 57286413 57286781 
chr8 PTDSS1 + 97343342 MTERFD1 - 97342972 97343011 
chr8 POP1 + 99199243 HRSP12 - 99198594 99198711 
chr8 ENY2 + 110415811 NUDCD1 - 110415526 110415728 
chr8 KIFC2 + 145662545 CYHR1 - 145661839 145662500 
chr8 LRRC14 + 145714198 RECQL4 - 145714008 145714060 
chr9 IFT74 + 26937309 PLAA - 26937139 26937238 
chr9 NUDT2 + 34319503 KIF24 - 34319198 34319283 
chr9 DNAI1 + 34448810 C9orf25 - 34448568 34448731 
chr9 CREB3 + 35722316 TLN1 - 35722128 35722277 
chr9 OSTF1 + 76893217 C9orf95 - 76892953 76893093 
chr9 SLC31A1 + 115023688 FKBP15 - 115023462 115023588 
chr9 C9orf43 + 115212842 POLE3 - 115212773 115212816 
chr9 MRRF + 124066967 RBM18 - 124066911 124066933 
chr9 SLC25A25 + 129870299 NAIF1 - 129869212 129870271 
chr9 LRRC8A + 130684211 CCBL1 - 130684175 130684185 
chr9 C9orf163 + 138497767 SEC16A - 138497328 138497349 
chr9 C8G + 138959518 FBXW5 - 138958994 138959000 
chr9 NDOR1 + 139220003 TMEM203 - 139219911 139219972 
chrX MOSPD2 + 14801483 FANCB - 14801105 14801133 
chrX KIF4A + 69426619 PDZD11 - 69426523 69426591 
chrX TMEM187 + 152891184 HCFC1 - 152890013 152890109 




















ZFPL1 159.09 ZNF764 8.19 LITAF 5.74 
TRIP13 129.83 TRIM27 8.16 NR2F2 5.74 
BRD9 129.83 TRIM27 8.16 OPTN 5.72 
FOXM1 99.85 KLF6 8.15 ZNF354A 5.72 
TCF19 96.65 ZNF684 8.15 PCGF2 5.72 
LRRC14 92.92 RNF4 8.13 OSR2 5.72 
CTCF 90.35 ZBTB44 8.11 KLF9 5.68 
HMX2 89.87 C14orf166 8.09 IRF2 5.68 
UHRF1 73.63 PER2 8.09 RNF141 5.68 
ZNF653 69.64 TAF6 8.08 NUFIP2 5.68 
ZNF688 66.69 CTNNB1 8.07 ZNF420 5.68 
C14orf106 62.05 EGR1 8.07 MSX1 5.66 
HMGB2 54.51 ZNF256 8.07 NAB1 5.66 
TIMELESS 47.06 ULK2 8.05 ZFAND5 5.66 
C15orf42 46.82 ELK1 8.04 GRHL1 5.66 
RBL1 46.58 MYST2 8.03 BCL11A 5.64 
DMTF1 46.05 ZNF84 7.99 ZNF582 5.63 
MYBL2 45.14 ZNF687 7.99 SNAPC3 5.62 
E2F3 44.55 RFXANK 7.96 ZNF202 5.62 
SLC25A40 44.03 MEF2B 7.96 DLX2 5.62 
ASH2L 42.69 TULP3 7.95 CNOT3 5.61 
SUV39H1 40.1 ZNF138 7.95 JMJD1C 5.6 
IRF8 39.89 NFAT5 7.94 PHF17 5.6 
JMJD2D 39.69 HIC1 7.93 NR2F6 5.59 
E2F2 37.06 PAWR 7.92 ZNF691 5.59 
HDAC4 37.02 ENO1 7.91 RUNX3 5.58 
ZNF331 35.02 YY1 7.91 BACH1 5.58 
MTF2 34.34 ZNF282 7.89 ZNF323 5.57 
IRF3 34.2 HCFC2 7.89 ZNF32 5.56 
YEATS4 33.01 KLF13 7.89 UBP1 5.56 
NFKBIL2 32.7 ZNF589 7.87 CDR2L 5.56 
SART3 32.15 RNF8 7.86 SHOX2 5.55 
NFYA 31.93 FOXK2 7.84 TAF1A 5.55 




MYBL1 31.35 ZNF695 7.82 HSF1 5.54 
ZNF689 30.42 HDAC1 7.81 ZNRF1 5.54 
RFX2 29.88 ELF2 7.81 NR1H3 5.53 
ARID3B 28.37 CUX1 7.75 ZNF236 5.53 
FOXN2 27.75 ZNF267 7.74 ZNF214 5.53 
SUPT4H1 27.13 ZNF318 7.73 PHF21A 5.53 
WHSC1 25.63 BTBD6 7.73 ZNF44 5.52 
MYB 24.59 ZNF646 7.72 ZNF655 5.52 
TFDP1 24.47 ZNF668 7.72 MYCL1 5.51 
ZNF473 24.32 IRF7 7.71 GFI1 5.51 
AATF 24.14 SETBP1 7.71 ZNF623 5.51 
TCF15 23.58 ATF5 7.7 GTF2E1 5.5 
YAF2 23.32 ARNTL 7.64 SCMH1 5.5 
ZNF519 22.21 RING1 7.63 CITED2 5.49 
TAF5 22.07 SSRP1 7.62 GTF2I 5.45 
HMGB3 21.28 TBPL1 7.62 AHR 5.45 
SP4 21.22 ZNF827 7.62 CEBPA 5.45 
HLTF 21.03 TRIM13 7.61 ECD 5.44 
HMGN2 20.81 HDAC2 7.6 VSX1 5.44 
FIZ1 20.78 JUN 7.59 INSM2 5.44 
ZNF524 20.78 SUPT16H 7.58 EP300 5.43 
EED 20.11 TRIM24 7.57 POU2AF1 5.43 
YBX2 20.02 NFYC 7.57 ZNF643 5.43 
ATF7IP 18.48 ZNF276 7.57 ZNF57 5.43 
BLOC1S1 18.43 REL 7.56 IRF1 5.41 
PIAS4 18.05 DBP 7.55 JMJD1B 5.41 
EZH2 18 FOXO1 7.55 MXD1 5.4 
ZFAT 17.81 HIVEP2 7.55 ZNF490 5.4 
ZNF770 17.48 ZNF497 7.53 SP1 5.4 
CNBP 17.26 HEY2 7.52 ATOH7 5.4 
KLHL12 17.16 CREG1 7.51 ZNF791 5.4 
ZNF266 17.07 RNF115 7.51 ZNF773 5.4 
ZNF443 17.01 CBX6 7.48 ZNF581 5.39 
DIDO1 16.48 ATG4B 7.46 ZNF768 5.39 
SPEN 16.46 ZFAND3 7.46 SMAD6 5.38 
SAFB 16.37 FOSL2 7.45 SOX12 5.38 




CNPY3 16.32 ETV2 7.43 MED14 5.36 
TRIM33 16.31 HPCAL1 7.43 BARHL1 5.36 
IER2 15.95 ZNF398 7.42 BHLHB2 5.35 
BTAF1 15.94 ZNF100 7.42 ZHX2 5.35 
CIAO1 15.94 GABPA 7.41 GTF2H3 5.34 
NR4A2 15.91 ZNF324 7.41 KLF7 5.34 
ZNF274 15.82 ZXDC 7.4 ZNF671 5.34 
RFX1 15.63 SMARCA4 7.38 ZNF3 5.33 
CBX3 15.6 ZNF133 7.38 ZNF3 5.33 
NR2C2 15.56 IRF5 7.32 CDK5 5.31 
MYC 15.52 CAND1 7.31 HOXC8 5.31 
ZNF184 15.45 NFE2L3 7.3 DLX1 5.3 
ZNF180 15.42 ZNF273 7.3 ZNF703 5.29 
HMGB1 15.3 ETV5 7.28 CIC 5.28 
ZNF436 15.16 MESP1 7.28 CSRP2 5.27 
ZNF341 14.89 BPTF 7.26 NCOA4 5.27 
TFEB 14.88 NFKBIA 7.24 C19orf6 5.27 
STAT1 14.79 ZNF74 7.23 ISL2 5.24 
MXD3 14.74 ADNP 7.23 TP53BP2 5.23 
ZBTB1 14.7 TCF12 7.22 C19orf28 5.23 
ZBTB25 14.7 HMG20A 7.2 PRDM15 5.22 
NR6A1 14.56 KLF16 7.2 MANSC1 5.2 
EME2 14.44 IKZF3 7.19 TFB1M 5.19 
RUNX1 14.38 SMARCE1 7.17 IKZF1 5.18 
ZNF785 14.32 ZNF140 7.17 ZXDB 5.18 
HSF2BP 14.29 ZNF174 7.15 SAP30BP 5.18 
ZNF786 14.25 ETV3 7.15 SRF 5.17 
POU2F1 13.96 ZNF434 7.15 RERE 5.17 
CDR2 13.92 BRD7 7.1 SMARCC2 5.16 
GTF3C5 13.8 NCOA2 7.08 TEF 5.16 
TCERG1 13.65 ZFP36L2 7.07 NEUROG3 5.16 
PBX4 13.61 SMAD2 7.05 ZNF574 5.15 
ZNF567 13.49 ZEB1 7.05 LHX4 5.14 
TTLL4 13.45 ZNF584 7.05 KLF5 5.13 
ZNF101 13.42 ZNF10 7.04 TRIP10 5.13 
GTF3A 13.35 USF2 7.03 HOXA11 5.13 
ZNF200 13.35 TAF15 7.01 ZNF277 5.13 




CSRP1 13.26 TSC22D2 6.96 FOXH1 5.12 
RBL2 13.19 HOXB5 6.95 E4F1 5.12 
MNX1 13.1 NFKB2 6.93 INSM1 5.11 
ZNF107 13.1 TTLL5 6.92 RNF114 5.11 
MAZ 13.09 HOXA1 6.91 AFF1 5.1 
CBX5 13.06 BANP 6.91 SNAI1 5.09 
CREB3 13.04 MLL 6.9 ZFHX3 5.08 
HEXIM1 13.03 JARID2 6.87 TFB2M 5.08 
C16orf80 12.81 THRAP3 6.87 ZNF7 5.07 
PLAGL2 12.75 NANOG 6.87 MYCBP 5.07 
CBX1 12.57 GTF3C2 6.86 MLL3 5.07 
SMAD4 12.44 SAP30 6.83 ESRRA 5.06 
PIAS1 12.43 MORF4L2 6.83 ZNF514 5.06 
TP53 12.37 ZNF337 6.82 ZFP3 5.06 
PRDM2 12.36 KLHDC5 6.82 TRIM26 5.05 
MXD4 12.13 ZBTB2 6.82 SOX10 5.05 
ZNF76 12.03 PAX6 6.81 PRDM16 5.05 
ZNF93 12.02 RBBP9 6.81 AKAP9 5.05 
PBX3 11.94 ZFP1 6.79 SOX9 5.04 
ADPGK 11.94 FOXN4 6.79 TADA2L 5.04 
TRIM4 11.83 ZNF22 6.77 ZNF416 5.03 
IRF4 11.69 FOXF1 6.76 ZNF416 5.03 
NFE2L2 11.62 RUFY3 6.76 PKNOX1 5.02 
ZNF672 11.56 MBD1 6.74 SUPT3H 5.01 
ZNF568 11.55 FOS 6.73 MEF2D 5.01 
RB1 11.53 EGR3 6.72 CEBPD 5 
TRIM28 11.45 HOXC6 6.72 TOX 5 
HMGA1 11.43 HOXC4 6.72 SERTAD2 4.99 
ZNF692 11.42 HOXC5 6.72 CBX8 4.99 
ZNF18 11.33 BCLAF1 6.69 MAFG 4.97 
MBD2 11.32 TRIM9 6.69 BRPF1 4.96 
BRD2 11.27 MYBBP1A 6.68 RORA 4.96 
DPF2 11.2 NEUROG2 6.68 GTF2F2 4.93 
MLXIP 11.18 MICALL1 6.68 SATB2 4.93 
DPF1 11.12 SMAD5 6.67 ZNF146 4.92 
HIRA 11.11 RBAK 6.63 MYST4 4.91 
PATZ1 11.11 ETS2 6.62 ZNF322A 4.91 




OTP 11.07 CBFA2T2 6.61 HNF1B 4.9 
PHTF1 11.06 ZNF160 6.61 SIM1 4.88 
TAF5L 11.05 HOXB2 6.58 NFIL3 4.88 
ZNF670 10.99 ZNF212 6.54 ZNF593 4.88 
ZNF509 10.98 ZFHX4 6.54 LEF1 4.87 
SIAH1 10.96 TRIM39 6.54 L3MBTL3 4.87 
FOSB 10.94 CROCC 6.5 ZNF431 4.87 
ZNF382 10.88 SOX4 6.48 MAX 4.86 
HES1 10.75 SF1 6.48 NMI 4.86 
MFSD3 10.75 ZMYND11 6.48 PHF16 4.86 
ZNF696 10.72 MLL4 6.46 OTUD7B 4.86 
CBX7 10.7 ZNF148 6.46 POU6F1 4.85 
XBP1 10.68 PIAS3 6.45 SPIB 4.85 
ARID1A 10.64 ZNF195 6.45 PDLIM5 4.85 
C19orf25 10.56 SETD4 6.43 L3MBTL 4.85 
ZNF294 10.45 IGHMBP2 6.42 ZNF396 4.85 
REV3L 10.42 SP2 6.38 FOXJ1 4.84 
MGA 10.4 ZNF33A 6.36 ZSCAN29 4.84 
BRD3 10.33 JMJD2C 6.36 ZNF141 4.83 
SIX5 10.33 ZNF268 6.35 ZBTB17 4.83 
SNAPC4 10.3 ZNF264 6.34 KLF2 4.83 
HHEX 10.28 RBBP5 6.34 KLF2 4.83 
RCOR3 10.28 RASSF7 6.33 ZNF746 4.83 
TP73 10.19 SMAD1 6.32 ZNF746 4.83 
ASPH 10.17 TFAM 6.31 HNF4G 4.82 
ZNF239 9.98 ZNF426 6.31 MXI1 4.82 
ZNF430 9.97 MZF1 6.3 ACVR2A 4.81 
DRAP1 9.79 ATF4 6.3 ZSCAN22 4.79 
ZNF446 9.7 NFE2L1 6.28 TFAP4 4.78 
PSIP1 9.7 CLOCK 6.27 ZFP36 4.78 
NR4A3 9.7 ZNF639 6.27 NFYB 4.78 
RNF24 9.69 LAS1L 6.27 SNW1 4.78 
KEAP1 9.67 FHL2 6.26 NKX2-4 4.77 
TBC1D10B 9.66 HEY1 6.26 ZMYM4 4.76 
ZNF800 9.66 TSHZ1 6.26 MIER3 4.76 
ZNF41 9.65 LZTR1 6.26 MTA1 4.75 
ZNF143 9.63 PHF15 6.26 NR2C1 4.74 




TAF12 9.6 POU2F3 6.25 HES6 4.73 
ZNF142 9.58 ZNF445 6.24 MIXL1 4.73 
NR1D2 9.57 ARID1B 6.23 KBTBD7 4.73 
LMO4 9.57 TRMT1 6.22 CEBPB 4.71 
ZFP62 9.56 ATXN2 6.2 DLX4 4.7 
TAF4B 9.55 PER1 6.19 MYF6 4.7 
MED26 9.53 MTA2 6.19 SMAD7 4.7 
PMF1 9.53 CCT4 6.18 RORB 4.7 
ZNF85 9.52 KLHL21 6.18 ASCL1 4.68 
MLLT1 9.48 ZNF767 6.18 FOXG1 4.67 
TRIP4 9.47 CHD4 6.17 ELK4 4.67 
SCAND1 9.47 MED7 6.17 FLI1 4.66 
LHX2 9.42 MAFF 6.17 MYOD1 4.66 
SND1 9.41 ARFGAP2 6.17 ZNF613 4.65 
MEIS2 9.37 MLLT10 6.16 CHD1 4.64 
JUNB 9.36 CSDA 6.16 RNF144A 4.64 
PLAGL1 9.35 ZNF675 6.15 ZXDA 4.63 
UBR4 9.35 FOXN3 6.12 RNF13 4.63 
TAF1B 9.34 ZNF706 6.12 FOXD1 4.62 
ZNF384 9.33 GRHL3 6.12 ASCL2 4.62 
ARIH2 9.33 ZNF576 6.12 BAZ1A 4.62 
ZNF215 9.33 EP400 6.11 ZNF23 4.62 
ERMP1 9.22 NR3C1 6.09 METTL3 4.61 
TRIP11 9.21 ZNF544 6.09 TRIP6 4.6 
TAF3 9.19 ZNF606 6.07 ELK3 4.6 
ZNF287 9.18 ZNF75A 6.06 SOX13 4.6 
NFX1 9.14 TAF4 6.05 POU4F1 4.6 
BRF1 9.13 ZNF248 6.05 SAMD4B 4.58 
SMARCA2 9.09 NFATC1 6.05 EPAS1 4.57 
ZNF410 9.06 STAT5A 6.04 MNAT1 4.56 
CREB3L4 9.04 HOXB7 6.04 IVNS1ABP 4.56 
ARID3A 9.03 ZNF225 6.04 ZNF669 4.56 
ZFP91 9.01 EGR2 6.03 POU3F1 4.54 
TRIOBP 8.99 FOXD2 6.03 ATF1 4.54 
INTS4 8.98 DMRT2 6 ATF1 4.54 
TBX6 8.97 PURA 6 ILF3 4.54 
ATOH8 8.97 TRIM14 6 IKZF2 4.54 




TSC22D1 8.89 BTBD1 5.97 HSF4 4.52 
PREB 8.88 MESP2 5.97 NFKB1 4.51 
RFX3 8.87 ZNF92 5.95 DKFZP434B0335 4.51 
ARNTL2 8.87 ZBTB4 5.95 ZFP64 4.51 
MBD4 8.85 NR2F1 5.94 ZNF167 4.51 
ZNF681 8.85 ZSCAN2 5.94 HAND2 4.5 
DR1 8.82 LSR 5.93 AFF2 4.49 
ID3 8.82 TP53I13 5.93 FOSL1 4.49 
RELA 8.8 ZNF664 5.91 ZNF24 4.49 
ZNF682 8.8 ZNF664 5.91 ZNF701 4.49 
ZNF605 8.8 ZFX 5.9 HOXB9 4.49 
ZDHHC17 8.74 DEAF1 5.89 ZNF419 4.49 
ZNF263 8.73 PTTG1IP 5.87 TAF10 4.48 
ZNF295 8.73 MAP3K8 5.87 JDP2 4.48 
ZNF575 8.72 MORF4L1 5.87 GTF2F1 4.47 
SUV420H1 8.69 MIER1 5.87 STAT4 4.47 
TMEM175 8.67 RLF 5.85 AFF4 4.47 
TCF3 8.66 ZBTB20 5.84 E2F5 4.46 
SMARCA5 8.66 ZNF329 5.84 ARNT2 4.46 
SMARCC1 8.62 ZFAND6 5.83 USF1 4.45 
MNT 8.6 REPIN1 5.82 RNF10 4.45 
FOXO3 8.58 MLLT3 5.81 IFT172 4.45 
HMX3 8.54 NCOR1 5.81 RRN3 4.45 
GABPB1 8.52 NFIC 5.81 ZNF557 4.44 
JMJD2B 8.51 TBP 5.8 ZNF784 4.44 
STAT5B 8.48 UBTF 5.8 SRCAP 4.43 
CHD1L 8.45 PAX5 5.8 KLF11 4.42 
HIF1A 8.44 ZNF26 5.8 KLHL25 4.42 
LDB1 8.42 ZNF8 5.8 ZNF136 4.41 
ZNF219 8.34 CIZ1 5.78 CNOT8 4.41 
CEBPG 8.31 SRXN1 5.77 MED15 4.41 
BHLHB5 8.31 PLAG1 5.76 PRR7 4.41 
RNF2 8.29 PACS2 5.76 SCML4 4.41 
SP3 8.24 TSC22D4 5.75 VDR 4.4 
JMJD4 8.24 ARID5B 5.75 TEAD3 4.4 
ZNF335 8.2 CRIP1 5.74 CREBBP 4.4 





Appendix D. Putative miRNA targets of E2F4. 
Chr Start End score miRNA miRNA position 
chr5 54504758 54504850 12.7 
hsa-mir-
449a chr5:54502121-54502202 (-) 
chr10 105982121 105982204 14.24 hsa-mir-609 chr10:105968543-105968626 (-) 
chr10 105981964 105982140 5.82 hsa-mir-609 chr10:105968543-105968626 (-) 
chr10 98581759 98581823 6.62 hsa-mir-607 chr10:98578421-98578501 (-) 
chr10 98582592 98582816 4.79 hsa-mir-607 chr10:98578421-98578501 (-) 
chr11 61491733 61491815 8.33 hsa-mir-611 chr11:61316538-61316611 (-) 
chr12 61282889 61283115 5.05 hsa-let-7i chr12:61283728-61283825 (+) 
chr12 12770213 12770260 5.64 hsa-mir-613 chr12:12808850-12808939 (+) 
chr13 90797881 90798063 11.33 hsa-mir-17 chr13:90800863-90800941 (+) 
chr13 49554127 49554209 14.92 
hsa-mir-16-
1 chr13:49521111-49521195 (-) 
chr13 40261526 40261650 4.51 hsa-mir-621 chr13:40282915-40282992 (+) 
chr13 98650837 98651006 11.66 hsa-mir-623 chr13:98806391-98806479 (+) 
chr14 99843038 99843167 5.27 hsa-mir-345 chr14:99843956-99844033 (+) 
chr15 39739987 39740139 10.4 hsa-mir-626 chr15:39771096-39771163 (+) 
chr15 39739851 39740028 8.26 hsa-mir-626 chr15:39771096-39771163 (+) 
chr15 53487779 53487920 7.39 hsa-mir-628 chr15:53452434-53452510 (-) 
chr15 29295474 29295559 6.9 hsa-mir-211 chr15:29144544-29144621 (-) 
chr15 62125569 62125671 6.11 
hsa-mir-
422a chr15:61950185-61950272 (-) 
chr16 15644523 15644636 5.65 hsa-mir-484 chr16:15644614-15644690 (+) 
chr16 65818331 65818474 6.1 hsa-mir-328 chr16:65793721-65793803 (-) 
chr17 72245107 72245234 32.28 hsa-mir-636 chr17:72244133-72244213 (-) 
chr17 26910823 26910964 4.79 
hsa-mir-
193a chr17:26911138-26911213 (+) 
chr17 26909855 26909956 5.22 
hsa-mir-
193a chr17:26911138-26911213 (+) 
chr17 1901174 1901264 5.03 hsa-mir-132 chr17:1899963-1900040 (-) 
chr17 7078080 7078289 4.76 hsa-mir-324 chr17:7067341-7067417 (-) 
chr19 14501324 14501404 11.89 hsa-mir-639 chr19:14501355-14501447 (+) 
chr19 10689668 10689852 8.33 hsa-mir-638 chr19:10690085-10690183 (+) 
chr19 50834435 50834526 4.82 hsa-mir-330 chr19:50834097-50834178 (-) 
chr19 57464594 57464647 16.36 hsa-mir-643 chr19:57476873-57476953 (+) 




chr3 161600209 161600344 9.19 hsa-mir-15b chr3:161605087-161605166 (+) 
chr3 161599954 161600101 7.35 hsa-mir-15b chr3:161605087-161605166 (+) 
chr5 167939108 167939216 6.08 
hsa-mir-
103-1 chr5:167920477-167920558 (-) 
chr5 148717717 148717845 11.91 hsa-mir-143 chr5:148788690-148788764 (+) 
chr6 33284091 33284289 4.56 
hsa-mir-
219-1 chr6:33283600-33283682 (+) 
chr6 45453737 45453879 5.01 hsa-mir-586 chr6:45273404-45273480 (-) 
chr6 30647074 30647143 10.84 hsa-mir-877 chr6:30660078-30660180 (+) 
chr6 126702912 126702994 101.59 hsa-mir-588 chr6:126847475-126847552 (+) 
chr8 22158338 22158438 5.96 hsa-mir-320 chr8:22158423-22158496 (-) 
chr8 105670591 105670720 11.13 
hsa-mir-
548a-3 chr8:105565778-105565855 (-) 
chr9 20674086 20674209 11.1 hsa-mir-491 chr9:20706109-20706184 (+) 



























Appendix E. Putative miRNA targets of E2F4 discovered from ChIP-
seq. 
Chr peak position score miRNA Strand Distance  
chr1 153431317 9.03 hsa-mir-92b + 275 
chr1 153431134 7.73 hsa-mir-92b + 458 
chr1 94084516 8.53 hsa-mir-760 + 460 
chr1 94084892 5.12 hsa-mir-760 + 84 
chr1 154658080 5.02 hsa-mir-9-1 - 1235 
chr1 1083231 4.77 hsa-mir-200b + 9116 
chr1 1083231 4.77 hsa-mir-200a + 9875 
chr10 104182388 9.09 hsa-mir-146b + 3871 
chr10 112730754 5.04 hsa-mir-548e + 7920 
chr10 21829592 4.81 hsa-mir-1915 - 4016 
chr11 61341051 12.09 hsa-mir-1908 - 1763 
chr11 566462 9.64 hsa-mir-210 - 8264 
chr11 61339371 8.8 hsa-mir-1908 - 83 
chr11 63883159 8.11 hsa-mir-1237 + 9491 
chr11 565680 4.91 hsa-mir-210 - 7482 
chr11 63884358 4.64 hsa-mir-1237 + 8292 
chr11 93845269 4.66 hsa-mir-548l - 5875 
chr11 558607 14.97 hsa-mir-210 - 409 
chr11 558944 6.75 hsa-mir-210 - 746 
chr13 90797833 13.05 hsa-mir-18a + 3173 
chr13 90797833 13.05 hsa-mir-19a + 3313 
chr13 90797833 13.05 hsa-mir-20a + 3487 
chr13 90797833 13.05 hsa-mir-19b-1 + 3614 
chr13 90797833 13.05 hsa-mir-92a-1 + 3736 
chr13 90798040 11.33 hsa-mir-18a + 2966 
chr13 90798040 11.33 hsa-mir-19a + 3106 
chr13 90798040 11.33 hsa-mir-20a + 3280 
chr13 90798040 11.33 hsa-mir-19b-1 + 3407 
chr13 90798040 11.33 hsa-mir-92a-1 + 3529 
chr13 89676530 4.8 hsa-mir-622 + 4907 
chr15 94674819 5.74 hsa-mir-1469 + 2675 
chr16 2258131 15.78 hsa-mir-940 + 3618 




chr16 68157940 7.94 hsa-mir-1538 - 668 
chr16 68157419 5.56 hsa-mir-1538 - 147 
chr16 2257713 5.31 hsa-mir-940 + 4036 
chr16 2258927 5.1 hsa-mir-940 + 2822 
chr16 33872095 16.72 hsa-mir-1826 + 914 
chr16 33869607 6.06 hsa-mir-1826 + 3402 
chr16 33872496 5.77 hsa-mir-1826 + 513 
chr17 1566694 10.46 hsa-mir-22 - 2663 
chr17 54587826 8.1 hsa-mir-301a - 4462 
chr17 1905078 7.97 hsa-mir-212 - 4654 
chr17 1903898 7.47 hsa-mir-212 - 3474 
chr17 1905441 6.34 hsa-mir-212 - 5017 
chr17 1905704 4.72 hsa-mir-212 - 5280 
chr17 1907289 4.5 hsa-mir-212 - 6865 
chr17 1908895 7.45 hsa-mir-212 - 8471 
chr17 1908641 5.59 hsa-mir-212 - 8217 
chr17 2600045 6.73 hsa-mir-1253 - 1819 
chr17 30502385 98.58 hsa-mir-923 - 39 
chr17 44069087 5.39 
hsa-mir-196a-
1 - 4167 
chr17 53770484 5.34 hsa-mir-142 - 6806 
chr17 1901238 5.03 hsa-mir-212 - 814 
chr18 45267713 8.31 hsa-mir-1539 + 28 
chr18 45267514 4.55 hsa-mir-1539 + 227 
chr19 2187317 54.19 hsa-mir-1227 - 2169 
chr19 2187773 15.5 hsa-mir-1227 - 2625 
chr19 10375258 5.98 hsa-mir-1181 - 44 
chr19 10515743 5.92 hsa-mir-1238 + 8055 
chr19 3922168 5.18 hsa-mir-637 - 9658 
chr19 50864675 4.83 hsa-mir-642 + 5351 
chr19 13814421 6.46 hsa-mir-24-2 - 6248 
chr19 13814421 6.46 hsa-mir-27a - 6090 
chr19 13814421 6.46 hsa-mir-23a - 5948 
chr19 58899173 4.89 
hsa-mir-526a-
1 + 2145 
chr19 58899173 4.89 hsa-mir-520c + 3346 
chr19 58899173 4.89 hsa-mir-518c + 4628 




chr19 58899173 4.89 hsa-mir-517a + 8161 
chr19 58899173 4.89 hsa-mir-519d + 9240 
chr19 13814787 4.66 hsa-mir-24-2 - 6614 
chr19 13814787 4.66 hsa-mir-27a - 6456 
chr19 13814787 4.66 hsa-mir-23a - 6314 
chr19 2191953 4.6 hsa-mir-1227 - 6805 
chr2 232281283 24.81 hsa-mir-1244 + 4985 
chr2 232280086 17.61 hsa-mir-1244 + 6182 
chr2 232283388 8.52 hsa-mir-1244 + 2880 
chr2 218972774 7.78 hsa-mir-26b + 2839 
chr2 218972515 6.73 hsa-mir-26b + 3098 
chr2 218971082 5.85 hsa-mir-26b + 4531 
chr2 70338959 5.58 
hsa-mir-1285-
2 - 5318 
chr2 232282264 5.5 hsa-mir-1244 + 4004 
chr2 232281788 4.68 hsa-mir-1244 + 4480 
chr2 218973758 4.41 hsa-mir-26b + 1855 
chr2 132731092 26 hsa-mir-663b - -31 
chr2 132736274 14.09 hsa-mir-663b - 5151 
chr2 132732348 11.04 hsa-mir-663b - 1225 
chr2 132732125 9.72 hsa-mir-663b - 1002 
chr2 132731743 6.24 hsa-mir-663b - 620 
chr2 114057804 5.07 
hsa-mir-1302-
3 - 661 
chr2 232283751 6.89 hsa-mir-1244 + 2517 
chr2 219867926 6.86 hsa-mir-153-1 - 760 
chr2 176713680 6.36 hsa-mir-10b + 9597 
chr2 218969086 5.62 hsa-mir-26b + 6527 
chr20 47328481 18.61 hsa-mir-1259 + 1773 
chr20 2581215 14.8 hsa-mir-1292 + 208 
chr20 33506358 5.35 
hsa-mir-1289-
1 - 1025 
chr20 62048277 6.15 hsa-mir-1914 - 4936 
chr20 62048277 6.15 hsa-mir-647 - 3754 
chr20 26136962 9.85 hsa-mir-663 - 48 
chr20 26137237 8.93 hsa-mir-663 - 323 
chr20 26138170 6.94 hsa-mir-663 - 1256 
chr22 18447645 25.49 hsa-mir-1306 + 5936 




chr22 39817236 4.68 hsa-mir-1281 + 1227 
chr22 20336362 16.14 hsa-mir-301b + 908 
chr22 20336362 16.14 hsa-mir-130b + 1231 
chr3 49041896 20.14 hsa-mir-425 - 9225 
chr3 49041896 20.14 hsa-mir-191 - 8750 
chr3 161600286 9.19 hsa-mir-16-2 + 4941 
chr3 187983726 8.46 hsa-mir-1248 + 3429 
chr3 49034541 8.29 hsa-mir-425 - 1870 
chr3 49034541 8.29 hsa-mir-191 - 1395 
chr3 161600034 7.38 hsa-mir-16-2 + 5193 
chr3 161601500 5.1 hsa-mir-16-2 + 3727 
chr3 49034247 4.53 hsa-mir-425 - 1576 
chr3 49034247 4.53 hsa-mir-191 - 1101 
chr4 166519681 4.63 hsa-mir-578 + 7163 
chr5 54504806 12.7 hsa-mir-449b - 2479 
chr5 36188014 9.62 hsa-mir-580 - 4167 
chr5 149089888 8.66 hsa-mir-378 + 2693 
chr5 149091625 6.18 hsa-mir-378 + 956 
chr5 179165491 6.01 hsa-mir-1229 - 7539 
chr5 179166532 5.77 hsa-mir-1229 - 8580 
chr5 175721268 4.79 hsa-mir-1271 + 6287 
chr5 175725791 4.67 hsa-mir-1271 + 1764 
chr5 88006165 7.13 hsa-mir-9-2 - 7652 
chr6 32034712 10.82 hsa-mir-1236 - 2016 
chr7 99537011 38.18 hsa-mir-93 - 7605 
chr7 99537011 38.18 hsa-mir-25 - 7809 
chr7 99537011 38.18 hsa-mir-106b - 7378 
chr7 99536438 18.23 hsa-mir-93 - 7032 
chr7 99536438 18.23 hsa-mir-25 - 7236 
chr7 99536438 18.23 hsa-mir-106b - 6805 
chr7 99536204 13.06 hsa-mir-93 - 6798 
chr7 99536204 13.06 hsa-mir-25 - 7002 
chr7 99536204 13.06 hsa-mir-106b - 6571 
chr7 30290857 8.61 hsa-mir-550-1 + 5078 
chr7 30290474 5.32 hsa-mir-550-1 + 5461 
chr7 30291185 4.47 hsa-mir-550-1 + 4750 
chr7 25957361 8.31 hsa-mir-148a - 1230 




chr7 1034338 4.62 hsa-mir-339 - 5150 
chr7 1033703 4.54 hsa-mir-339 - 4515 
chr7 5503584 4.4 hsa-mir-589 - 1510 
chr8 144970028 10.68 hsa-mir-937 - 2828 
chr8 145605724 9.52 hsa-mir-1234 - 9357 
chr8 145098970 6.25 hsa-mir-661 - 7535 
chr8 145098389 5.11 hsa-mir-661 - 6954 
chr9 95968323 17.71 hsa-let-7a-1 + 9737 
chr9 95968843 10.84 hsa-let-7a-1 + 9217 
chr9 95968843 10.84 hsa-let-7f-1 + 9607 
chr9 130052598 4.92 hsa-mir-199b - 5668 
chrX 133510918 5.75 hsa-mir-450b - 8960 
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